

Formula XIII

Habte 10/824,005

10/22/2004


=> d que

L24

STR

NH~G2 G2~N~G2 Cb @49 Cb @50 Hy @51 O=C~Ak
@44 45 46 @47 48 52 53 54

Ak~G7~Cy O~Ak~G7~Cy N~G7~Cy Cb~G6 Hy~G6
@55 56 57 @58 59 60 61 @62 63 64 @66 67 @68 69



VAR G1=NH2/44/47

VAR G2=AK/49/50/51

REP G3=(0-1) A

VAR G6=55/58/62

REP G7=(2-10) A

VAR G8=66/68

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 50

CONNECT IS E1 RC AT 51

CONNECT IS E1 RC AT 54

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 49

GGCAT IS UNS AT 50

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M6 C AT 50

ECOUNT IS E6 C AT 66

ECOUNT IS E5 C E1 N AT 68

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE

L27 1 SEA FILE=REGISTRY SSS FUL L24

L28 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L27

=> d ibib abs hitstr

L28 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1976:123275 HCAPLUS

DOCUMENT NUMBER: 84:123275

TITLE: Dyeing polyurethane plastics

INVENTOR(S): Hugl, Herbert; Wolfrum, Gerhard

PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 66 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2426180	A1	19751218	DE 1974-2426180	19740529
GB 1450674	A	19760922	GB 1975-21188	19750519
US 4038240	A	19770726	US 1975-580036	19750522
JP 51005395	A2	19760117	JP 1975-62607	19750527
BE 829579	A1	19751128	BE 1975-156782	19750528
ES 438012	A1	19770616	ES 1975-438012	19750528
NL 7506374	A	19751202	NL 1975-6374	19750529
FR 2275507	A1	19760116	FR 1975-16816	19750529
FR 2275507	B1	19790803		
CH 626103	A	19811030	CH 1975-15061	19751120
PRIORITY APPLN. INFO.:			DE 1974-2426180	19740529
			CH 1975-6779	19750527

GI For diagram(s), see printed CA Issue.


AB Polyurethane elastomers suitable for fiber and foam manufacture are dyed fast yellow shades with a dye capable of forming covalent bonds with the polymer, i.e. the azo dye (I) [58547-73-2]. I was prepared by treating 4-amino-2'-hydroxy-5'-methylazobenzene [25717-11-7] with 2,4,6-trifluoro-5-chloropyrimidine [697-83-6] to give an intermediate which was treated with ethanolamine [141-43-5]. Thus, a dispersion of I in an adipic acid-2,2-dimethyl-1,3-propanediol-1,6-hexanediol polyester was mixed with N,N-bis(β-hydroxypropyl)methylamine and diphenylmethane-4,4'-diisocyanate to give a NCO-containing adduct which reacted with terephthalic acid bis(m-aminoanilide) to give a polyurethane [58560-04-6] product which was wet or dry spun into yellow highly-elastic fibers with very good wet- and lightfastness as well as thermal and mech. properties.

IT **58547-93-6P**

RL: IMF (Industrial manufacture); PREP (Preparation)
 (preparation of)

RN 58547-93-6 HCAPLUS

CN Butanamide, 2-[[2,5-dichloro-4-[[5-chloro-2,6-bis[(2-hydroxyethyl)amino]-4-pyrimidinyl]amino]phenyl]azo]-N-(2,5-dichlorophenyl)-3-oxo- (9CI) (CA INDEX NAME)



Formula XI


Habte 10/824,005

10/22/2004


=> d que 118

L9

STR



Page 1-A



Page 2-A

VAR G1=NH/15/17/O/S/20

VAR G2=22/23/25/28/29/30

VAR G3=H/37/39/43/47/NH/50/53/58/60/62/CN/X/66/67

VAR G4=H/37/39/43/47/NH/50/53/58/60/62/CN/X/66/67/OH/NO2/73/74

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 19

CONNECT IS E2 RC AT 20

CONNECT IS E2 RC AT 22

CONNECT IS E3 RC AT 23

CONNECT IS E3 RC AT 25

CONNECT IS E1 RC AT 27

CONNECT IS E2 RC AT 28

```

CONNECT IS E2 RC AT 29
CONNECT IS E2 RC AT 30
CONNECT IS E1 RC AT 38
CONNECT IS E1 RC AT 41
CONNECT IS E1 RC AT 45
CONNECT IS E2 RC AT 51
CONNECT IS E2 RC AT 55
CONNECT IS E1 RC AT 58
CONNECT IS E2 RC AT 62
CONNECT IS E1 RC AT 73
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 58
GGCAT IS SAT AT 66
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M6 C AT 58

```

GRAPH ATTRIBUTES:

```

RSPEC 9 3
NUMBER OF NODES IS 78


```

STEREO ATTRIBUTES: NONE

```

L11 420422 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC3/ES AND C6/ES
L13 2384 SEA FILE=REGISTRY SUB=L11 SSS FUL L9
L14 STR

```




Page 1-A

8

6

Page 1-B



Page 2-A

VAR G1=NH/15/17/O/S/20

REP G2=(2-10) A

VAR G3=H/37/39/43/47/NH/50/53/58/60/62/CN/X/66/67

VAR G4=H/37/39/43/47/NH/50/53/58/60/62/CN/X/66/67/OH/NO2/73/74

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 19

CONNECT IS E2 RC AT 20

CONNECT IS E1 RC AT 38

CONNECT IS E1 RC AT 41

CONNECT IS E1 RC AT 45

CONNECT IS E2 RC AT 51

CONNECT IS E2 RC AT 55

CONNECT IS E1 RC AT 58

CONNECT IS E2 RC AT 62

CONNECT IS E1 RC AT 73

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 58

GGCAT IS SAT AT 66

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M6 C AT 58

GRAPH ATTRIBUTES:

RSPEC 1 9

NUMBER OF NODES IS 69

STEREO ATTRIBUTES: NONE

L15 931 SEA FILE=REGISTRY SUB=L13 SSS FUL L14

L18 67 SEA FILE=HCAPLUS ABB=ON PLU=ON L15

=> d l18 ibib ab hitstr 1-67

L18 ANSWER 1 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:780679 HCAPLUS

TITLE: Preparation of novel 2,4-di(phenylamino)pyrimidines
useful in the treatment of neoplastic diseases,
inflammatory and immune system disordersINVENTOR(S): Garcia-Echeverria, Carlos; Kanazawa, Takanori;
Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko;
Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 185 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080980	A1	20040923	WO 2004-EP2616	20040312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-5929 A 20030314
 GB 2003-19227 A 20030815
 GB 2003-22370 A 20030924

AB The title pyrimidine derivs. I [R0-R3 = H, alkyl, aryl, etc.; or R0 and R1, R1 and R2, and/or R2 and R3 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, halo, etc.; R7-R10 = alkyl, cycloalkyl, aryl, etc.; or R7 and R8, R8 and R9, and/or R9 and R10 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; A = C, N], useful as FAK or/and IGF-1 receptor inhibitors in the treatment of neoplastic diseases, inflammatory and immune system disorders, were prepared and formulated. E.g., a 2-step synthesis of II from 2,4-dichloro-5-nitropyrimidine, 2-amino-N-methylbenzenesulfonamide, and 2,5-dimethoxyaniline which showed IC50 of 140 nM in FAK assay, was given. The pharmaceutical composition comprising the compound I is claimed.


IT 761436-77-5P 761437-15-4P 761438-53-3P
 761438-54-4P 761438-58-8P 761439-20-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 761436-77-5 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 761437-15-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 761438-53-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 761438-54-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 761438-58-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 761439-20-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L18 ANSWER 2 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:595113 HCAPLUS
 DOCUMENT NUMBER: 141:273257
 TITLE: CORES: An Automated Method for Generating Three-Dimensional Models of Protein/Ligand Complexes
 AUTHOR(S): Hare, Brian J.; Walters, W. Patrick; Caron, Paul R.; Bemis, Guy W.
 CORPORATE SOURCE: Vertex Pharmaceuticals, Cambridge, MA, 02139, USA
 SOURCE: Journal of Medicinal Chemistry (2004), 47(19), 4731-4740
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB We describe a new, automated method for building 3D models of small-mol. ligands complexed with proteins. Modeling templates are constructed from frameworks (i.e., ring systems and linkers) of ligands extracted from 3D structures of ligands complexed with proteins that are structurally related to the target protein. These templates are typically substructures of the target ligand and are used to build models that constrain the ligand's conformation and binding orientation in the active site of the target protein. The practical utility of the method is shown by demonstrating that most ligands containing related frameworks bind protein kinases in the same orientation. Moreover, models for 15 of 19 cdk2/ligand complexes in the protein data bank built using our method deviate from the X-ray structure by less than 2 Å (rms). Finally, we show that over 70% of small-mol. protein kinase inhibitors published in J. Med. Chemical since 1993 can be modeled using a template extracted from a 3D protein kinase structure in the protein data bank.

IT 152459-79-5 760211-97-0
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (inhibitor framework; application of CORES as an automated method for generating three-dimensional models of protein/ligand complexes)
 RN 152459-79-5 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 760211-97-0 HCAPLUS
 CN Benzamide, 4-(1-piperazinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:467870 HCAPLUS

DOCUMENT NUMBER: 141:38625

TITLE: Preparation of Chk-, pdk- and akt-inhibitory pyrimidines

INVENTOR(S): Bryant, Judi; Kochanny, Monica; Yuan, Shendong; Khim, Seock-Kuy; Buckman, Brad; Arnaiz, Damian; Boemer, Ulf; Briem, Hans; Esperling, Peter; Huwe, Peter; Kuhnke, Joachim; Schaefer, Martina; Wortmann, Lars; Kosemund, Dirk; Eckle, Emil; Feldman, Richard; Phillips, Gary

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048343	A1	20040610	WO 2003-EP13443	20031128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004186118 A1 20040923 US 2003-722591 20031128

PRIORITY APPLN. INFO.: EP 2002-26607 A 20021128

OTHER SOURCE(S): MARPAT 141:38625

AB The title compds. [I; A, B = CN, halo, H, OH, etc.; X = O, (un)substituted NH; R1 = H, halo, CH2OH, alkyl, etc.; R2 = H, (un)substituted NHCO-aryl or alkyl] which are inhibitors of kinases useful as medications for treating various diseases, were prepared E.g., a multi-step synthesis of 5-bromo-4-[2-(1H-imidazol-4-yl)ethylamino]-2-(4-pyrrolidin-1-ylmethylphenylamino)pyrimidine, starting from 5-bromouracil, was given. Biol. data for inhibition of Akt-2, Chk-1, and VEGFR-II (KDR) were given.

The pharmaceutical composition comprising the compds. I is claimed.


IT 702673-71-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of Chk-, pdk- and akt-inhibitory pyrimidines)

RN 702673-71-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[(3-aminopropyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 702672-41-1P 702672-43-3P 702672-45-5P
 702672-47-7P 702672-50-2P 702672-52-4P
 702672-54-6P 702672-56-8P 702672-58-0P
 702672-60-4P 702673-65-2P 702673-73-2P
 702673-74-3P 702673-77-6P 702673-78-7P
 702673-79-8P 702673-80-1P 702673-81-2P
 702673-82-3P 702673-83-4P 702673-84-5P
 702673-85-6P 702673-86-7P 702673-87-8P
 702673-88-9P 702673-89-0P 702673-90-3P
 702673-91-4P 702673-93-6P 702673-96-9P
 702673-97-0P 702673-98-1P 702674-19-9P
 702674-21-3P 702674-56-4P 702674-75-7P
 702674-76-8P 702674-81-5P 702674-82-6P
 702674-83-7P 702674-84-8P 702674-85-9P
 702674-88-2P 702674-93-9P 702674-94-0P
 702674-95-1P 702675-03-4P 702675-04-5P
 702675-05-6P 702675-07-8P 702675-08-9P
 702675-09-0P 702675-10-3P 702675-11-4P
 702675-12-5P 702675-14-7P 702675-15-8P
 702675-16-9P 702675-17-0P 702675-18-1P
 702675-19-2P 702675-20-5P 702675-21-6P
 702675-22-7P 702675-24-9P 702675-25-0P
 702675-27-2P 702675-29-4P 702675-30-7P
 702675-31-8P 702675-32-9P 702675-33-0P
 702675-34-1P 702675-35-2P 702675-36-3P
 702675-37-4P 702675-38-5P 702675-39-6P
 702675-40-9P 702675-41-0P 702675-42-1P
 702675-43-2P 702675-45-4P 702675-46-5P
 702675-47-6P 702675-48-7P 702675-49-8P
 702675-50-1P 702675-51-2P 702675-52-3P
 702675-53-4P 702675-54-5P 702675-55-6P
 702675-56-7P 702675-57-8P 702675-58-9P
 702675-59-0P 702675-60-3P 702675-61-4P
 702675-62-5P 702675-63-6P 702675-64-7P

702675-65-8P 702675-66-9P 702675-67-0P
702675-68-1P 702675-69-2P 702675-70-5P
702675-71-6P 702675-72-7P 702675-73-8P
702675-74-9P 702675-75-0P 702675-76-1P
702675-77-2P 702675-78-3P 702675-79-4P
702675-80-7P 702675-81-8P 702675-82-9P
702675-84-1P 702675-85-2P 702675-86-3P
702675-87-4P 702675-88-5P 702675-89-6P
702675-92-1P 702675-93-2P 702675-94-3P
702675-95-4P 702675-96-5P 702675-97-6P
702675-98-7P 702676-00-4P 702676-01-5P
702676-04-8P 702676-05-9P 702676-06-0P
702676-07-1P 702676-08-2P 702676-09-3P
702676-12-8P 702676-13-9P 702676-14-0P
702676-15-1P 702676-16-2P 702676-17-3P
702676-18-4P 702676-20-8P 702676-22-0P
702676-23-1P 702676-25-3P 702676-44-6P
702676-50-4P 702676-52-6P 702676-54-8P
702676-55-9P 702676-56-0P 702676-57-1P
702676-58-2P 702676-59-3P 702676-60-6P
702676-61-7P 702676-62-8P 702676-63-9P
702676-64-0P 702676-65-1P 702676-66-2P
702676-67-3P 702676-68-4P 702676-69-5P
702676-70-8P 702676-71-9P 702676-72-0P
702676-73-1P 702676-74-2P 702676-75-3P
702676-76-4P 702676-77-5P 702676-78-6P
702676-79-7P 702676-80-0P 702676-81-1P
702676-82-2P 702676-83-3P 702676-84-4P
702676-85-5P 702676-86-6P 702676-87-7P
702676-88-8P 702676-89-9P 702676-90-2P
702676-91-3P 702676-92-4P 702676-93-5P
702676-95-7P 702676-96-8P 702676-97-9P
702676-98-0P 702677-01-8P 702677-02-9P
702677-03-0P 702677-04-1P 702677-05-2P
702677-06-3P 702677-08-5P 702677-09-6P
702677-10-9P 702677-11-0P 702677-12-1P
702677-13-2P 702677-14-3P 702677-15-4P
702677-16-5P 702677-17-6P 702677-18-7P
702677-19-8P 702677-20-1P 702677-21-2P
702677-22-3P 702677-23-4P 702677-24-5P
702677-25-6P 702677-26-7P 702677-27-8P
702677-28-9P 702677-29-0P 702677-31-4P
702677-32-5P 702677-33-6P 702677-34-7P
702677-35-8P 702677-37-0P 702677-39-2P
702677-40-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of Chk-, pdk- and akt-inhibitory pyrimidines)

RN 702672-41-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]-
5-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 702672-43-3 HCAPLUS

CN Carbamic acid, [3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 702672-45-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(propylsulfonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702672-47-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(phenylamino)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702672-50-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(ethylamino)thioxomethyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702672-52-4 HCAPLUS

CN Carbamothioic acid, [3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-, S-ethyl ester (9CI) (CA INDEX NAME)




RN 702672-54-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[(aminosulfonyl)amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702672-56-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-oxo-3-(propylamino)propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702672-58-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[[(3-aminophenyl)methyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702672-60-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(3-thienylmethyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702673-65-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[[(2S)-2-amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-73-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-74-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-2-amino-1-oxo-3-phenylpropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-77-6 HCAPLUS


CN Carbamic acid, [1-[[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl

ester (9CI) (CA INDEX NAME)




RN 702673-78-7 HCAPLUS

CN Carbamic acid, [1-[[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 702673-79-8 HCAPLUS

CN Cyclopentanecarboxamide, 1-amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702673-80-1 HCAPLUS

CN Cyclohexanecarboxamide, 1-amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702673-81-2 HCAPLUS

CN 1,3-Benzenediamine, N-[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]-N'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 702673-82-3 HCAPLUS


CN Phenol, 4-[[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]aminomethyl]phenol] (9CI) (CA INDEX NAME)



RN 702673-83-4 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-84-5 HCAPLUS


CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702673-85-6 HCAPLUS


CN Carbamic acid, [1-[[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 702673-86-7 HCAPLUS
 CN Phenol, 2-[[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]aminomethyl]- (9CI) (CA INDEX NAME)




RN 702673-87-8 HCAPLUS
 CN Benzenepropanamide, N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 702673-88-9 HCAPLUS
 CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702673-89-0 HCAPLUS
 CN Benzenepropanamide, N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-3,4-dihydroxy- (9CI) (CA INDEX NAME)



RN 702673-90-3 HCAPLUS

CN Benzeneacetamide, N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-α-hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-91-4 HCAPLUS


CN Benzeneacetamide, N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702673-93-6 HCAPLUS


CN 2-Propenamide, N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-3-(3,4-dihydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 702673-96-9 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-97-0 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-4-methyl-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702673-98-1 HCAPLUS


CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]-4-methyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702674-19-9 HCAPLUS

CN Benzeneacetic acid, 2,4-dichloro-, [3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]-5-[[[(2,4-dichlorophenyl)acetyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 702674-21-3 HCAPLUS

CN Benzoic acid, 3-bromo-, [3-[(3-bromobenzoyl)amino]-5-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 702674-56-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702674-75-7 HCAPLUS

CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-cyclopropyl- (9CI) (CA INDEX NAME)



RN 702674-76-8 HCAPLUS


CN 4-Morpholinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702674-81-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702674-82-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702674-83-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(1-methyl-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702674-84-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[(4-aminobutyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702674-85-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-hydroxy-1,1-dimethylethyl)amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702674-88-2 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702674-93-9 HCAPLUS
 CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702674-94-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702674-95-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2-(hydroxymethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702675-03-4 HCAPLUS


CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 702675-04-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702675-05-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2-(hydroxymethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 702675-07-8 HCAPLUS

CN Carbamic acid, [3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702675-08-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(5-methyl-1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-09-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 702675-10-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 702675-11-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-12-5 HCAPLUS

CN 1H-Pyrrole-1-carboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,5-dihydro- (9CI) (CA INDEX NAME)




RN 702675-14-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-15-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-16-9 HCAPLUS


CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 702675-17-0 HCAPLUS

CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702675-18-1 HCAPLUS

CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702675-19-2 HCAPLUS

CN Urea, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N'-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)




RN 702675-20-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(4-methyl-5-thiazolyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-21-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-chloro-4-[[3-[(methylsulfonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-22-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-(3-nitrophenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-24-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[2-(1H-benzimidazol-2-yl)ethyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-25-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[[3-[(aminoacetyl)amino]phenyl]methyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-27-2 HCAPLUS

CN Benzamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-29-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(3-pyridinylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-30-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(trans-4-hydroxycyclohexyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 702675-31-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-32-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[[(1R)-2-hydroxy-1-(1H-imidazol-4-ylmethyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702675-33-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(2-methyl-1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-34-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-35-2 HCAPLUS
 CN 1,2,3-Thiadiazole-5-carboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 702675-36-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(1-oxobutyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-37-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(3-hydroxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-38-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-furanylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-39-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(5-oxo-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-40-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702675-41-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-3-(dimethylamino)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702675-42-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-43-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(3-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl] - (9CI)
 (CA INDEX NAME)




RN 702675-45-4 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl] - (9CI) (CA INDEX NAME)



RN 702675-46-5 HCAPLUS
 CN 2-Pyridinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl] - (9CI) (CA INDEX NAME)




RN 702675-47-6 HCAPLUS
 CN Pyrazinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl] - (9CI) (CA INDEX NAME)




RN 702675-48-7 HCAPLUS

CN 5-Pyrimidinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)



RN 702675-49-8 HCAPLUS


CN Carbamic acid, [2-[[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 702675-50-1 HCAPLUS


CN Carbamic acid, [(1R)-2-[[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702675-51-2 HCAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)




RN 702675-52-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-(benzoylamino)propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702675-53-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(methylamino)acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702675-54-5 HCAPLUS


CN 3-Pyridinepropanamide, α-amino-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 702675-55-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.




RN 702675-56-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2S)-2-pyrrolidinylcarbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 702675-57-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-58-9 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(3-methyl-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-59-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[(benzo[b]thien-2-ylcarbonyl)amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-60-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702675-61-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[4-[(2-thienylcarbonyl)amino]butyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-62-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-chloro-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-63-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-fluoro-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-64-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-cyano-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-65-8 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[(2R)-2-amino-3-(4-hydroxyphenyl)-
1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




RN 702675-88-9 HCAP105
CN 3-Isoquinolinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 702675-67-0 HCAFL05
CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2R)-aminophenylacetyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702675-68-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-(acetylamino)propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-69-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(methoxyacetyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-70-5 HCAPLUS


CN 1,1-Cyclopropanedicarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 702675-71-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-72-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(phenylacetyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-73-8 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-2-amino-1-oxo-3-(3-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


thienyl)propyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl] -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 702675-74-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-iodo-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl] - (9CI)
(CA INDEX NAME)




RN 702675-75-0 HCAPLUS

CN Propanoic acid, 3-[[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]amino]-3-oxo- (9CI) (CA INDEX NAME)




RN 702675-76-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-
[(hydroxyacetyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 702675-77-2 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-
yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-78-3 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(3-pyridinyl)ethyl]amino]-2-
pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-79-4 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-hydroxyethyl)amino]-2-
pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-80-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-(aminomethyl)phenyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-81-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(4-piperidinylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702675-82-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(1S)-2-hydroxy-1-(1H-imidazol-4-ylmethyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702675-84-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(4-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-85-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[5-methyl-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
 (CA INDEX NAME)




RN 702675-86-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[4,5-dibromo-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
 (CA INDEX NAME)



RN 702675-87-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-bromo-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
 (CA INDEX NAME)




RN 702675-88-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[5-nitro-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
 (CA INDEX NAME)




RN 702675-89-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[5-bromo-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 702675-92-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-(thienylamino)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-93-2 HCAPLUS

CN 1H-Imidazole-1-carboxylic acid, 4-[2-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 702675-94-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(4,5-dihydro-2-oxazolyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702675-95-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702675-96-5 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[(3-amino-2,2-dimethylpropyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702675-97-6 HCAPLUS
CN Cyclohexanecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702675-98-7 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-thienylmethyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702676-00-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]phenyl]-3-(dimethylamino)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-01-5 HCAPLUS

CN Benzeneacetamide, N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]phenyl]-3-(dimethylamino)-, (3R)- (9CI) (CA INDEX NAME)



RN 702676-04-8 HCAPLUS


CN Benzoic acid, 2-[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]hydrazide (9CI) (CA INDEX NAME)




RN 702676-05-9 HCAPLUS

CN Urea, N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]phenyl]-N-ethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 702676-06-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702676-07-1 HCAPLUS
 CN Urea, N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-methyl-N-[2-(1-piperidinyl)ethyl] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702676-08-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-cyanoethyl)amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702676-09-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702676-12-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-thienylsulfonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702676-13-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-(2-thiazolylamino)propyl]amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)



RN 702676-14-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(4-thiazolyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702676-15-1 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-amino-N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702676-16-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, 3-(acetamido)-N-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-(3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-17-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[(2-aminoethyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702676-18-4 HCAPLUS


CN Benzenepropanamide, α-amino-N-[3-[[4-[(3-aminopropyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-20-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(ethylamino) carbonyl] amino] propyl] amino]-2-pyrimidinyl] amino]phenyl]-, (9CI) (CA INDEX NAME)



RN 702676-22-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(2-piperidiny)ethyl] amino]-2-pyrimidinyl] amino]phenyl]-, (9CI) (CA INDEX NAME)



RN 702676-23-1 HCAPLUS


CN Benzenepropanamide, α -amino-N-[3-[[4-[(3-aminopropyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-25-3 HCAPLUS

CN Cyclohexanecarboxamide, 1-amino-N-[3-[[4-[(3-aminopropyl)amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-44-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[(3-aminopropyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-50-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-methyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-52-6 HCAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 702676-54-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[4,5-dimethyl-2-furanyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-55-9 HCAPLUS

CN 5-Isoxazolecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 702676-56-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[5-amino-2-thienyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-57-1 HCAPLUS
CN Butanediamide, N'-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 702676-58-2 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(2-thienylacetyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-59-3 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(3-thienylacetyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-60-6 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[5-acetyl-2-

thienyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 702676-61-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-ethoxy-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)



RN 702676-62-8 HCAPLUS

CN Butanediarnide, 2-(acetylarnino)-N1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)arnino]phenyl]arnino]-4-pyrimidinyl]arnino]propyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702676-63-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2S)-4-oxo-2-azetidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 702676-64-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2R)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702676-65-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-66-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(3-chloro-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702676-67-3 HCAPLUS


CN Butanediamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 702676-68-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2R)-2-pyrrolidinylcarbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-69-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(3-oxocyclopentyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702676-70-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2-methylcyclopropyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702676-71-9 HCAPLUS


CN 4-Thiazolidinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-2-oxo-(4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702676-72-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(cyclopropylacetyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702676-73-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(4,4,4-trifluoro-1-oxobutyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702676-74-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(1-methylcyclopropyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702676-75-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2,2-dimethyl-3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702676-76-4 HCAPLUS

CN 4-Imidazolidinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-(9CI) (CA INDEX NAME)




RN 702676-77-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[1-hydroxycyclopropyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-78-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[2-ethyl-1-oxobutyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-79-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[2,2-dimethyl-1-oxobutyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702676-80-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(tetrahydro-2-furanyl) carbonyl] amino] propyl] amino]-2-pyrimidinyl] amino] phenyl] - (9CI)
(CA INDEX NAME)



RN 702676-81-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2S)-2-methyl-1-oxobutyl] amino] propyl] amino]-2-pyrimidinyl] amino] phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702676-82-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(tetrahydro-3-furanyl) carbonyl] amino] propyl] amino]-2-pyrimidinyl] amino] phenyl] - (9CI)
(CA INDEX NAME)



RN 702676-83-3 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2R)-tetrahydro-2-furanyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 702676-84-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(cyclopropylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-85-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(3,4,5-trichloro-2-thienyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 702676-86-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclopropyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-87-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-88-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[3-fluoro-2-thienyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-89-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[5-fluoro-2-thienyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-90-2 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702676-91-3 HCAPLUS
 CN Butanediamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 702676-92-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[(3-methyl-1-oxobutyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-93-5 HCAPLUS

CN Propanediamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 702676-95-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-[(aminocarbonyl)amino]-2-methyl-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702676-96-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 702676-97-9 HCAPLUS
 CN Butanediamide, 2-amino-N1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 702676-98-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-2-amino-3-(4-bromophenyl)-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 702677-01-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(acetylamino)acetyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-02-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-03-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[(aminoacetyl)amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-04-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-[(2-thienylcarbonyl)amino]ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702677-05-2 HCAPLUS


CN Ethanediame, [3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 702677-06-3 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-08-5 HCAPLUS


CN 1,1-Cyclopropanedicarboxamide, N-[3-[[5-bromo-2-[[3-[[[(2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-09-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(1-aminocyclopentyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702677-10-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(methylthio)acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702677-11-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-amino-4-methyl-1-oxopentyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-12-1 HCAPLUS
 CN 4-Imidazolidineacetamide, N-[3-[[5-bromo-2-[[3-[(1S)-2-amino-4-methyl-1-imidazolidinyl]carbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702677-13-2 HCAPLUS
 CN 1,1-Cyclopropanedicarboxamide, N-[3-[[5-iodo-2-[[3-[(1S)-2-amino-4-methyl-1-imidazolidinyl]carbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,5-dioxo- (9CI) (CA INDEX NAME)

pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-
(9CI) (CA INDEX NAME)




RN 702677-14-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-15-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-oxo-3-(2-thiazolylamino)propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-16-5 HCAPLUS

CN 2-Thiazolecarboxamide, N-[3-[[5-bromo-2-[[3-[[[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 702677-17-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-18-7 HCAPLUS
 CN 3-Pyrrolidinecarboxylic acid, 1-[3-[[2-[[3-[[[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 702677-19-8 HCAPLUS
 CN Propanediamide, N-[3-[[2-[[3-[[[(2S)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-20-1 HCAPLUS

CN Propanediamide, N-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-21-2 HCAPLUS

CN Pentanoic acid, 4-amino-5-[[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]amino]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

Ph

RN 702677-22-3 HCAPLUS

CN Propanediamide, N-[3-[[5-bromo-2-[[3-[[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-23-4 HCAPLUS

RN 702677-23-4 HCAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 ---OH

RN 702677-24-5 HCAPLUS

RN 702677-24-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-25-6 HCAPLUS

CN Propanediamide, N-[3-[[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-26-7 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-27-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-28-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2R)-2-amino-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 702677-29-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2S)-2-amino-3-hydroxy-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 702677-31-4 HCAPLUS

CN 1,1-Cyclopentanedicarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 702677-32-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[(2-amino-2,3-dihydro-1H-inden-2-yl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 702677-33-6 HCAPLUS

CN 2-Piperazinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)




RN 702677-34-7 HCAPLUS

CN beta-Alanine, N-[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 702677-35-8 HCAPLUS


CN Glycinamide, N-[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]-beta-alanyl- (9CI) (CA INDEX NAME)



RN 702677-37-0 HCAPLUS

CN Propanediamide, N-[3-[[2-[[3-[[2S]-aminophenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-39-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2R,3R]-2-amino-3-hydroxy-1-oxobutyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702677-40-5 HCAPLUS

CN Propanediamide, N-[3-[[2-[[3-[[1-aminocyclohexyl]carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




IT 702677-41-6P 702677-42-7P 702677-43-8P
 702677-44-9P 702677-45-0P 702677-46-1P
 702677-47-2P 702677-48-3P 702677-49-4P
 702677-50-7P 702677-51-8P 702677-52-9P
 702677-53-0P 702677-56-3P 702677-57-4P
 702677-58-5P 702677-59-6P 702677-60-9P
 702677-63-2P 702677-64-3P 702677-65-4P
 702677-66-5P 702677-67-6P 702677-68-7P
 702677-69-8P 702677-70-1P 702677-92-7P
 702677-93-8P 702677-94-9P 702677-95-0P
 702677-96-1P 702677-97-2P 702677-98-3P
 702677-99-4P 702678-00-0P 702678-01-1P
 702678-02-2P 702678-03-3P 702678-04-4P
 702678-05-5P 702678-06-6P 702678-07-7P
 702678-08-8P 702678-09-9P 702678-10-2P
 702678-12-4P 702678-13-5P 702678-14-6P
 702678-15-7P 702678-16-8P 702678-17-9P
 702678-18-0P 702678-19-1P 702678-21-5P
 702678-22-6P 702678-23-7P 702678-24-8P
 702678-25-9P 702678-26-0P 702678-27-1P
 702678-67-9P 702678-68-0P 702678-69-1P
 702678-70-4P 702678-71-5P 702678-72-6P
 702678-73-7P 702678-74-8P 702678-75-9P
 702678-76-0P 702678-77-1P 702678-78-2P
 702678-79-3P 702678-80-6P 702678-81-7P
 702678-82-8P 702678-83-9P 702678-84-0P
 702678-85-1P 702678-86-2P 702678-87-3P
 702678-88-4P 702678-89-5P 702678-90-8P
 702678-91-9P 702678-92-0P 702678-93-1P
 702678-94-2P 702678-95-3P 702678-96-4P
 702678-98-6P 702678-99-7P 702679-00-3P
 702679-01-4P 702679-02-5P 702679-03-6P
 702679-04-7P 702679-05-8P 702679-06-9P
 702679-07-0P 702679-08-1P 702679-09-2P
 702679-10-5P 702679-12-7P 702679-48-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Chk-, pdk- and akt-inhibitory pyrimidines)

RN 702677-41-6 HCAPLUS


CN 4-Piperidinecarboxamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)



RN 702677-42-7 HCAPLUS


CN 1,1-Cyclopropanedicarboxamide, N-[3-[[2-[[3-[[[(2S)-aminophenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-43-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-pyrrolidinylcarbonyl]amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 702677-44-9 HCAPLUS

CN 3-Piperidinecarboxamide, N-[3-[[5-bromo-2-[[3-[[1-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)



RN 702677-45-0 HCAPLUS


CN 2-Piperidinecarboxamide, N-[3-[[5-bromo-2-[[3-[[1-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)



RN 702677-46-1 HCAPLUS


CN Propanediamide, N-[3-[[2-[[3-[[[(2S)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-47-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[(2-amino-2-methyl-1-oxopropyl)amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702677-48-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[2-methyl-1-oxo-2-[(trifluoroacetyl)amino]propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-49-4 HCAPLUS


CN Propanediamide, N-[3-[[2-[[3-[[2S]-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 702677-50-7 HCAPLUS

CN Propanediamide, N-[3-[[2-[[3-[[2R]-2-(acetylamino)-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-51-8 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[[1-(acetylamino)cyclopentyl]carbo

nyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-52-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-(acetylamino)-4-(methylthio)-1-oxobutyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702677-53-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-(acetylamino)-3-mercapto-3-methyl-1-oxobutyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702677-56-3 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-(2R)-2-amino-3-(methylthio)-1-oxopropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702677-57-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2S)-2-(formylamino)-4-(methylthio)-1-oxobutyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702677-58-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-(acetylamino)-4-methyl-1-oxopentyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702677-59-6 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-(acetylamino)-1-oxo-3-phenylpropyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 702677-60-9 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[3-[[2-(acetylamino)-3-methyl-1-oxopentyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 702677-63-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[2,2-dimethyl-1-oxopropyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-64-3 HCAPLUS


CN Propanediamide, N-[3-[[5-fluoro-2-[[3-[[1-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 702677-65-4 HCAPLUS
 CN Propanediamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 702677-66-5 HCAPLUS
 CN Butanoic acid, 4-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 702677-67-6 HCAPLUS
 CN Propanoic acid, 3-[[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]amino]-2,2-dimethyl-3-oxo- (9CI) (CA INDEX NAME)




RN 702677-68-7 HCAPLUS

CN Propanediamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl
]amino]-4-pyrimidinyl]amino]propyl]-N',2,2-trimethyl- (9CI) (CA INDEX
NAME)




RN 702677-69-8 HCAPLUS

CN Propanediamide, N'-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl
]amino]-4-pyrimidinyl]amino]propyl]-N,N,2,2-tetramethyl- (9CI) (CA INDEX
NAME)




RN 702677-70-1 HCAPLUS

CN Propanediamide, N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl
]amino]-4-pyrimidinyl]amino]propyl]-N,2,2-trimethyl- (9CI) (CA INDEX
NAME)




RN 702677-92-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-(2-propynylamino)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-93-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-phenylethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-94-9 HCAPLUS

CN Glycine, N-[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 702677-95-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-96-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-(dimethylamino)propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-97-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-(4-morpholinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702677-98-3 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1-piperidinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702677-99-4 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(1-piperidinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-00-0 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-methoxyethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-01-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[2-(acetylamino)ethyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-02-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-[[2-[bis(2-hydroxyethyl)amino]ethyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702678-03-3 HCAPLUS


CN Alanine, N-[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 702678-04-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702678-05-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(1-phenylpropyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-06-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(5-hydroxy-1H-indol-3-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-07-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(4-hydroxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-08-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-methoxy-1-methylethyl)amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702678-09-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-hydroxy-2-(3-hydroxyphenyl)ethyl)amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702678-10-2 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(3-(1-pyrrolidinyl)propyl)amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702678-12-4 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(1-methyl-3-phenylpropyl)amino]-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 702678-13-5 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(3-phenylpropyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702678-14-6 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-15-7 HCAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(cyanomethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-16-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[4-methylphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-17-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702678-18-0 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-furanylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702678-19-1 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-phenylpropyl)amino]-2-

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-21-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-22-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[4-(1-azetidiny)-5-bromo-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-23-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-24-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-methylphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-25-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(1,2-diphenylethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-26-0 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-(2-methyl-1-piperidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702678-27-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702678-67-9 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-(2-propynylamino)-2-

pyrimidinyl]aminophenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-68-0 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[(2-phenylethyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-69-1 HCAPLUS

CN Glycine, N-[2-[[3-[[2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-70-4 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-71-5 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[3-(dimethylamino)propyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-72-6 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-(1-piperidinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-73-7 HCAPLUS


CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702678-74-8 HCAPLUS
 CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[(2-methoxyethyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702678-75-9 HCAPLUS
 CN Benzenepropanamide, N-[3-[[4-[[2-(acetylamino)ethyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]- α -amino-, (α R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702678-76-0 HCAPLUS
 CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702678-77-1 HCAPLUS
 CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-(1H-indol-3-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-78-2 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[4-[[2-[bis(2-hydroxyethyl)amino]ethyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-, (αR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-79-3 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[[[(3,4-dimethylphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-80-6 HCAPLUS

CN Alanine, N-[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-81-7 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-82-8 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[(1-phenylpropyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-83-9 HCAPLUS

CN L-Tyrosine, N-[2-[[3-[[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-84-0 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[[2-(3-hydroxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 702678-85-1 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[[4-hydroxy-3-methoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702678-86-2 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[[2,4-dimethoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-87-3 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[[2-(5-hydroxy-1H-indol-3-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-88-4 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[[2-(4-hydroxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-89-5 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[(2-methoxy-1-methylethyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-90-8 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-hydroxy-2-(3-hydroxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-91-9 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[(2-cyanoethyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-92-0 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[(3-phenylpropyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-93-1 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-94-2 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[(4-methylphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702678-95-3 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702678-96-4 HCAPLUS

CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[(2-

furanylmethyl)amino]-2-pyrimidinyl]amino]phenyl]-, (α R) - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 702678-98-6 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R) - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 702678-99-7 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-(1H-indol-3-yl)-1-methylethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R) - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 702679-00-3 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[3-methylphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 702679-01-4 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-(1-piperidinyl)-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702679-02-5 HCAPLUS

CN Benzenepropanamide, α -amino-N-[3-[[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-, (α R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 702679-03-6 HCAPLUS


CN Benzenepropanamide, α-amino-N-[3-[[5-bromo-4-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]phenyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702679-04-7 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(2,4-dichlorophenyl)acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 1-B




RN 702679-05-8 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(4-bromophenyl)acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702679-06-9 HCAPLUS

1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[4-methylphenyl]acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702679-07-0 HCAPLUS

1-Pyrrolidinecarboxamide, N-[3-[5-bromo-4-[[3-[(2,4-difluorophenyl)acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 702679-08-1 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 702679-09-2 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[[(3R)-1-oxo-3-phenylbutyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702679-10-5 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-bromobenzoyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 702679-12-7 HCAPLUS


CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[2-(4-methyl-5-thiazolyl)ethoxy]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 702679-48-9 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-bromo-4-[[3-[[3-(2,3-dichlorophenyl)-1-oxobutyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 702679-31-0P 702679-32-1P 702679-38-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Chk-, pdk- and akt-inhibitory pyrimidines)

RN 702679-31-0 HCAPLUS

CN Benzoic acid, 3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]-5-[[[(2R)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702679-32-1 HCAPLUS


CN Carbamic acid, [(1R)-2-[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]-5-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702679-38-7 HCAPLUS

CN β -Alanine, N-[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:453191 HCAPLUS

DOCUMENT NUMBER: 141:23546

TITLE: Preparation of 2,4-bis(phenylamino)pyrimidine derivatives for treating hyperproliferative disorders

INVENTOR(S): Wood, Jill E.; Bierer, Donald; Bear, Brian; Brennan, Catherine; Chandler, Brent; Chen, Gang; Chen, Yuanwei; Dixon, Julie; Fu, Wenlang; Guernon, Leatte; Liu, Donglei; McClure, Andrea; Miranda, Karl; Nagarathnam, Dhanapalan; Sibley, Robert; Turner, Michael; Verma, Sharad; Wang, Chunguang; Yi, Lin; Zhao, Jin; Zhu, Qingming

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046118	A2	20040603	WO 2003-US14294	20030506
WO 2004046118	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-378329P P 20020506

OTHER SOURCE(S): MARPAT 141:23546

AB Title compds. I [p = 0-2; X = alkyl, CF₃, halo; R₁ = H, OH, halo, etc.; R₂ = H, S(O)₂NH₂, halo, etc.; R₃ = H, alkyl, halo, etc.; R₄ = H, halo, ethynyl, etc.; R₅₋₆ = H, halo, CF₃; R₇ = H, halo, alkoxy; R₈ = H, alkyl, alkoxy, halo; R₉ = H, alkoxy] are prepared. For instance, 4-fluoroaniline is alkylated with 5-bromo-2,4-dichloropyrimidine (THF, H₂O, NaOAc); this intermediate is treated with 3-(1-methyl-1H-pyrazol-3-yl)benzeneamine (t-BuOH, HCl) to give II. Compds. of the invention inhibit cell proliferation (no data).

IT **698347-91-0P**, 5-Bromo-2-[[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy)phenyl]amino]-4-[[4-(4-fluorophenyl)amino]pyrimidine


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 2,4-bis(phenylamino)pyrimidine derivs. for treating hyperproliferative disorders)

RN 698347-91-0 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[[4(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-N4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 698996-42-8P, N-[5-Bromo-4-[(4-fluorophenyl)amino]-2-pyrimidinyl]-N-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amine
 698996-47-3P, N-[5-Bromo-4-[(4-fluorophenyl)amino]-2-pyrimidinyl]-N-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amine 698996-52-0P
 , N-[5-Bromo-4-[(4-fluorophenyl)amino]-2-pyrimidinyl]-N-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amine 698997-21-6P,
 N-[5-Bromo-4-[(4-fluorophenyl)amino]-2-pyrimidinyl]-N-[4-methoxy-3-[[2-(4-morpholinyl)ethoxy]methyl]phenyl]amine 698997-54-5P,
 N-[5-Bromo-4-[(3-fluorophenyl)amino]-2-pyrimidinyl]-N-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amine 698997-55-6P,
 N-[5-Bromo-2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]-N-(4-methoxyphenyl)amine 698997-77-2P,
 5-Bromo-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-[(4-methoxyphenyl)amino]pyrimidine trifluoroacetate 698998-40-2P,
 5-Bromo-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-[[3-(1H-pyrazol-3-yl)phenyl]amino]pyrimidine trifluoroacetate 698998-42-4P
 , 5-Bromo-4-[(3-ethynylphenyl)amino]-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]pyrimidine trifluoroacetate
 698998-44-6P, 5-Bromo-4-[(1H-indol-5-yl)amino]-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]pyrimidine trifluoroacetate
 698998-46-8P, 1-[3-[[5-Bromo-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]ethanone trifluoroacetate 698998-48-0P, 1-[4-[[5-Bromo-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-1-butanone trifluoroacetate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-bis(phenylamino)pyrimidine derivs. for treating hyperproliferative disorders)


RN 698996-42-8 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(4-fluorophenyl)-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 698996-47-3 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(4-fluorophenyl)-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 698996-52-0 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(4-fluorophenyl)-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 698997-21-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(4-fluorophenyl)-N2-[4-methoxy-3-[[2-(4-morpholinyl)ethoxy]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 698997-54-5 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(3-fluorophenyl)-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 698997-55-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 698997-77-2 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-N4-(4-methoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 698997-76-1


CMF C24 H28 Br N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 698998-40-2 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-N4-[3-(1H-pyrazol-3-yl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 698998-39-9


CMF C26 H28 Br N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 698998-42-4 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(3-ethynylphenyl)-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 698998-41-3


CMF C25 H26 Br N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 698998-44-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-1H-indol-5-yl-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 698998-43-5


CMF C25 H27 Br N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 698998-46-8 HCAPLUS

CN Ethanone, 1-[3-[[5-bromo-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 698998-45-7


CMF C25 H28 Br N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 698998-48-0 HCAPLUS

CN 1-Butanone, 1-[4-[[5-bromo-2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 698998-47-9


CMF C27 H32 Br N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L18 ANSWER 5 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:433768 HCAPLUS

DOCUMENT NUMBER: 141:7140

TITLE: Preparation of amides, which contain pyridinyl, pyrimidinyl and pyrazinyl moieties, as potassium channel openers

INVENTOR(S): Wu, Yong-Jin; Sun, Li-Qiang; Chen, Jie; He, Huan

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102449	A1	20040527	US 2003-719538	20031121
WO 2004047739	A2	20040610	WO 2003-US37306	20031121
WO 2004047739	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-428352P

P 20021122

OTHER SOURCE(S):

MARPAT 141:7140

AB Amides, such as I [R1 = unsubstituted- or substituted-Ph, pyridinyl, 3-quinolinyl, cycloalkyl, thienyl, furanyl; R2 = CF3, CH2OH, alkyl; R3, R4, R5, R6 = H, F; A = -CH:CH-, -(CH2)n-; B = pyridinyl, pyrimidinyl, pyrazinyl, benzyl; Z = O, CH2, -(CH2)mN(R7)-; R7 = H, alkyl; n = 0, 1, 2, 3; m = 0, 1], were prepared for therapeutic use as openers or activators of KCNQ potassium channels and were claimed for use in the treatment of migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety. Thus, amide II was prepared via an amidation reaction of cinnamic acid with (S)-1-[3-(pyridin-2-yloxy)phenyl]ethylamine using EDAC.HCl and DMAP in CH2Cl2. The prepared amides were assayed for K+ channel activity using a KCNO patch-clamp method.

IT 694511-25-6P 694511-26-7P 694511-27-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinyl, pyrimidinyl and pyrazinyl amides for use in pharmaceutical compns. as potassium channel openers)

RN 694511-25-6 HCAPLUS

CN 2-Propenamide, 3-(2-fluorophenyl)-N-[(1S)-1-[3-(2-pyrimidinylloxy)phenyl]ethyl]-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 694511-26-7 HCAPLUS

CN 2-Propenamide, 3-(2,3-difluorophenyl)-N-[(1S)-1-[3-(2-pyrimidinylloxy)phenyl]ethyl]-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 694511-27-8 HCAPLUS

CN 2-Propenamide, 3-(2,6-difluorophenyl)-N-[(1S)-1-[3-(2-pyrimidinylloxy)phenyl]ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L18 ANSWER 6 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:236703 HCAPLUS

DOCUMENT NUMBER: 140:423636

TITLE: Solid-Phase Synthesis of 2,4-Diaminopyrimidines via
Lewis Acid-Mediated Aromatic Nucleophilic Substitution
AUTHOR(S): Arvanitis, Elena A.; Chadha, Naresh; Pottorf, Richard
S.; Player, Mark R.

CORPORATE SOURCE: 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ,
08512, USA

SOURCE: Journal of Combinatorial Chemistry (2004), 6(3),
414-419

CODEN: JCCHFF; ISSN: 1520-4766

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Primary amines were immobilized on (4-formyl-3,5-dimethoxyphenoxy)methylpolystyrene resin via reductive amination. Attachment of two different 4-chloro-2-methylthiopyrimidines, followed by sulfide oxidation, led to the sulfone intermediates. Aromatic nucleophilic substitution with various anilines or heteroarom. amines in the presence of trimethylaluminum afforded the desired 2,4-diaminopyrimidines after acidic cleavage from the resin. The synthetic methodol. described herein was validated with the synthesis of a small 162-member library.

IT 691402-47-8P 691402-65-0P 691402-83-2P
691403-01-7P 691403-20-0P 691403-38-0P
691403-65-3P 691403-92-6P 691404-19-0P
691404-42-9P 691404-68-9P 691404-91-8P
691405-12-6P 691405-30-8P 691405-50-2P
691405-68-2P 691405-86-4P 691406-04-9P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)

(solid-phase combinatorial synthesis of 2,4-diaminopyrimidines via Lewis acid-mediated aromatic nucleophilic substitution)


RN 691402-47-8 HCAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)phenyl]-N4-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-46-7


CMF C24 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-65-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)phenyl]-N4-[(tetrahydro-2-furanyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-64-9


CMF C22 H24 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-83-2 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-[3-(phenylmethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-82-1


CMF C25 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-01-7 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-[3-(phenylmethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-00-6


CMF C23 H28 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-20-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-[3-(phenylmethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-19-7


CMF C25 H22 Cl2 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-38-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-[3-(phenylmethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-37-9


CMF C27 H28 N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691403-65-3 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-[3-(phenylmethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691403-64-2
CMF C25 H24 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691403-92-6 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-[3-(phenylmethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691403-91-5
CMF C24 H21 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-19-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)phenyl]-N4-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-18-9


CMF C20 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-42-9 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)phenyl]amino]-4-[(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-41-8


CMF C25 H21 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-68-9 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)phenyl]amino]-4-
 [[(tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA
 INDEX NAME)

CM 1

CRN 691404-67-8


CMF C23 H23 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-91-8 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[4-methylphenyl)methyl]amino]-2-[[3-
 (phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX
 NAME)


CM 1

CRN 691404-90-7
 CMF C26 H23 N5 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691405-12-6 HCAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691405-11-5
 CMF C24 H27 N5 O2



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 691405-30-8 HCAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-29-5


CMF C26 H21 Cl2 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-50-2 HCAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-49-9


CMF C28 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-68-2 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(benzylmethoxy)phenyl]amino]-2-[[3-(benzylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-67-1

CMF C26 H23 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-86-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[[4-fluorophenyl)methyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691405-85-3
CMF C25 H20 F N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691406-04-9 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)phenyl]amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691406-03-8
CMF C21 H21 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:142963 HCAPLUS

DOCUMENT NUMBER: 140:199334

TITLE: Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases

INVENTOR(S): Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim, Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 811 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014382	A1	20040219	WO 2003-US24087	20030729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-399673P P 20020729
US 2003-443949P P 20030131

US 2003-452339P

P 20030306

US 2003-631029

A 20030729

OTHER SOURCE(S): MARPAT 140:199334

AB The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).


IT 575481-22-0P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)

RN 575481-22-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 575477-87-1P 575481-27-5P 575481-30-0P
575481-35-5P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575477-87-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-N2-[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 575481-27-5 HCAPLUS


CN Phenol, 4-[[5-fluoro-2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,6-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 575481-30-0 HCAPLUS


CN Phenol, 2-chloro-4-[[5-fluoro-2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 575481-35-5 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


IT 575477-45-1P 575479-77-5P 575480-07-8P
 575480-17-0P 575480-25-0P 575480-31-8P
 575480-54-5P 575480-59-0P 575481-26-4P
 575482-64-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575477-45-1 HCAPLUS

CN 2-Furancarboxylic acid, 4-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 575479-77-5 HCAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 575480-07-8 HCAPLUS

CN Piperazine, 1-[[3-[[4-[(3-chloro-4-hydroxy-5-methylphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-17-0 HCAPLUS

CN Piperazine, 1-[[3-[[5-fluoro-4-[(4-methoxy-3,5-dimethylphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-25-0 HCAPLUS

CN Piperazine, 1-[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-31-8 HCAPLUS

CN Morpholine, 4-[[3-[[5-fluoro-4-[(4-hydroxy-3,5-dimethylphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-54-5 HCAPLUS

CN Morpholine, 4-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-59-0 HCAPLUS

CN Piperazine, 1-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 575481-26-4 HCAPLUS


CN Phenol, 4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 575482-64-3 HCAPLUS

CN 2H-Isoindole-2-acetic acid, α -[3-[[3-[[4-[(3-aminophenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]-3-oxopropyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NH₂


IT 575475-04-6P 575476-77-6P 575476-79-8P
 575477-88-2P 575479-75-3P 575479-79-7P
 575479-80-0P 575480-61-4P 575480-70-5P
 575480-71-6P 575480-72-7P 575480-94-3P
 575480-97-6P 575480-99-8P 575481-02-6P
 575481-03-7P 575481-08-2P 575481-09-3P
 575481-10-6P 575481-13-9P 575481-19-5P
 575481-31-1P 575481-33-3P 575481-39-9P
 575481-42-4P 575481-43-5P 575481-98-0P
 575481-99-1P 575482-02-9P 575482-62-1P
 575482-63-2P 575483-06-6P 662222-86-8P
 662223-01-0P 662232-22-6P 662232-33-9P
 662232-38-4P 662232-45-3P 662232-52-2P
 662233-99-0P 662234-05-1P 662234-23-3P
 662234-38-0P 662236-09-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575475-04-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N,N'-bis[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 575476-77-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N,N'-bis[3-[[2-(phenylmethoxy)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 575476-79-8 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-aminophenyl)-5-fluoro-N2-[3-[[2-(phenylmethoxy)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 575477-88-2 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-[4-(1-methylethoxy)phenyl]-N2-[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 575479-75-3 HCAPLUS

Phenol, 3-[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 575479-79-7 HCAPLUS

2-Benzofurancarboxylic acid, 5-[[[5-fluoro-2-[[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 575479-80-0 HCAPLUS

2-Benzofurancarboxamide, 5-[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 575480-61-4 HCAPLUS

575480-81-4 ACAPLOS
Acetamide, N-cyclohexyl-2-[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 575480-70-5 HCAPLUS

CN Morpholine, 4-[[3-[[4-[(3-chloro-4-hydroxy-5-methylphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-71-6 HCAPLUS

CN Morpholine, 4-[[3-[[4-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 575480-72-7 HCAPLUS


CN Piperazine, 1-[[3-[[4-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-94-3 HCAPLUS

CN Acetamide, 2-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 575480-97-6 HCAPLUS
 CN Morpholine, 4-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 575480-99-8 HCAPLUS
 CN Piperazine, 1-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 575481-02-6 HCAPLUS
 CN Piperazine, 1-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 575481-03-7 HCAPLUS
 CN Acetamide, 2-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]-N-[2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575481-08-2 HCAPLUS

CN Morpholine, 4-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 575481-09-3 HCAPLUS

CN Piperazine, 1-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 575481-10-6 HCAPLUS

CN Piperazine, 1-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 575481-13-9 HCAPLUS


CN Acetamide, 2-[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA

INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 575481-19-5 HCAPLUS
 CN 2-Furancarboxamide, 4-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 575481-31-1 HCAPLUS
 CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(4-methoxy-3,5-dimethylphenyl)-N2-[3-[2-(1-piperazinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 575481-33-3 HCAPLUS
 CN Piperazine, 1-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 575481-39-9 HCAPLUS
 CN Piperazine, 1-[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 575481-42-4 HCAPLUS
 CN Phenol, 4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,6-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 575481-43-5 HCAPLUS
 CN Phenol, 2-chloro-4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●_x HCl


RN 575481-98-0 HCAPLUS

```

RN      575481-98-0   HCAPLOS
CN      Acetamide, 2-[[[3-[[[5-fluoro-4-[[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-
pyrimidinyl]amino]phenyl]amino]-N-[2-[(phenylmethyl)amino]ethyl]- (9CI)
(CA INDEX NAME)

```

PAGE 1-A




PAGE 1-B

$$-\text{CH}_2-\text{OH}$$


RN 575481-99-1 HCAPLUS

RN 575481-99-1 HCAPLOS
CN Morpholine, 4-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575482-02-9 HCAPLUS

CN Acetamide, 2-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575482-62-1 HCAPLUS

CN Piperazine, 1-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575482-63-2 HCAPLUS
 CN Piperazine, 1-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 575483-06-6 HCAPLUS
 CN Acetamide, N-cyclopropyl-2-[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 662222-86-8 HCAPLUS
 CN Acetamide, 2-[3-[[4-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 662223-01-0 HCAPLUS
 CN Acetamide, 2-[3-[[4-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-2-

pyrimidinyl]amino]phenoxy]-N-cyclobutyl- (9CI) (CA INDEX NAME)




RN 662232-22-6 HCAPLUS

CN Acetamide, N-cyclobutyl-2-[3-[[5-fluoro-4-[[4-(4-morpholinyl)phenyl]amino]-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 662232-33-9 HCAPLUS

CN Acetamide, N-cyclobutyl-2-[3-[[5-fluoro-4-[[4-(4-morpholinyl)phenyl]amino]-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 662232-38-4 HCAPLUS

CN Acetamide, N-cyclopropyl-2-[3-[[4-(cyclopropylamino)-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 662232-45-3 HCAPLUS

CN Acetamide, N-cyclobutyl-2-[3-[[4-(cyclopropylamino)-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 662232-52-2 HCAPLUS

CN Acetamide, 2-[3-[[4-(cyclopropylamino)-5-fluoro-2-pyrimidinyl]amino]phenoxy]-N-(4-(4-morpholinyl)phenyl)- (9CI) (CA INDEX NAME)



RN 662233-99-0 HCAPLUS


CN Acetamide, N-cyclobutyl-2-[3-[[4-[(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 662234-05-1 HCAPLUS


CN Acetamide, N-cyclobutyl-2-[3-[[4-[(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 662234-23-3 HCAPLUS

CN Acetamide, 2-[3-[[4-(cyclobutylamino)-5-fluoro-2-pyrimidinyl]amino]phenoxy]-N-cyclobutyl- (9CI) (CA INDEX NAME)




RN 662234-38-0 HCAPLUS

CN Acetamide, N-cyclobutyl-2-[3-[[4-(cyclobutylamino)-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 662236-09-1 HCAPLUS

CN Acetamide, N-cyclobutyl-2-[3-[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 575481-44-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)

RN 575481-44-6 HCAPLUS

CN Phenol, 2-chloro-4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757684 HCAPLUS

DOCUMENT NUMBER: 139:292258

TITLE: Pyrimidine derivatives

INVENTOR(S): Baenteli, Rolf; Zenke, Gerhard; Cooke, Nigel Graham; Duthaler, Rudolf; Thoma, Gebhard; Von Matt, Anette; Honda, Toshiyuki; Matsuura, Naoko; Nonomura, Kazuhiko; Ohmori, Osamu; Umemura, Ichiro; Hinterding, Klaus; Papageorgiou, Christos

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078404	A1	20030925	WO 2003-EP2710	20030314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: GB 2002-6215 A 20020315

OTHER SOURCE(S): MARPAT 139:292258

AB The pyrimidine derivs. (I) are claimed, wherein X = =CR or =N, R, R1, R2, R3, R4 independently is H, OH, C1-8alkyl, C2-8alkenyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-8alkyl, hydroxyC1-8alkyl, C1-8alkoxyC1-8alkyl, hydroxyC1-8alkoxyC1-8alkyl, arylC1-8alkyl which optionally may be substituted on the ring by OH, C1-8alkoxy, carboxy, C1-8alkoxycarbonyl or R3 and R4 form together with N and C atoms to which they are attached to a 5-10 membered heterocyclic ring containing 1, 2 or 3 heteroatoms of N, O or S; R1 and R2 form together with C atoms to which they are attached aryl of 5-10 membered heteroaryl moiety containing 1-2 heteroatoms of N, O, S; R and R6 independently is H, halo, CN, C1-8alkyl, haloC1-8alkyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkyl, C3-8cycloalkylC1-8alkyl, C5-10arylC1-8alkyl;; R7, R8 and R9 is independently H, OH, C1-8alkyl, C2-8alkenyl, haloC1-8alkyl, C1-8alkoxy, C3-8cycloalkyl, C3-8cycloalkylC1-8, arylC1-8alkyl. disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK. I are useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK. Pharmaceutical compns. containing I are claimed.

IT 604800-98-8P 604800-99-9P 604801-00-5P
604801-01-6P 604801-02-7P 604801-03-8P
604801-07-2P 604801-11-8P 604801-13-0P
604801-14-1P 604801-15-2P 604801-16-3P
604801-18-5P 604801-21-0P 604801-25-4P
604801-27-6P 604801-30-1P 604801-34-5P
604801-60-7P 604801-61-8P 604801-62-9P
604801-63-0P 604801-68-5P 604801-69-6P


604801-71-0P 604801-72-1P 604801-75-4P
604801-77-6P 604801-96-9P 604801-97-0P
604802-00-8P 604802-01-9P 604802-02-0P
604802-03-1P 604802-04-2P 604802-05-3P
604802-07-5P 604802-08-6P 604802-09-7P
604802-10-0P 604802-11-1P 604802-12-2P
604802-14-4P 604802-15-5P 604802-17-7P
604802-18-8P 604802-19-9P 604802-22-4P
604802-24-6P 604802-26-8P 604802-28-0P
604802-29-1P 604802-30-4P 604802-33-7P
604802-34-8P 604802-35-9P 604802-36-0P
604802-37-1P 604802-38-2P 604802-49-5P
604802-50-8P 604802-52-0P 604802-53-1P
604802-58-6P 604802-60-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation as protein kinase inhibitor)


RN 604800-98-8 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604800-99-9 HCAPLUS

CN Phenol, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-00-5 HCAPLUS

CN Phenol, 2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-01-6 HCAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-02-7 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-03-8 HCAPLUS
 CN Phenol, 2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 604801-07-2 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-11-8 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 604801-13-0 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-14-1 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-15-2 HCAPLUS

CN Phenol, 2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-16-3 HCAPLUS

CN Phenol, 2-[[2-[[3-[2-(1H-imidazol-1-yl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-18-5 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-21-0 HCAPLUS

CN Phenol, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-25-4 HCAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-27-6 HCAPLUS


CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-30-1 HCAPLUS
 CN 2,4-Pyrimidinediamine, N2-[3-[(3-pyridinylmethyl)amino]phenyl]-N4-[2-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 604801-34-5 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 604801-60-7 HCAPLUS
 CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-61-8 HCAPLUS
 CN Phenol, 3-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-62-9 HCAPLUS
 CN Phenol, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-63-0 HCAPLUS
 CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 604801-68-5 HCAPLUS
 CN Phenol, 3-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-69-6 HCAPLUS
 CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 604801-71-0 HCAPLUS
 CN Phenol, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-72-1 HCAPLUS

CN Phenol, 3-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-75-4 HCAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 604801-77-6 HCAPLUS

CN Phenol, 3-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-96-9 HCAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-methoxy-3-[2-(1-methyl-4-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604801-97-0 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI) (CA INDEX NAME)




RN 604802-00-8 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 604802-01-9 HCAPLUS
 CN Phenol, 5-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-4-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 604802-02-0 HCAPLUS
 CN Phenol, 5-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)




RN 604802-03-1 HCAPLUS
 CN Phenol, 2-methoxy-5-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amin

o]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-04-2 HCAPLUS

CN Phenol, 2-methoxy-5-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-05-3 HCAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-07-5 HCAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-08-6 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)-(9CI) (CA INDEX NAME)




RN 604802-09-7 HCAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(1-piperidinyloxy)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)





RN 604802-10-0 HCAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-3-methyl-(9CI) (CA INDEX NAME)




RN 604802-11-1 HCAPLUS

CN Benzenesulfonamide, 2-methoxy-3-methyl-6-[[2-[[3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)




RN 604802-12-2 HCAPLUS

CN Benzenesulfonamide, 2-(1-methylethoxy)-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)




RN 604802-14-4 HCAPLUS

CN Benzenesulfonamide, 6-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,3-dimethyl-(9CI) (CA INDEX NAME)




RN 604802-15-5 HCAPLUS


CN Benzenesulfonamide, 5-methoxy-2-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)




RN 604802-17-7 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI)
 (CA INDEX NAME)



RN 604802-18-8 HCAPLUS
 CN Benzenesulfonamide, 5-methoxy-2-[[2-[[3-[2-(1-methylpiperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-19-9 HCAPLUS
 CN Benzenesulfonamide, 5-methoxy-2-[[2-[[4-methoxy-3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-22-4 HCAPLUS

CN Benzenesulfonamide, 2,3-dimethoxy-6-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-24-6 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-cyclopentyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI) (CA INDEX NAME)




RN 604802-26-8 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-28-0 HCAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-[4-(phenylmethyl)-1-piperazinyl]ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-29-1 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[3-(2-cyclopentylethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 604802-30-4 HCAPLUS
 CN Benzenesulfonamide, 5-bromo-2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 604802-33-7 HCAPLUS
 CN Phenol, 4-chloro-2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-34-8 HCAPLUS
 CN Phenol, 4-chloro-2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-4-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-35-9 HCAPLUS

CN Phenol, 4-chloro-2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-36-0 HCAPLUS

CN Phenol, 4-chloro-2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-37-1 HCAPLUS

CN Phenol, 4-chloro-2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-38-2 HCAPLUS

CN Phenol, 4-chloro-2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-49-5 HCAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)-(9CI) (CA INDEX NAME)




RN 604802-50-8 HCAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 604802-52-0 HCAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[3-(1-piperidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI) (CA INDEX NAME)




RN 604802-53-1 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI)
 (CA INDEX NAME)



RN 604802-58-6 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI) (CA INDEX NAME)



RN 604802-60-0 HCAPLUS
 CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:689661 HCAPLUS


DOCUMENT NUMBER: 139:374254

TITLE: Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase


AUTHOR(S): Rachid, Zakaria; Katsoulas, Athanasia; Brahim, Fouad; Jean-Claude, Bertrand Jacques

CORPORATE SOURCE: Department of Medicine, Division of Medical Oncology, Cancer Drug Research Laboratory, McGill


University/Royal Victoria Hospital, Montreal, QC, 687,
Can.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),
13(19), 3297-3300
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:374254
AB The synthesis and abl tyrosine kinase inhibitory activities of
alkyltriazenes conjugated to phenylaminopyrimidines are described.
Significant abl inhibitory activities were observed only when a benzamido
spacer was inserted between the 1,2,3-triazene chain and the
2-phenylaminopyridopyrimidine moiety.
IT **623901-00-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of pyrimidinopyridine-triazene conjugates targeted to abl
tyrosine kinase and cytotoxicity structure activity)
RN 623901-00-8 HCAPLUS
CN Benzamide, 4-amino-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



IT **623901-02-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(synthesis of pyrimidinopyridine-triazene conjugates targeted to abl
tyrosine kinase and cytotoxicity structure activity)
RN 623901-02-0 HCAPLUS
CN Benzamide, 4-[3-(2-methoxyethyl)-1-triazenyl]-N-[3-[[4-(3-pyridinyl)-2-
pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT **623900-98-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of pyrimidinopyridine-triazene conjugates targeted to abl
tyrosine kinase and cytotoxicity structure activity)
RN 623900-98-1 HCAPLUS
CN Benzamide, 4-nitro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:610204 HCAPLUS

DOCUMENT NUMBER: 139:164801

TITLE: Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction

INVENTOR(S): Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan; Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 648 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063794	A2	20030807	WO 2003-US3022	20030131
WO 2003063794	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004029902	A1	20040212	US 2003-355543	20030131
PRIORITY APPLN. INFO.:			US 2002-353267P	P 20020201
			US 2002-353333P	P 20020201
			US 2002-399673P	P 20020729
			US 2002-434277P	P 20021217

OTHER SOURCE(S): MARPAT 139:164801

AB Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with

4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. The treatment and prevention of allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, inflammation, and scarring are targeted uses (no data).


IT 575481-22-0P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)

RN 575481-22-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 575477-87-1P 575481-27-5P 575481-30-0P


575481-35-5P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)


RN 575477-87-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-N2-[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 575481-27-5 HCAPLUS


CN Phenol, 4-[[5-fluoro-2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,6-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 575481-30-0 HCAPLUS


CN Phenol, 2-chloro-4-[[5-fluoro-2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 575481-35-5 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 575477-45-1P 575479-77-5P 575480-07-8P
575480-17-0P 575480-25-0P 575480-31-8P
575480-54-5P 575480-59-0P 575481-26-4P
575482-64-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)

RN 575477-45-1 HCAPLUS


CN 2-Furancarboxylic acid, 4-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]methyl]-, methyl ester

(9CI) (CA INDEX NAME)




RN 575479-77-5 HCAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 575480-07-8 HCAPLUS

CN Piperazine, 1-[[3-[[4-[(3-chloro-4-hydroxy-5-methylphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-17-0 HCAPLUS

CN Piperazine, 1-[[3-[[5-fluoro-4-[(4-methoxy-3,5-dimethylphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-25-0 HCAPLUS

CN Piperazine, 1-[[3-[[3-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-31-8 HCAPLUS

CN Morpholine, 4-[[3-[[5-fluoro-4-[(4-hydroxy-3,5-dimethylphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-54-5 HCAPLUS

CN Morpholine, 4-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-59-0 HCAPLUS

CN Piperazine, 1-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 575481-26-4 HCAPLUS


CN Phenol, 4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 575482-64-3 HCAPLUS

CN 2H-Isoindole-2-acetic acid, α -[3-[[3-[[4-[(3-aminophenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]-3-oxopropyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

NH₂


IT 575475-04-6P 575476-77-6P 575476-79-8P
 575477-88-2P 575479-75-3P 575479-79-7P
 575479-80-0P 575480-61-4P 575480-70-5P
 575480-71-6P 575480-72-7P 575480-94-3P
 575480-97-6P 575480-99-8P 575481-02-6P
 575481-03-7P 575481-08-2P 575481-09-3P
 575481-10-6P 575481-13-9P 575481-19-5P
 575481-31-1P 575481-33-3P 575481-39-9P
 575481-42-4P 575481-43-5P 575481-98-0P
 575481-99-1P 575482-02-9P 575482-62-1P
 575482-63-2P 575483-06-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)


RN 575475-04-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N,N'-bis[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 575476-77-6 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N,N'-bis[3-[[2-(phenylmethoxy)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 575476-79-8 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-aminophenyl)-5-fluoro-N2-[3-[[2-(phenylmethoxy)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 575477-88-2 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-[4-(1-methylethoxy)phenyl]-N2-[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 575479-75-3 HCAPLUS


CN Phenol, 3-[[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 575479-79-7 HCAPLUS
 CN 2-Benzofurancarboxylic acid, 5-[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 575479-80-0 HCAPLUS
 CN 2-Benzofurancarboxamide, 5-[[5-fluoro-2-[[3-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 575480-61-4 HCAPLUS
 CN Acetamide, N-cyclohexyl-2-[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 575480-70-5 HCAPLUS
 CN Morpholine, 4-[[3-[[4-[(3-chloro-4-hydroxy-5-methylphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)




RN 575480-71-6 HCAPLUS
 CN Morpholine, 4-[[3-[[4-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 575480-72-7 HCAPLUS


CN Piperazine, 1-[[3-[[4-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl] - (9CI) (CA INDEX NAME)




RN 575480-94-3 HCAPLUS

CN Acetamide, 2-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]-N-[2-(4-morpholinyl)ethyl] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575480-97-6 HCAPLUS


CN Morpholine, 4-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]acetyl] - (9CI) (CA INDEX NAME)



RN 575480-99-8 HCAPLUS
 CN Piperazine, 1-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 575481-02-6 HCAPLUS
 CN Piperazine, 1-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 575481-03-7 HCAPLUS
 CN Acetamide, 2-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]amino]-N-[2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 575481-08-2 HCAPLUS
 CN Morpholine, 4-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 575481-09-3 HCAPLUS

CN Piperazine, 1-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 575481-10-6 HCAPLUS


CN Piperazine, 1-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 575481-13-9 HCAPLUS

CN Acetamide, 2-[[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575481-19-5 HCAPLUS

CN 2-Furancarboxamide, 4-[[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 575481-31-1 HCAPLUS
CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(4-methoxy-3,5-dimethylphenyl)-N2-[3-[2-(1-piperazinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 575481-33-3 HCAPLUS
CN Piperazine, 1-[[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 575481-39-9 HCAPLUS
CN Piperazine, 1-[[3-[[5-fluoro-4-[(3-hydroxyphenyl)amino]-2-pyrimidinyl]amino]phenoxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 575481-42-4 HCAPLUS


CN Phenol, 4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,6-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 575481-43-5 HCAPLUS


CN Phenol, 2-chloro-4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 575481-98-0 HCAPLUS

CN Acetamide, 2-[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]-N-[2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


--CH₂--OH

RN 575481-99-1 HCAPLUS
CN Morpholine, 4-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575482-02-9 HCAPLUS
CN Acetamide, 2-[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575482-62-1 HCAPLUS

CN Piperazine, 1-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 575482-63-2 HCAPLUS

CN Piperazine, 1-[[[3-[[5-fluoro-4-[[3-[(2-hydroxyethyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenyl]amino]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 575483-06-6 HCAPLUS

CN Acetamide, N-cyclopropyl-2-[3-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




IT 575481-44-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)

RN 575481-44-6 HCAPLUS

CN Phenol, 2-chloro-4-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (9CI) (CA INDEX NAME)



L18 ANSWER 11 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:261683 HCAPLUS

DOCUMENT NUMBER: 138:271699

TITLE: Preparation of 2-phenylamino-4-(5-pyrazolylamino)pyrimidines as kinase inhibitors, in particular, as SRC kinase inhibitors

INVENTOR(S): Dixon, Julie; Dumas, Jacques; Brennan, Catherine; Hatoum-Mokdad, Holia; Lee, Wendy; Sibley, Robert; Bear, Brian; Chandler, Brent; Miranda, Karl; Chen, Gang; Chen, Zhi; Brittelli, David; Clark, Roger B.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026666	A1	20030403	WO 2002-US30984	20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-325110P P 20010926

OTHER SOURCE(S): MARPAT 138:271699

AB The invention provides novel substituted 2,4-diaminopyrimidine compds. (shown as I; variables defined below; e.g. N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine; L is a linker = -O-(CH₂)₁₋₄-, S(O)₀₋₂-(CH₂)₁₋₄-, -N(R₁)-(CH₂)₁₋₄-, -(CH₂)₁₋₄-O-(CH₂)₁₋₄-, -N(R₁)-C(O)-(CH₂)₁₋₄-, and diradicals of cyclopentanol, cyclohexanol, pyrrolidine and piperidine with the heteroatom as one radical center; G = NR₅R₆; alternatively, L = -OCH[(CH₂)₁₋₃-] [(CH₂)₂₋₃-] or N[(CH₂)₂-] [(CH₂)₂-] and G = NR₁; other definitions are given in the claims) and pharmaceutical compns. thereof.

The invention also provides methods of use of I and pharmaceutical compns. thereof as inhibitors of SRC kinase enzymes. Exemplary diseases that can be treated by the compds. of the invention include cell proliferative diseases, such as cancer and non-malignant cell proliferative diseases, osteoporosis and inflammatory diseases. Also provided are methods for preparing the compds. of the present invention. About 100 examples of I were found to inhibit SRC kinase with IC50 values less than 150 nM. Many general methods of preparation of I and several specific examples are included; characterization data are included for 260 examples of I. For example, N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(diethylamino)ethoxy]phenyl]-2,4-pyrimidinediamine was prepared in 70% yield from N-(3-tert-butyl-1H-pyrazol-5-yl)-2-chloro-4-pyrimidinamine and N-[2-(3-aminophenoxy)ethyl]-N,N-diethylamine; procedures for preparing the reactants are also included.

IT **503566-16-3P**, N2-[4-Methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-17-4P**, 5-Fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-18-5P**, N4-(3-tert-Pentyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-19-6P**, N2-[4-Methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-20-9P**, 5-Fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-21-0P**, N2-[3-[2-(4-Methyl-1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-22-1P**, N2-[3-[(1-Methyl-3-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-27-6P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-28-7P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-29-8P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-30-1P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-31-2P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-32-3P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503566-33-4P**, N2-[3-[2-((3R,5S)-3,5-Dimethyl-1-piperidinyl)ethoxy]phenyl]-N4-[3-(1-ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-2,4-pyrimidinediamine **503566-35-6P**, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-36-7P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-37-8P**, N4-(3-Cyclopropyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine **503566-39-0P**, N2-[3-[2-(Benzylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-40-3P**, N2-[3-[2-(Benzylamino)ethoxy]phenyl]-5-bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-41-4P**, N2-[3-[2-[Benzyl(2-methoxyethyl)amino]ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine **503566-44-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-45-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine **503566-46-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(4-methoxyphenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine

503566-47-0P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-
[(4-methoxyphenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine
503566-48-1P, N2-[3-[2-(Benzothiazol-6-ylamino)ethoxy]phenyl]-N4-
(3-tert-butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine 503566-49-2P
, N2-[3-[2-(1H-Benzimidazol-2-ylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-
pyrazol-5-yl)-2,4-pyrimidinediamine 503566-50-5P,
N2-[3-[2-(1H-Benzimidazol-2-ylamino)ethoxy]phenyl]-5-fluoro-N4-(3-tert-
butyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine 503566-51-6P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-indazol-5-
ylamino)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-52-7P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-indazol-5-
ylamino)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-53-8P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-methyl-1-
piperazinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-55-0P,
5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-methyl-1-
piperazinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-56-1P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(2R)-2-(methoxymethyl)-1-
pyrrolidinyl]ethoxy]phenyl]-2,4-pyrimidinediamine 503566-57-2P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-
piperidinyl]ethoxy]phenyl]-2,4-pyrimidinediamine 503566-58-3P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-
piperidinyl]ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine
503566-59-4P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-
(cyclohexylamino)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-60-7P
, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-
5-fluoro-2,4-pyrimidinediamine 503566-61-8P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(2,2,6,6-tetramethyl-1-
piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-64-1P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(2R,6S)-2,6-dimethyl-1-
piperidinyl]ethoxy]phenyl]-2,4-pyrimidinediamine 503566-65-2P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(2R,6S)-2,6-dimethyl-1-
piperidinyl]ethoxy]phenyl]-5-fluoro-2,4-pyrimidinediamine
503566-67-4P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-methyl-
1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-68-5P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(4-methyl-1-
piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-69-6P,
N2-[3-[2-(4-Benzyl-1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-butyl-1H-
pyrazol-5-yl)-2,4-pyrimidinediamine 503566-70-9P,
N2-[3-[2-(4-Benzyl-1-piperidinyl)ethoxy]phenyl]-N4-(3-tert-butyl-1H-
pyrazol-5-yl)-5-fluoro-2,4-pyrimidinediamine 503566-71-0P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(4-
morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-75-4P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(4-
morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-77-6P,
N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-chloro-N2-[3-[2-(4-
morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-79-8P,
5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-
morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503566-80-1P,
N2-[3-[2-(Benzylamino)ethoxy]phenyl]-N4-(3-tert-butyl-1H-pyrazol-5-yl)-5-
fluoro-2,4-pyrimidinediamine 503566-84-5P, N4-(3-tert-Butyl-1H-
pyrazol-5-yl)-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine
503566-85-6P, 1-[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-
pyrimidinyl]amino]phenoxy]ethyl]-N,N-diethyl-3-piperidinecarboxamide
503566-97-0P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-
methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine
503566-98-1P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-
[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine
503566-99-2P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-
methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine


503567-00-8P, N2-[4-Methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine 503567-01-9P, 5-Fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N4-(3-tert-pentyl-1H-pyrazol-5-yl)-2,4-pyrimidinediamine 503567-02-0P, N-[5-Fluoro-2-[(3-[(1-methyl-3-piperidinyl)methoxy]phenyl)amino]-4-pyrimidinyl]-N-(3-tert-pentyl-1H-pyrazol-5-yl)amine 503567-03-1P, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine 503567-04-2P, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine 503567-05-3P, N4-[3-(1-Ethyl-1-methylpropyl)-1H-pyrazol-5-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine 503567-06-4P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine 503567-07-5P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine 503567-08-6P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]-2,4-pyrimidinediamine 503567-18-8P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(cyclohexylmethyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine 503567-20-2P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[(4-methylcyclohexyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine 503567-21-3P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(cyclopentylamino)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-26-8P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]-2,4-pyrimidinediamine 503567-27-9P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]-2,4-pyrimidinediamine 503567-31-5P, 5-Bromo-N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine 503567-32-6P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine 503567-37-1P, 3-[[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]amino]benzoic acid 503567-38-2P, 3-[[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]amino]benzoic acid 503567-43-9P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-47-3P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-48-4P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-49-5P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-51-9P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-[methyl(phenyl)amino]ethoxy]phenyl]-2,4-pyrimidinediamine 503567-52-0P, 1-[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-2-pyrrolidinone 503567-53-1P, 1-[2-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]-2-pyrrolidinone 503567-54-2P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-55-3P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-59-7P, 1-[2-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]-2-pyrrolidinone 503567-69-9P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine 503567-70-2P, 1-[2-[[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]benzyl]oxy]ethyl]-2-pyrrolidinone 503567-71-3P

, 1-[2-[[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]benzyl]oxy]ethyl]-2-pyrrolidinone **503567-72-4P**
 , 1-[2-[[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methoxybenzyl]oxy]ethyl]-2-pyrrolidinone **503567-73-5P**,
 1-[2-[[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxybenzyl]oxy]ethyl]-2-pyrrolidinone
503567-87-1P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine
503567-88-2P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine
503567-89-3P, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,4-pyrimidinediamine **503567-90-6P**
 , N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)acetamide **503567-91-7P**
 , N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-(1-piperidinyl)acetamide **503567-92-8P**
 , N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(1-piperidinyl)acetamide **503567-95-1P**
 , N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-(1-pyrrolidinyl)acetamide **503567-96-2P**
 , N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(1-pyrrolidinyl)acetamide **503567-97-3P**
 , N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)acetamide **503567-98-4P**
 , N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503567-99-5P**
 , N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503568-03-4P**
 , 1-[2-[5-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]-2-pyrrolidinone **503568-04-5P**,
 N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-pyrimidinediamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)

RN 503566-16-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-17-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-18-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[3-(2-(1-piperidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-19-6 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-(2-(1-piperidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-20-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[5-fluoro-4-methoxy-3-(2-(1-piperidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-21-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-22-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-3-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-27-6 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-28-7 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-29-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-30-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-31-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-32-3 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-33-4 HCAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-[2-[(3S,5R)-3,5-dimethyl-1-piperidinyloxy]phenyl]-N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-35-6 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-3-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-36-7 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[3-[(1-methyl-


3-piperidinyl)methoxy]phenyl] - (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-37-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl] - (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-39-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(phenylmethyl)amino]ethoxy]phenyl] - (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503566-40-3 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(phenylmethyl)amino]ethoxy]phenyl] - (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-41-4 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-
 [(2-methoxyethyl)(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX
 NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-44-7 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-
 [(4-fluorophenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-45-8 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-
 N2-[3-[2-[(4-fluorophenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503566-46-9 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-
 [(4-methoxyphenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-47-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-[(4-methoxyphenyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-48-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-[2-(6-benzothiazolylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-49-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-[2-(1H-benzimidazol-2-ylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-50-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N2-[3-[2-(1H-benzimidazol-2-ylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-51-6 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-indazol-5-ylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-52-7 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1H-indazol-5-ylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-53-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-55-0 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-56-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-57-2 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-58-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(3R,5S)-3,5-dimethyl-1-piperidinyl]ethoxy]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-59-4 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-60-7 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-[3-[2-(cyclohexylamino)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-61-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-64-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-65-2 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethoxy]phenyl]-5-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503566-67-4 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-68-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-69-6 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-70-9 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503566-71-0 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-75-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-77-6 HCAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-79-8 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-80-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-


N2-[3-[2-[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-84-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-85-6 HCAPLUS


CN 3-Piperidinecarboxamide, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-97-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-98-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503566-99-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-00-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-01-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-02-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-03-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[(1-methyl-3-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-04-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1-methyl-3-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-05-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-ethyl-1-methylpropyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-06-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503567-07-5 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-08-6 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-
 N2-[3-[(1-methyl-2-piperidiny)methoxy]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-18-8 HCAPLUS
 CN 2,4-Pyrimidinediamine, N2-[3-[2-[(cyclohexylmethyl)amino]ethoxy]phenyl]-N4-
 [5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-20-2 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-
 [(4-methylcyclohexyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-21-3 HCAPLUS
 CN 2,4-Pyrimidinediamine, N2-[3-[2-(cyclopentylamino)ethoxy]phenyl]-N4-[5-
 (1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503567-26-8 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503567-27-9 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-[[2-(4-morpholinyl)ethyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-31-5 HCAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-32-6 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-37-1 HCAPLUS


CN Benzoic acid, 3-[[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-38-2 HCAPLUS


CN Benzoic acid, 3-[[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-43-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-47-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-48-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-49-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-51-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(methylphenylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-52-0 HCAPLUS


CN 2-Pyrrolidinone, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-53-1 HCAPLUS


CN 2-Pyrrolidinone, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-54-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-55-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-59-7 HCAPLUS


CN 2-Pyrrolidinone, 1-[2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-69-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503567-70-2 HCAPLUS

CN 2-Pyrrolidinone, 1-[2-[[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-71-3 HCAPLUS
 CN 2-Pyrrolidinone, 1-[2-[[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-72-4 HCAPLUS
 CN 2-Pyrrolidinone, 1-[2-[[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methoxyphenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-73-5 HCAPLUS
 CN 2-Pyrrolidinone, 1-[2-[[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]-2-methoxyphenyl]methoxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 503567-87-1 HCAPLUS
 CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-88-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-89-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-90-6 HCAPLUS


CN 4-Morpholineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-91-7 HCAPLUS


CN 1-Piperidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-92-8 HCAPLUS


CN 1-Piperidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-95-1 HCAPLUS


CN 1-Pyrrolidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-96-2 HCAPLUS


CN 1-Pyrrolidineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-97-3 HCAPLUS


CN 4-Morpholineacetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-98-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(1-piperidiny)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503567-99-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[[2-(1-piperidiny)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503568-03-4 HCAPLUS


CN 2-Pyrrolidinone, 1-[2-[5-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-2-methoxyphenoxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503568-04-5 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:261682 HCAPLUS

DOCUMENT NUMBER: 138:271698

TITLE: Preparation of 2-phenylamino-4-(5-pyrazolylamino)pyrimidines as kinase inhibitors, in particular, SRC kinase inhibitors for treating cancers
 INVENTOR(S): Dixon, Julie; Scott, William J.; Dumas, Jacques; Brennan, Catherine; Hatoum-Mokdad, Holia

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026665	A1	20030403	WO 2002-US30980	20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-325110P	P 20010926

OTHER SOURCE(S): MARPAT 138:271698

AB This application discloses and claims 5-substituted-2,4-diaminopyrimidines, (shown as I; e.g. 3-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-1,2-propanediol; R1 = C1-6 alkyl, C3-6 cycloalkyl, adamantyl, Ph, or a 5-membered heteroarom. containing a single heteroatom = N, O, and S; R2 = H, F, Cl, or C1-4 alkyl; R3 = H, halogen, O(C1-4 alkyl), or C1-6alkyl; R4 = halogen, NO2, C1-6 alkyl, NR5R6, O(CH2)1-4CO2R7, O(CH2)1-4C(O)NR5R6, N(R5)C(O)CH2OR8, OC(O)R9, C(O)NR5R6, CO2R7, CN, or O(C1-4alkyl) optionally substituted by OH or phenoxy; addnl. definitions are in the claims), pharmaceutical compns. containing them, a method of making them, and methods of using them for treatment of cancers. Eleven examples of I were found to inhibit SRC kinase with IC50 values less than 500 nM. Many general methods of preparation of I and several specific examples are included; characterization data are included for 35 examples of I. For example, 3-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenoxy]-1,2-propanediol was prepared from N-(3-tert-butyl-1H-pyrazol-5-yl)-2-chloro-4-pyrimidinamine and 3-(3-aminophenoxy)-1,2-propanediol in 21% yield; prepns. of the reactants are also included.

IT **503538-11-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-(2-phenoxyethoxy)phenyl]-2,4-pyrimidinediamine **503538-24-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-2,4-pyrimidinediamine **503538-27-0P**, 2-(Benzyloxy)-N-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]acetamide **503538-28-1P**,

N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]-2-phenoxyacetamide **503538-29-2P**, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]amino]phenyl]benzamide

503538-30-5P, 2-(Benzyloxy)-N-[3-[[4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]acetamide


503538-31-6P, N-[3-[[4-[(3-tert-Butyl-1H-pyrazol-5-yl)amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-phenoxyacetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors for treating cancers)

RN 503538-11-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(2-phenoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503538-24-7 HCAPLUS


CN Morpholine, 4-[[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]acetyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503538-27-0 HCAPLUS

CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503538-28-1 HCAPLUS

CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-


pyrimidinyl]amino]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503538-29-2 HCAPLUS


CN Benzamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503538-30-5 HCAPLUS


CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503538-31-6 HCAPLUS

CN Acetamide, N-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-5-fluoro-2-pyrimidinyl]amino]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:261681 HCAPLUS
 DOCUMENT NUMBER: 138:271697
 TITLE: Preparation of 2-phenylamino-4-(5-pyrazolylamino)pyrimidines as kinase inhibitors, in particular, SRC kinase inhibitors
 INVENTOR(S): Dixon, Julie; Dumas, Jacques; Brennan, Catherine; Hatoum-Mokdad, Holia; Lee, Wendy; Sibley, Robert; Bear, Brian
 PATENT ASSIGNEE(S): Bayer Corporation, USA
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026664	A1	20030403	WO 2002-US30836	20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-325110P	P 20010926
OTHER SOURCE(S):		MARPAT 138:271697		

AB The invention provides novel substituted 2,4-diaminopyrimidine compds. (shown as I; variables defined below; e.g. N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine), pharmaceutical compns. containing them, a method of making them, and methods of using them for treatment of cell proliferative diseases such as cancer, and non-malignant cell proliferative diseases, as well as osteoporosis and inflammatory diseases. Fifty examples of I were found to inhibit SRC kinase with IC50 values less than 500 nM. Many general methods of preparation of I and several specific examples are included; characterization data are included for 101 examples of I. For example, N4-(3-tert-butyl-1H-pyrazol-5-yl)-N2-[4-(3-pyridinylmethyl)phenyl]-2,4-pyrimidinediamine was prepared in 4 steps starting with 3-benzylpyridine and involving intermediates 3-(4-nitrobenzyl)pyridine, 3-(4-aminobenzyl)pyridine, and N-(3-tert-butyl-1H-pyrazol-5-yl)-2-chloro-4-pyrimidinamine (from 2,4-dichloropyrimidine and 5-amino-3-tert-butylpyrazole). For I: Y1 = H or C1-4 alkyl. Y2 = CF3, C1-6 alkyl; C3-6 cycloalkyl; or Ph optionally substituted with halogen, C1-4 alkyl, or C1-4 alkoxy; n = 0-2; X = halogen or C1-4 alkyl; p = 0-2; Z = halogen, C1-4 alkyl, or C1-4 alkoxy; and q = 0-2. L = a chemical bond, C1-4 alkylene, O, O(C1-4 alkylene), CH(C1-6 alkoxy), S(O)0-2, S(O)0-2(C1-4 alkylene), (C1-4 alkylene)S(O)0-2, NH(C1-4 alkylene), C(O), or C(O)(C1-4 alkylene). D = pyridinyl, imidazolyl, thiazolyl, pyrrolyl, thienyl, pyrazolyl, furyl, thiadiazolyl, oxazolyl, or benzimidazolyl. The pyridinyl and benzimidazolyl groups D each may be optionally substituted by up to three substituents = C1-4 alkyl, OH, C1-4

alkoxy, CN, NR1R2, C(O)NR1R2, halogen, and CO2(C1-6 alkyl), in which R1 and R2 = H, C1-4 alkyl, and C3-6 cycloalkyl. Alternatively, R1 and R2 may be joined to form a 5-6 membered saturated heterocycle -NQ in which Q = O, S(O)O-2, N-Y1, or C(Y1)2.

IT **503473-50-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(2-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-51-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(2-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-52-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(3-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-53-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(3-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-54-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(4-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-55-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(4-pyridinylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-56-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-57-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-58-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1H-imidazol-2-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-59-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[(1H-imidazol-2-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-60-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-61-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-62-9P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(3-furylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-63-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(3-thienylmethyl)amino]phenyl]-2,4-pyrimidinediamine **503473-64-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1-methyl-1H-pyrrol-2-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-65-2P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[(1,3-thiazol-2-yl)methyl]amino]phenyl]-2,4-pyrimidinediamine **503473-66-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-67-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine **503473-86-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-yl)ethyl]amino]phenyl]-2,4-pyrimidinediamine **503473-94-7P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503473-95-8P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-chloro-3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503473-96-9P**, 1-[2-[3-[[4-[(5-tert-Butyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-1H-benzimidazole-5-carboxylic acid **503474-05-3P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[3-(1H-imidazol-1-yl)propyl]phenyl]-2,4-pyrimidinediamine **503474-06-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[3-(1H-imidazol-1-yl)propyl]phenyl]-2,4-pyrimidinediamine **503474-07-5P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503474-08-6P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503474-10-0P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503474-11-1P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-5-fluoro-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]-2,4-pyrimidinediamine **503474-22-4P**, N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[2-chloro-5-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-2,4-pyrimidinediamine **503474-48-4P**,


N4-(3-tert-Butyl-1H-pyrazol-5-yl)-N2-[4-[2-(4-pyridinyl)ethyl]phenyl]-2,4-pyrimidinediamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylamino pyrazolylamino pyrimidines as SRC kinase inhibitors)

RN 503473-50-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(2-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-51-6 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(2-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-52-7 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-53-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-54-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(4-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-55-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(4-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-56-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[[2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-57-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-methyl-1H-imidazol-4-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-58-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(1H-imidazol-2-ylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-59-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[(1H-imidazol-2-ylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-60-7 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-61-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(2-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-62-9 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(3-furanylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-63-0 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(3-thienylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-64-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[1-methyl-1H-pyrrol-2-yl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-65-2 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[(2-thiazolylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-66-3 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-67-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(3-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-86-7 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[[2-(1H-imidazol-1-yl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-94-7 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-95-8 HCAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-chloro-3-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503473-96-9 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-[2-[3-[[4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-05-3 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[3-(1H-imidazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-06-4 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-


N2-[3-[3-(1H-imidazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-07-5 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-08-6 HCAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-10-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-11-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-5-fluoro-


N2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-22-4 HCAPLUS


CN 2,4-Pyrimidinediamine, N2-[2-chloro-5-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 503474-48-4 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(4-pyridinyl)ethyl]phenyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:42089 HCAPLUS

DOCUMENT NUMBER: 138:100912

TITLE: Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis

INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre

PATENT ASSIGNEE(S): AB Science, Fr.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004006	A2	20030116	WO 2002-IB3295	20020628
WO 2003004006	A3	20030530		
WO 2003004006	C1	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1401412	A2	20040331	EP 2002-755510	20020628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530730	T2	20041007	JP 2003-510017	20020628
PRIORITY APPLN. INFO.:			US 2001-301407P	P 20010629
			WO 2002-IB3295	W 20020628

OTHER SOURCE(S): MARPAT 138:100912


AB The present invention relates to a method for inhibiting tumor angiogenesis comprising administering a c-kit inhibitor to a human in need of such treatment, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

IT **481054-84-6D**, derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potent, selective, and non-toxic c-kit inhibitors for treating tumor angiogenesis)

RN 481054-84-6 HCAPLUS

CN Benzamide, N-[3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 15 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:22677 HCAPLUS

DOCUMENT NUMBER: 138:95589

TITLE: Use of tyrosine kinase inhibitors for treating autoimmune diseases

INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre

PATENT ASSIGNEE(S): AB Science, Fr.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002109	A2	20030109	WO 2002-IB3302	20020628
WO 2003002109	C1	20030501		
WO 2003002109	A3	20040527		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-301405P	P	20010629
US 2001-301409P	P	20010629
US 2001-301410P	P	20010629
US 2001-341273P	P	20011220

OTHER SOURCE(S):

MARPAT 138:95589

AB The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthrititis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft- vs. host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compds. can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.


IT 481054-84-6D, derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of tyrosine kinase inhibitors for treating autoimmune diseases)

RN 481054-84-6 HCAPLUS

CN Benzamide, N-[3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 16 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:22676 HCAPLUS

DOCUMENT NUMBER: 138:83365

TITLE: Use of tyrosine kinase inhibitors for treating inflammatory diseases

INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre

PATENT ASSIGNEE(S): AB Science, Fr.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002108	A2	20030109	WO 2002-IB3301	20020628
WO 2003002108	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1401415	A2	20040331	EP 2002-758693	20020628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-301410P	P 20010629
			WO 2002-IB3301	W 20020628
OTHER SOURCE(S): MARPAT 138:83365				
AB	The present invention relates to a method for treating inflammatory diseases such as rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.			
IT	481054-84-6D , derivs. RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tyrosine kinase inhibitors for treating inflammatory diseases)			
RN	481054-84-6 HCAPLUS			
CN	Benzamide, N-[3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)			



L18 ANSWER 17 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:22675 HCAPLUS
 DOCUMENT NUMBER: 138:95588
 TITLE: Use of tyrosine kinase inhibitors for treating multiple sclerosis
 INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre
 PATENT ASSIGNEE(S): AB Science, Fr.
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 13
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002107	A2	20030109	WO 2002-IB3298	20020628
WO 2003002107	A3	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1401414	A2	20040331	EP 2002-758692	20020628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-301409P	P 20010629
			WO 2002-IB3298	W 20020628
OTHER SOURCE(S): MARPAT 138:95588				
AB The present invention relates to a method for treating Multiple Sclerosis (MS) comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.				
IT 481054-84-6D , derivs.				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(tyrosine kinase inhibitors for treating multiple sclerosis)				
RN 481054-84-6 HCAPLUS				
CN Benzamide, N-[3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)				



L18 ANSWER 18 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:22674 HCAPLUS

DOCUMENT NUMBER: 138:83364

TITLE: Use of tyrosine kinase inhibitions for treating allergic diseases

INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre

PATENT ASSIGNEE(S): AB Science, Fr.

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002106	A2	20030109	WO 2002-IB3297	20020628

WO 2003002106 A3 20030530
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1401413 A2 20040331 EP 2002-755512 20020628
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-301408P P 20010629
 WO 2002-IB3297 W 20020628

OTHER SOURCE(S): MARPAT 138:83364


AB The present invention relates to a method for treating allergic diseases such as asthma, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

IT 481054-84-6D, derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tyrosine kinase inhibitions for treating allergic diseases)

RN 481054-84-6 HCAPLUS

CN Benzamide, N-[3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 19 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:22673 HCAPLUS

DOCUMENT NUMBER: 138:95587

TITLE: Use of tyrosine kinase inhibitors for treating bone loss

INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre

PATENT ASSIGNEE(S): AB Science, Fr.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002105	A2	20030109	WO 2002-IB3288	20020628
WO 2003002105	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1401411 A2 20040331 EP 2002-755506 20020628
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004530722 T2 20041007 JP 2003-508344 20020628
 PRIORITY APPLN. INFO.: US 2001-301411P P 20010629
 WO 2002-1B3288 W 20020628
 OTHER SOURCE(S): MARPAT 138:95587
 AB The present invention relates to a method for treating bone loss such as
 osteoporosis comprising administering a tyrosine kinase inhibitor to a
 human in need of such treatment, more particularly a non-toxic, selective
 and potent c-kit inhibitor. Preferably, said inhibitor is unable to
 promote death of IL-3 dependent cells cultured in presence of IL-3.
 IT **481054-84-6D**, derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (tyrosine kinase inhibitors for treating bone loss)
 RN 481054-84-6 HCAPLUS
 CN Benzamide, N-[3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 20 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:5781 HCAPLUS
 DOCUMENT NUMBER: 138:73179
 TITLE: Preparation of phenylvinyl-nicotinic acid derivatives
 for therapeutic use glucokinase (GLK) activators
 INVENTOR(S): Hayter, Barry Raymond; Currie, Gordon Stuart;
 Hargreaves, Rodney Brian; Caulkett, Peter William
 Rodney; James, Roger
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000262	A1	20030103	WO 2002-GB2903	20020624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1406620 A1 20040414 EP 2002-743377 20020624

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

SE 2001-2299 A 20010626
 WO 2002-GB2903 W 20020624

OTHER SOURCE(S): MARPAT 138:73179

AB Phenylvinyl-nicotinic acid derivs., such as I [R1 = OH, (CH2)1-4OH, NO2, NH2, haloalkyl, haloalkyloxy, alkyl, alkenyl, alkylamino, etc.; R2 = X-Y; X = linking group, such as O, CO, amino, Z-O-Z, etc; Z = alkylene, alkenylene, etc.; R3 = OH, alkoxy, alkylamino, etc.; m = 0-2; n = 0-4; m + n > 0], as well as other phenylvinyl-heteroaryl derivs., were prepared for pharmaceutical use in the treatment of diseases or conditions mediated through glucokinase (GLK), such as type 2 diabetes. Thus, nicotinic acid derivative II (R3 = OH) was prepared via condensation of Me 6-methylnicotinate with PhO-3-C6H4CHO using AcOH at 120° for 24 h to give the corresponding Me ester II (R3 = OMe) in 49% yield, followed by hydrolysis of the ester using 1M aqueous NaOH in THF to give the desired acid in 76% yield. The prepared compds. were assayed for their effect on GLK activity, and pharmaceutical compds. of the prepared compds. were presented.

IT 479723-36-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylvinyl-nicotinic acid derivs. for therapeutic use glucokinase (GLK) activators)

RN 479723-36-9 HCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(1E)-2-[3,5-bis[(2-chlorophenyl)methoxy]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 21 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:927427 HCAPLUS

DOCUMENT NUMBER: 138:14054

TITLE: Preparation of thiazole compounds as inhibitors of protein kinases

INVENTOR(S): Cochran, John; Nanthakumar, Suganthini; Harrington, Edmund; Wang, Jian

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096905	A1	20021205	WO 2002-US16352	20020523
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003119856	A1	20030626	US 2002-154118	20020523
US 6762179	B2	20040713		
EP 1392684	A1	20040303	EP 2002-737123	20020523
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2001-295158P	P 20010601
			US 2001-295196P	P 20010531
			WO 2002-US16352	W 20020523

OTHER SOURCE(S): MARPAT 138:14054

AB Thiazole compds. [I; wherein R1 = H, (substituted) (C1-C6)alkyl, CN, halogen, NO2, (substituted) (C1-C4)alkylidene; Ar1 = (substituted) 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially saturated, or

aryl ring, 3-7 membered heterocyclic ring, 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring] were prepared For example, (II) was prepared in three steps from 2-acetylthiazole. These compds. are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. For example, compound II showed IC50 ≤ 0.5 μM against Syk mammalian protein kinase.

IT 477769-08-7P 477769-11-2P 477769-13-4P
 477769-14-5P 477769-20-3P 477769-23-6P
 477769-26-9P 477769-29-2P 477769-32-7P
 477769-35-0P 477769-40-7P 477769-43-0P
 477769-46-3P 477769-49-6P 477769-52-1P
 477769-81-6P 477769-84-9P 477769-87-2P
 477769-90-7P 477769-93-0P 477769-96-3P
 477769-99-6P 477770-05-1P 477770-07-3P
 477770-10-8P 477770-13-1P 477770-16-4P
 477770-19-7P 477770-22-2P 477770-23-3P
 477770-24-4P 477770-25-5P 477770-26-6P


477770-27-7P 477770-28-8P 477770-29-9P
 477770-30-2P 477770-32-4P 477770-33-5P
 477770-34-6P 477770-35-7P 477770-36-8P
 477770-37-9P 477770-38-0P 477770-39-1P
 477770-41-5P 477770-42-6P 477770-43-7P
 477770-44-8P 477770-45-9P 477770-46-0P
 477770-50-6P 477770-51-7P 477770-52-8P
 477770-54-0P 477770-55-1P 477770-56-2P
 477770-57-3P 477770-58-4P 477770-59-5P
 477770-60-8P 477770-61-9P 477770-62-0P
 477770-71-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thiazole compds. as inhibitors of protein kinases)


RN 477769-08-7 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,4-dichlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-11-2 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[[4-(methylsulfonyl)phenyl]methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-13-4 HCAPLUS

CN 2-Pyrimidinamine, N-[3-(phenylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-14-5 HCAPLUS

CN 2-Pyrimidinamine, N-[3-(4-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)
 (CA INDEX NAME)




RN 477769-20-3 HCAPLUS


CN 2-Pyrimidinamine, N-[3-[(3-aminophenyl)methoxy]phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)

RN 477769-23-6 HCAPLUS


CN 2-Pyrimidinamine, N-[3-(1,3-benzodioxol-5-ylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477769-26-9 HCAPLUS

CN 2-Pyrimidinamine, N-[3-(2-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)


RN 477769-29-2 HCAPLUS

CN 2-Pyrimidinamine, N-[3-(3-pyridinylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI)
(CA INDEX NAME)

RN 477769-32-7 HCAPLUS


CN 2-Pyrimidinamine, N-[3-(3-pyridinylmethoxy)phenyl]-N-(3-pyridinylmethyl)-4-

(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-35-0 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-pyrrol-1-yl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-40-7 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-nitrophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-43-0 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-aminophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-46-3 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-49-6 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-methoxyphenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-52-1 HCAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477769-81-6 HCAPLUS

CN 2-Pyrimidinamine, N-[3-(cyclohexylmethoxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-84-9 HCAPLUS

CN Benzonitrile, 3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 477769-87-2 HCAPLUS

CN Benzoic acid, 4-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]methyl]-
 , methyl ester (9CI) (CA INDEX NAME)




RN 477769-90-7 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,4-difluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-93-0 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-chlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477769-96-3 HCAPLUS

CN 1,3-Benzenediamine, N-[(2,6-dichlorophenyl)methyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477769-99-6 HCAPLUS

CN 1,3-Benzenediamine, N-[(2,6-difluorophenyl)methyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-05-1 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(3-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 477770-07-3 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(3,5-difluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-10-8 HCAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-13-1 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(4-fluorophenyl)methoxy]phenyl]-4-(2-thiazolyl)-
(9CI) (CA INDEX NAME)


RN 477770-16-4 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2,3-dichlorophenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-19-7 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[(2-methylphenyl)methoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-22-2 HCAPLUS


CN 4-Piperidinemethanol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 477770-23-3 HCAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-24-4 HCAPLUS

CN 1-Piperazineethanol, 4-[3-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 477770-25-5 HCAPLUS

CN 3-Piperidinol, 1-[3-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 477770-26-6 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-morpholinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-27-7 HCAPLUS

CN 2-Pyrimidinamine, 4-(2-thiazolyl)-N-[3-[3-(4-thiomorpholinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 477770-28-8 HCAPLUS


CN 4-Piperidinemethanol, 1-[3-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 477770-29-9 HCAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[3-[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-30-2 HCAPLUS

CN 4-Piperidinol, 1-[3-[[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 477770-32-4 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(3-amino-1-piperidinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-33-5 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[3-(4-ethyl-1-piperazinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-34-6 HCAPLUS


CN 2-Pyrimidinamine, N-[3-[3-(1-piperazinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-35-7 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[3-[4-(4-pyridinylmethyl)-1-piperazinyl]propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-36-8 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[3-(1-pyrrolidinyl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-37-9 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-38-0 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[3-(4-methyl-1H-imidazol-1-yl)propoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-39-1 HCAPLUS
 CN 1,3-Benzenediamine, N-[3-(4-morpholinyl)propyl]-N'-[4-(2-thiazolyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477770-41-5 HCAPLUS

CN 1-Piperidinebutanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 477770-42-6 HCAPLUS


CN 4-Morpholineacetamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

RN 477770-43-7 HCAPLUS

CN 1-Piperazinebutanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


RN 477770-44-8 HCAPLUS

CN 1-Piperidinebutanamide, 4-(hydroxymethyl)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-45-9 HCAPLUS

CN 1H-Pyrrole-1-butanamide, N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-46-0 HCAPLUS

CN 1-Piperazinebutanamide, 4-(2-hydroxyethyl)-N-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 477770-50-6 HCAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, (tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)




RN 477770-51-7 HCAPLUS

CN Carbamic acid, [3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]-, (tetrahydro-2H-pyran-2-yl)methyl ester (9CI) (CA INDEX NAME)




RN 477770-52-8 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-54-0 HCAPLUS


CN 2-Pyrimidinamine, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-55-1 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(2-thiazolyl)-
 (9CI) (CA INDEX NAME)




RN 477770-56-2 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1-piperidiny)ethoxy]phenyl]-4-(2-thiazolyl)-
 (9CI) (CA INDEX NAME)



RN 477770-57-3 HCAPLUS
 CN 4-Piperidinol, 1-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]-
 (9CI) (CA INDEX NAME)




RN 477770-58-4 HCAPLUS
 CN 4-Piperidinemethanol, 1-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 477770-59-5 HCAPLUS
 CN 2-Pyrrolidininemethanol, 1-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477770-60-8 HCAPLUS

CN 1-Piperazineethanol, 4-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 477770-61-9 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1-piperazinyl)ethoxy]phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 477770-62-0 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(3-piperidinyloxy)phenyl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 477770-71-1 HCAPLUS

CN 1-Piperazineethanol, 4-[2-[3-[[4-(2-thiazolyl)-2-pyrimidinyl]amino]phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 22 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:927413 HCAPLUS

DOCUMENT NUMBER: 138:14070

TITLE: CDK inhibiting pyrimidines

INVENTOR(S): Brumby, Thomas; Jautelat, Rolf; Prien, Olaf; Schaefer,
Martina; Siemeister, Gerhard; Luecking, Ulrich; Huwe,
Christoph

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 240 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096888	A1	20021205	WO 2002-EP5669	20020523
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
DE 10127581	A1	20030102	DE 2001-10127581	20010529
DE 10212098	A1	20031023	DE 2002-10212098	20020311
NZ 529654	A	20031219	NZ 2002-529654	20020523
EP 1392662	A1	20040303	EP 2002-738100	20020523
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
BR 2002009774	A	20040601	BR 2002-9774	20020523
US 2004102630	A1	20040527	US 2002-156759	20021107
PRIORITY APPLN. INFO.:			DE 2001-10127581	A 20010529
			DE 2002-10212098	A 20020311
			WO 2002-EP5669	W 20020523

OTHER SOURCE(S): MARPAT 138:14070


AB Pyrimidines I [R = (un)substituted Ph; R1 = H, halogen, (un)substituted alkyl, NO₂, acyl, OCF₃, SCF₃, SO₂CF₃; R2 = (un)substituted alkyl, alkenyl, alkynyl; X = O, (un)substituted NH, cycloalkoxy; XR2 = (un)substituted cycloalkyl, heterocyclic] were prepared as inhibitors of the cyclin-dependent kinase. Thus, 2-chloro-4-propargylaminopyrimidine was treated with 4-F₂CHSC₆H₄NH₂.HCl to give I [X = NH, R = 4-F₂CHSC₆H₄, R1 = Br, R2 = CH₂C.tplbond.CH] which had IC₅₀ for inhibition of CDK2 of 180 nM and for inhibition of MCF7 tumor cell proliferation of 3 μM.

IT 477587-98-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and cyclin-dependent kinase inhibition of arylaminopyrimidines)

RN 477587-98-7 HCAPLUS

CN 2-Pyrimidinamine, 5-bromo-N-[3-(oxiranylmethoxy)phenyl]-4-(2-propynyloxy)-(9CI) (CA INDEX NAME)



IT 477590-13-9P 477590-14-0P 477590-15-1P

477590-16-2P 477590-17-3P 477590-18-4P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and cyclin-dependent kinase inhibition of arylaminopyrimidines)

RN 477590-13-9 HCAPLUS

CN 1-Azetidineethanol, α-[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenoxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-14-0 HCAPLUS

CN 1-Azetidineethanol, α-[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenoxy]methyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-15-1 HCAPLUS

CN 1-Piperazineethanol, α-[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenoxy]methyl]-4-methyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-16-2 HCAPLUS

CN 1-Piperazineethanol, α -[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenoxy]methyl]-4-methyl-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-17-3 HCAPLUS

CN 1-Piperidineethanol, α -[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenoxy]methyl]-4-(phenylmethyl)-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-18-4 HCAPLUS

CN 1-Piperidineethanol, α -[[3-[[5-bromo-4-(2-propynyloxy)-2-pyrimidinyl]amino]phenoxy]methyl]-4-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 23 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:906131 HCAPLUS

DOCUMENT NUMBER: 138:4420

TITLE: Preparation of trisubstituted N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamides as inhibitors of P2X3 and P2X2/P2X3 containing receptors for treating pain, urinary incontinence and bladder overactivity

INVENTOR(S): Lee, Chih-hung; Perner, Richard J.; Larson, Daniel P.; Koenig, John R.; Gomtsyan, Arthur R.; Zheng, Guo Zhu; Didomenico, Stanley; Stewart, Andrew O.; Bayburt, Erol K.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094767	A2	20021128	WO 2002-US15174	20020514
WO 2002094767	A3	20030731		
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2002173665	A1	20021121	US 2001-860254	20010518
US 2003083359	A1	20030501	US 2002-141989	20020510
EP 1392643	A2	20040303	EP 2002-739257	20020514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 2001-860254 A 20010518
US 2002-141989 A 20020510
US 2001-291823P P 20010518
WO 2002-US15174 W 20020514

OTHER SOURCE(S): MARPAT 138:4420

AB Trisubstituted N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamides (shown as I; e.g. 5-[[[3-(4-chlorophenoxy)benzyl]((1S)-1,2,3,4-tetrahydro-1-naphthalenyl)amino]carbonyl]-1,2,4-benzenetricarboxylic acid), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity. In I: A1 and A2 = alkoxycarbonyl, alkylcarbonyloxy, carboxy, hydroxy, hydroxyalkyl, (NRARB)carbonyl, (NRCS(O)2RD)carbonyl, -S(O)2OH and tetrazolyl; or A1 and A2 together with the C atoms to which they are attached form a five membered heterocycle containing a S atom wherein the five membered heterocycle is optionally substituted with 1 or 2 substituents mercapto and oxo. A3 = alkoxycarbonyl, alkylcarbonyloxy, carboxy, hydroxy, hydroxyalkyl, (NRARB)carbonyl, NRCS(O)2RD, -S(O)2OH and tetrazolyl; A4, A5, A6 and A7 = H, alkoxy, alkoxycarbonyl, alkenyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, aryl, carboxy, cyano, haloalkoxy, haloalkyl, halogen, heterocycle, hydroxy, hydroxyalkyl, nitro, -NRERF and (NRERF)carbonyl; A8, A9, A10 and A11 = H, alkoxy, alkoxycarbonyl, alkenyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, aryl, carboxy, haloalkoxy, haloalkyl, halogen, heterocycle, hydroxy, hydroxyalkyl, -NRERF and (NRERF)carbonyl and oxo. RA and RB = H, alkyl and cyano; RC = H and alkyl; RD = alkoxy, alkyl, aryl, arylalkoxy, arylalkyl, haloalkoxy and


haloalkyl; RE and RF = H, alkyl, alkylcarbonyl, formyl, and hydroxyalkyl. L1 = alkenylene, alkylene, alkynylene, $-(CH_2)_mO(CH_2)_n-$, $-(CH_2)_mS(CH_2)_n-$ and $-(CH_2)_pC(O)(CH_2)_q-$ wherein each group is drawn with the left end attached to N and the right end attached to R1; m = 0-10; n = 0-10; R1 = aryl, cycloalkenyl, cycloalkyl and heterocycle; L2 is absent or a covalent bond, alkenylene, alkylene, alkynylene, $-(CH_2)_pO(CH_2)_q-$, $-(CH_2)_pS(CH_2)_q-$, $-(CH_2)_pC(O)(CH_2)_q-$, $-(CH_2)_pC(OH)(CH_2)_q-$ and $-(CH_2)_pCH:NO(CH_2)_q-$ wherein each group is drawn with the left end attached to R1 and the right end attached to R2; p = 0-10; q = 0-10; and R2 is absent or aryl, cycloalkenyl, cycloalkyl and heterocycle. I are antagonists of the P2X3 containing receptor with potencies from 5000 nM to 0.5 nM. Addnl., I are antagonists of the P2X2/3 containing receptors with potencies from 4800 nM to 0.5 nM. I also have antinociceptive effects with potencies from 100 $\mu\text{mol/kg}$ to 15- $\mu\text{mol/kg}$. Although the methods of preparation are not claimed, .apprx.135 example preps. are included.

IT **475207-03-5P**, 5-[[[3-(2-Pyrimidinylloxy)benzyl] (1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of trisubstituted N-(tetrahydronaphthalenyl)benzamides as antagonists of P2X3 and P2X2/P2X3 containing receptors for treating pain, urinary incontinence and bladder overactivity)

RN 475207-03-5 HCAPLUS

CN 1,2,4-Benzenetricarboxylic acid, 5-[[[3-(2-pyrimidinylloxy)phenyl]methyl] (1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **475207-04-6P**, N-[3-(2-Pyrimidinylloxy)benzyl]-N-((1S)-1,2,3,4-tetrahydro-1-naphthalenyl)amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of trisubstituted N-(tetrahydronaphthalenyl)benzamides as antagonists of P2X3 and P2X2/P2X3 containing receptors for treating pain, urinary incontinence and bladder overactivity)

RN 475207-04-6 HCAPLUS

CN 1-Naphthalenamine, 1,2,3,4-tetrahydro-N-[[3-(2-pyrimidinylloxy)phenyl]methyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 24 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:889588 HCAPLUS

DOCUMENT NUMBER: 137:369981

TITLE: Preparation of trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamides as inhibitors of P2X3 and P2X2/P2X3 containing receptors

INVENTOR(S): Lee, Chih-hung; Perner, Richard J.; Larson, Daniel P.; Koenig, John R.; Gontsyan, Arthur R.; Zheng, Guo Zhu; Didomenico, Stanley; Stewart, Andrew O.; Bayburt, Erol K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 49 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002173665	A1	20021121	US 2001-860254	20010518
WO 2002094767	A2	20021128	WO 2002-US15174	20020514
WO 2002094767	A3	20030731		

W: CA, JP, MX

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

EP 1392643	A2	20040303	EP 2002-739257	20020514
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

PRIORITY APPLN. INFO.:			
	US 2001-291823P	P	20010518
	US 2001-860254	A	20010518
	US 2002-141989	A	20020510
	WO 2002-US15174	W	20020514

OTHER SOURCE(S): MARPAT 137:369981

AB Title compds. I [A1-3 = alkoxycarbonyl, alkylcarbonyl, carboxy, etc. or A1-2 together with the carbon atoms to which they are attached form a 5-membered heterocycle; A4-11 = H, alkoxy, alkoxycarbonyl, alkenyl, alkyl, alkylcarbonyl, etc.; L1 = alkenylene, alkylene, alkynylene, etc.; R1 = aryl, cycloalkenyl, cycloalkyl, heterocycle; L2 = bond, alkenylene, alkylene, alkynylene, etc.; R2 = absent, aryl, cycloalkenyl, cycloalkyl, heterocycle] were prepared For instance, (1S)-1,2,3,4-tetrahydro-1-naphthalenylamine was alkylated with 3-(4-Chlorophenoxy)benzaldehyde

(EtOH, NaBH₄) and the resulting product acylated with the di-anhydride of 1,2,4,5-benzenetetracarboxylic acid to afford II, after aqueous work-up. Compds. of the present invention were found to be antagonists of the P2X₂/P2X₃ containing receptors with potencies from 4800 nM to 1.4 nM. I are useful for the treatment of pain, urinary incontinence and bladder overactivity.


IT **475207-03-5P**, (S)-5-[[[3-[2-Pyrimidinylloxy]benzyl][1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic Acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamides as inhibitors of P2X₃ and P2X₂/P2X₃ containing receptors)

RN 475207-03-5 HCAPLUS

CN 1,2,4-Benzenetricarboxylic acid, 5-[[[3-(2-pyrimidinylloxy)phenyl]methyl][(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **475207-04-6P**, (S)-N-[3-[2-Pyrimidinylloxy]benzyl]-1,2,3,4-tetrahydro-1-naphthaleneamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamides as inhibitors of P2X₃ and P2X₂/P2X₃ containing receptors)

RN 475207-04-6 HCAPLUS

CN 1-Naphthalenamine, 1,2,3,4-tetrahydro-N-[[3-(2-pyrimidinylloxy)phenyl]methyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 25 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:889028 HCAPLUS
 DOCUMENT NUMBER: 137:379974
 TITLE: Pyridylpyrimidine derivatives as effective compounds
 against prion diseases
 INVENTOR(S): Stein-Gerlach, Matthias; Salassidis, Konstadinos;
 Bacher, Gerald; Mueller, Stefan
 PATENT ASSIGNEE(S): Axxima Pharmaceuticals A.-G., Germany
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002093164	A2	20021121	WO 2002-EP5420	20020516
WO 2002093164	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1395261	A2	20040310	EP 2002-769490	20020516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003176443	A1	20030918	US 2002-204041	20020816
PRIORITY APPLN. INFO.:				
			EP 2001-111858	A 20010516
			US 2001-293528P	P 20010529
			EP 2001-117113	A 20010713
			US 2001-305898P	P 20010718
			WO 2002-EP5420	W 20020516

OTHER SOURCE(S): MARPAT 137:379974
 AB The present invention relates to pyridylpyrimidine derivs. of the general formula (I) : wherein R represents hydrogen or Me and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine

derivs. as pharmaceutically active agents, especially for the prophylaxis and/or

treatment of prion infections and prion diseases, as well as compns. containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivs. Human cellular protein kinases, phosphatases and cellular signal transduction mols. are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD, which can be inhibited by the inventive pyridylpyrimidine derivs.


IT 152459-76-2 152459-79-5 152459-86-4
 152459-88-6 152459-90-0 152459-91-1
 152459-92-2 152459-93-3 475587-06-5
 475587-08-7 475587-09-8 475587-10-1
 475587-11-2 475587-12-3 475587-22-5
 475587-33-8 475587-34-9 475587-36-1
 475587-37-2 475587-39-4 475587-40-7
 475587-41-8 475587-42-9 475587-48-5
 475587-49-6 475587-50-9 475587-51-0
 475587-52-1 475587-53-2 475587-54-3
 475587-55-4 475587-56-5 475587-57-6
 475587-58-7 475587-59-8 475587-60-1
 475587-61-2 475587-62-3 475587-63-4
 475587-64-5 475587-65-6 475587-66-7
 475587-67-8 475587-70-3 475587-71-4
 475587-72-5 475587-73-6 475587-74-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyridylpyrimidine derivs. as effective compds. against prion diseases)


RN 152459-76-2 HCAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-79-5 HCAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-86-4 HCAPLUS


CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-88-6 HCAPLUS
 CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-90-0 HCAPLUS
 CN Cyclohexanecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)



RN 152459-91-1 HCAPLUS
 CN Benzamide, 4-methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-92-2 HCAPLUS
 CN Benzamide, 4-chloro-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-93-3 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-06-5 HCAPLUS

CN Benzamide, 4-(chloromethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-08-7 HCAPLUS

CN Benzamide, 3,4,5-trimethoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-09-8 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-10-1 HCAPLUS


CN Benzenesulfonamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-11-2 HCAPLUS
 CN 3-Thiophenecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-12-3 HCAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-22-5 HCAPLUS
 CN 5-Isoquinolinesulfonamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 475587-33-8 HCAPLUS
 CN Cyclohexanecarboxamide, N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 475587-34-9 HCAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-36-1 HCAPLUS

CN 3-Thiophenecarboxamide, N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-37-2 HCAPLUS

CN Benzenesulfonamide, 4-chloro-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-39-4 HCAPLUS

CN 5-Isoquinolinesulfonamide, N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-40-7 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-41-8 HCAPLUS

CN Benzamide, 4-cyano-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 475587-42-9 HCAPLUS

CN Benzamide, 3,4,5-trimethoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 475587-48-5 HCAPLUS

CN Benzamide, N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 475587-49-6 HCAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 475587-50-9 HCAPLUS

CN Benzamide, 4-methoxy-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 475587-51-0 HCAPLUS

CN Benzenesulfonamide, 4-chloro-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-52-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-53-2 HCAPLUS

CN 2-Naphthalenesulfonamide, N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-54-3 HCAPLUS

CN 5-Isoquinolinesulfonamide, N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-55-4 HCAPLUS

CN Cyclopentanecarboxamide, N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-56-5 HCAPLUS

CN 2-Naphthalenecarboxamide, N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-57-6 HCAPLUS

CN Benzamide, 4-cyano-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-58-7 HCAPLUS

CN Benzamide, 3,5-dimethoxy-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-59-8 HCAPLUS

CN Benzamide, 4-bromo-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 475587-60-1 HCAPLUS

CN Benzamide, 4-methyl-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 475587-61-2 HCAPLUS

CN Benzenesulfonamide, 4-fluoro-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 475587-62-3 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 475587-63-4 HCAPLUS


CN Benzamide, N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 475587-64-5 HCAPLUS
CN Benzenesulfonamide, 4-(chloromethyl)-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-65-6 HCAPLUS
CN Benzenesulfonamide, 4-methyl-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 475587-66-7 HCAPLUS
CN Benzenesulfonamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-67-8 HCAPLUS
CN 2-Naphthalenecarboxamide, N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-70-3 HCAPLUS
CN 1,8-Naphthyridine-2-carboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

pyrimidinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 475587-71-4 HCAPLUS

CN 1,8-Naphthyridine-2-carbothioamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-72-5 HCAPLUS

CN Benzamide, 2-methoxy-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-73-6 HCAPLUS

CN Benzamide, N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 475587-74-7 HCAPLUS

CN Benzamide, 4-methyl-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 26 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:658752 HCAPLUS
 DOCUMENT NUMBER: 137:201139
 TITLE: Substituted polycyclic aryl and heteroaryl
 tertiary-heteroalkylamines useful for inhibiting
 cholesteryl ester transfer protein activity
 INVENTOR(S): Sikorski, James A.; Durley, Richard C.; Mischke,
 Deborah A.; Reinhard, Emily J.; Fobian, Yvette M.;
 Tollefson, Michael B.; Wang, Lijuan; Grapperhaus,
 Margaret L.; Hickory, Brian S.; Massa, Mark A.;
 Norton, Monica B.; Vernier, William F.; Parnas, Barry
 L.; Promo, Michele A.; Hamme, Ashton T.; Spangler,
 Dale P.; Rueppel, Melvin L.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 157 pp., Division of U.S. Ser.
 No. 405,524.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002120011	A1	20020829	US 2001-991174	20011114
US 6479552	B2	20021112		
US 6448295	B1	20020910	US 2001-991208	20011114
US 6451823	B1	20020917	US 2001-990645	20011114
US 6451830	B1	20020917	US 2001-991085	20011114
US 6458852	B1	20021001	US 2001-991210	20011114
US 6458849	B1	20021001	US 2001-991273	20011114
US 6462092	B1	20021008	US 2001-990811	20011114
US 6476057	B1	20021105	US 2001-990833	20011114
US 2002165232	A1	20021107		
US 6476075	B1	20021105	US 2001-991301	20011114
US 2002165231	A1	20021107	US 2001-991241	20011114
US 6586433	B2	20030701		
US 6455519	B1	20020924	US 2001-991116	20011115
US 6458803	B1	20021001	US 2001-991084	20011123
US 2003032644	A1	20030213	US 2002-71518	20020207
US 6723753	B2	20040420		
US 2003087905	A1	20030508	US 2002-154726	20020523
US 6677353	B2	20040113		
US 2003096818	A1	20030522	US 2002-155921	20020523
US 6765023	B2	20040720		
US 2003100559	A1	20030529	US 2002-155095	20020523
US 6677379	B2	20040113		
US 2003105100	A1	20030605	US 2002-155451	20020523
US 6683099	B2	20040127		
US 2003119833	A1	20030626	US 2002-154571	20020523
US 6677375	B2	20040113		
US 2003125328	A1	20030703	US 2002-154788	20020523
US 6696472	B2	20040224		
US 2003125329	A1	20030703	US 2002-155346	20020523
US 6677380	B2	20040113		
US 6677382	B1	20040113	US 2002-155410	20020523
PRIORITY APPLN. INFO.:			US 1999-405524	A3 19990923
			US 2001-990645	A1 20011114
			US 2001-990811	A1 20011114
			US 2001-990833	A1 20011114

US 2001-991174	A1 20011114
US 2001-991210	A1 20011114
US 2001-991273	A1 20011114
US 2001-991301	A1 20011114
US 2001-991084	A1 20011123


OTHER SOURCE(S): MARPAT 137:201139

AB Title compds. I [X = NH, N(OH), N-alkyl; R16 = hydrido; n = 1-2; R1 = haloalkyl, haloalkoxyalkyl; R2 = hydrido, hydroxyalkyl, aryl, aralkyl, alkyl, alkenyl, alkynyl, etc.; R3 = hydrido, alkyl, alkenyl, alkoxyalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyloxyalkyl, etc.; Y = bond, alkyl; Z = bond, alkyl; R4, R8-9, R13 = hydrido, halo, haloalkyl, alkyl; R5-7, R10-12 = hydrido, perhaloaryloxy, alkanoylalkyl, alkanoylalkoxy, alkanoyloxy, N-aryl-N-alkylamino, heterocyclylalkoxy, etc.; with provisions] were prepared for the treatment of atherosclerosis and other coronary artery diseases. I are useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I). Examples include over 700 syntheses and data from two bioassays on CETP activity. For instance, reaction of 3-bromoaniline with 3-(1,1,2,2-tetrafluoroethoxy)benzaldehyde in the presence of NaBH(OAc)₃ and AcOH formed the secondary amine (96%). Addition of 1,1,1-trifluoro-2,3-epoxypropane in CH₂Cl₂ and Yb(OTf)₃ gave the alc. (99%), which was silylated with tert-butyldimethylsilyl trifluoromethanesulfonate (58%). Heating a solution of the tertiary amine with 4-chloro-3-ethylphenol, Cs₂CO₃, copper triflate benzene complex, and 1-naphthoic acid in 2:1 toluene:dimethylacetamide for 96 h gave II (23%). The latter inhibited CETP activity with IC₅₀ values of 0.034 μM and 0.88 μM, resp., in the reconstituted buffer and human plasma assays.

IT **263346-45-8P**, 2-Propanol, 1,1,1-trifluoro-3-[(3-phenoxyphenyl)[(3-(2-pyrimidinylloxy)phenyl)methyl]amino]-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines as cholesteryl ester transfer protein inhibitors for the treatment of atherosclerosis and other coronary artery disease)

RN 263346-45-8 HCAPLUS

CN 2-Propanol, 1,1,1-trifluoro-3-[(3-phenoxyphenyl)[(3-(2-pyrimidinylloxy)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



L18 ANSWER 27 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:559580 HCAPLUS

DOCUMENT NUMBER: 137:290256

TITLE: Nonlinear QSAR studies of herbicidal pyrimidinyl (thio) ether derivatives

AUTHOR(S): Yang, Guang-Fu; Yang, Hua-Zheng

CORPORATE SOURCE: Institute of Organic Synthesis, Central China Normal University, Wuhan, 430079, Peop. Rep. China

SOURCE: Huazhong Shifan Daxue Xuebao Ziranxexueban (2001), 35(1), 40-44
CODEN: HDZKEL; ISSN: 1000-1190

PUBLISHER: Huazhong Shifan Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal


LANGUAGE: Chinese

AB Using the method of artificial neural network anal., nonlinear QSAR studies are carried out for herbicidal pyrimidinyl (thio) ethers and as a result, the parameters have important effect on their herbicidal activity. Combined with the results of mol. mechanics and quantum chemical calcns., this paper proposes the initial action model of herbicidal pyrimidinyl (thio) ethers with the receptor, which will play an important role in design and synthesis of novel herbicides.

IT 120259-38-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nonlinear QSAR studies of herbicidal pyrimidinyl (thio) ether derivs.)

RN 120259-38-3 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-phenoxyethoxy)-(9CI) (CA INDEX NAME)



L18 ANSWER 28 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:661404 HCAPLUS

DOCUMENT NUMBER: 135:227011

TITLE: Preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents

INVENTOR(S): Pease, Elizabeth Janet; Williams, Emma Jane; Bradbury, Robert Hugh; Pearson, Stuart Eric

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Ltd.

SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064656	A1	20010907	WO 2001-GB829	20010226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1278735 A1 20030129 EP 2001-906021 20010226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2001008879 A 20030429 BR 2001-8879 20010226
 JP 2003525279 T2 20030826 JP 2001-563498 20010226
 NZ 520502 A 20040528 NZ 2001-520502 20010226
 ZA 2002006192 A 20031126 ZA 2002-6192 20020802
 US 2003181474 A1 20030925 US 2002-203025 20020805
 NO 2002004126 A 20020829 NO 2002-4126 20020829
 PRIORITY APPLN. INFO.: GB 2000-4887 A 20000301
 WO 2001-GB829 W 20010226

OTHER SOURCE(S): MARPAT 135:227011


AB The title compds. [I; Q1, Q2 = (un)substituted aryl, carbon linked heteroaryl; one of Q1 and Q2 or both is substituted on a ring carbon by one substituent selected from N-(di)alkylamino, Ph, heterocyclyl, etc.; G = O, NR₂; R₂ = H, alkyl, alkenyl, etc.; R₁ = H, halo, OH, etc.] and their pharmaceutically acceptable salts, useful as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors, were prepared and formulated. Thus, reacting 4-anilino-5-bromo-2-chloropyrimidine with 4-aminobenzyl alc. in the presence of ethereal HCl in BuOH/MeOH followed by treatment of the intermediate with ethylene glycol afforded 19% II which showed IC₅₀ of 0.679 μ M when tested in vitro assay for the CDK4 inhibitory activity.

IT 358789-42-1P 358789-49-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents)


RN 358789-42-1 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N4-phenyl- (9CI) (CA INDEX NAME)



RN 358789-49-8 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 29 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:911230 HCAPLUS
 DOCUMENT NUMBER: 134:71598
 TITLE: Preparation of 2-arylamino-5-cyanopyrimidines as
 inhibitors of KDR kinase and/or FGFR kinase.
 INVENTOR(S): Batchelor, Mark James; Moffat, David Festus Charles;
 Davis, Jeremy Martin; Hutchings, Martin Clive
 PATENT ASSIGNEE(S): Celltech Chiroscience Limited, UK
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078731	A1	20001228	WO 2000-GB2382	20000619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6579983	B1	20030617	US 2000-596952	20000616
BR 2000011770	A	20020305	BR 2000-11770	20000619
EP 1187816	A1	20020320	EP 2000-940569	20000619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 10084704	T	20020529	DE 2000-10084704	20000619
GB 2369360	A1	20020529	GB 2001-30563	20000619
JP 2003502406	T2	20030121	JP 2001-504897	20000619
ES 2188429	A1	20030616	ES 2001-50085	20000619
BG 106116	A	20020731	BG 2001-106116	20011119
ZA 2001009841	A	20020429	ZA 2001-9841	20011129
NO 2001006162	A	20020218	NO 2001-6162	20011217
US 2002147339	A1	20021010	US 2002-151518	20020520
US 2004180914	A1	20040916	US 2004-812293	20040329
PRIORITY APPLN. INFO.:			GB 1999-14258	A 19990618
			US 2000-596952	A1 20000616
			WO 2000-GB2382	W 20000619
			US 2002-151518	B1 20020520

OTHER SOURCE(S): MARPAT 134:71598

AB Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, alkyl; R2 = X1R3; X1 = bond, linker atom or group; R3 = (substituted) aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group] and the salts, solvates, hydrates and N-oxides thereof, were prepared Thus, 3,4,5-trimethoxyphenylguanidinium nitrate (preparation given), 1-phenyl-2-cyano-3-dimethylaminopropen-1-one, and NaOH were refluxed in EtOH to give 5-cyano-4-phenyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine. I inhibited KDR kinase and FGFR kinase with IC50 ≤1 μM.


IT 314267-49-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase)

RN 314267-49-7 HCAPLUS

CN Benzamide, N-[3-[[5-cyano-4-(2-thienyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 30 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:785772 HCAPLUS

DOCUMENT NUMBER: 133:350236

TITLE: Preparation of arylsulfinylpyrimidines and related compounds as herbicides and plant growth regulators.

INVENTOR(S): Luethy, Christoph

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: Ger. Offen., 22 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10021568	A1	20001109	DE 2000-10021568	20000503
			CH 1999-848	A 19990505

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 133:350236

AB Title compds. [I; R1, R2 = H, halo, alkyl, haloalkyl, alkoxy, methyl, cycloalkyl, alkenyl, alkynyl, OH, haloalkoxy, alkoxyalkoxy, (substituted) PhO, etc.; R3 = Q1, Q2; X = O, NR8, CR18R19, etc.; Y = O, S, imino; R4 = H, halo, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxy, alkoxyalkyl, HOCH2, CO2H, etc.; R5 = H, alkyl, halo, OH, (substituted) alkoxy, PhCO2, cycloalkoxy, etc.; R6 = H, OH, Sh, (substituted) alkoxy, alkylthio, PhCH2O, alkenyloxy, etc.; R7 = H, halo, alkoxy, (substituted) alkyl, alkenyl, Ph, PhCH2; R6R7 = O, S; R8 = H, OH, alkyl, cycloalkyl, haloalkyl, (substituted) alkoxy, etc.; R13 = H, halo, cyano, CHO, H, alkyl, haloalkyl; R2R13 = (substituted) CH2CH2O; R14 = H, halo, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, OH, alkoxy, haloalkoxy; R18 = H, halo, (substituted) alkyl, Ph; R19 = H, halo, alkyl; n = 1, 2], were prepared as herbicides and plant growth regulators (no data). Thus, 7-(4,6-dimethoxypyrimidin-2-ylthio)-3-hydroxy-3-methyl-3H-isobenzofuran-1-one was stirred with m-ClC6H4CO(OOH) in CHCl3 to give 7-(4,6-dimethoxypyrimidin-2-ylsulfinyl)-3-hydroxy-3-methyl-3H-isobenzofuran-1-one.

IT 304855-85-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylsulfinylpyrimidines and related compds. as herbicides

and plant growth regulators)

RN 304855-85-4 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)thio]-6-[1-[[[(3-fluorophenyl)amino]carbonyl]hydrazono]ethyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 31 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:457043 HCAPLUS

DOCUMENT NUMBER: 133:89537

TITLE: Preparation of 2,4-pyrimidinediamine derivatives as

anticancer agents

INVENTOR(S): Bradbury, Robert Hugh; Breault, Gloria Anne; Jewsbury, Philip John; Pease, Janet Elizabeth

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039101	A1	20000706	WO 1999-GB4325	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140860	A1	20011010	EP 1999-962375	19991220
EP 1140860	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916590	A	20011023	BR 1999-16590	19991220
JP 2002533446	T2	20021008	JP 2000-591012	19991220
AU 763091	B2	20030710	AU 2000-18743	19991220
NZ 512118	A	20030829	NZ 1999-512118	19991220
ZA 2001004413	A	20020829	ZA 2001-4413	20010529
NO 2001003038	A	20010822	NO 2001-3038	20010619
US 6593326	B1	20030715	US 2001-868602	20010823
PRIORITY APPLN. INFO.:				
			GB 1998-28511	A 19981224
			WO 1999-GB4325	W 19991220

OTHER SOURCE(S): MARPAT 133:89537

AB The present invention relates to the title compds. (I) [wherein R1 = H, (un)substituted alkyl, alkenyl, or alkynyl, benzyl, 2-phenylethyl,

phthalimidoalkyl, or cycloalkylalkyl; Rx = halo, OH, NO₂, NH₂, CN, SH, CO₂H, SO₂NH₂, NHCHO, ureido, etc.; Q1 and Q2 = independently (un)substituted aryl, 5- or 6-membered monocycle, or 9- or 10-membered bicyclic heterocycle], processes for their manufacture, and pharmaceutical compns. containing them. For example, addition of 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline•HCl in MeOH to 5-bromo-2-chloro-4-(indan-5-ylamino)pyrimidine in BuOH (preps. given) and heating to 100°C for 18 h gave II (42%). I inhibited the effects of cyclin-dependent serine/threonine kinases (CDKs), showing selectivity for CDK2 (no data), CDK4 (IC₅₀ ranging from 0.02 μM to 0.07 μM), and CDK6 (no data). In a tyrosine kinase activity assay using Sf21 cells transfected with plaque-pure FAK recombinant virus, I also inhibited focal adhesion kinase 3 (FAK3) with IC₅₀ ranging from 0.032 μM to 0.07 μM. Typical IC₅₀ values for I when tested for inhibition of cell growth in an Sulforhodamine B (SRB) assay were in the range of 1 mM to 1 nM. Thus, I possess anti-cancer properties, including anti-cell-migration, antiproliferation and/or apoptotic properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumors and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, and ocular diseases with retinal vessel proliferation.


IT 280580-85-0P, 4-Anilino-5-bromo-2-{3-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine 280580-87-2P, 4-Anilino-5-bromo-2-{3-[3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)


RN 280580-85-0 HCAPLUS

CN 1-Piperazineethanol, α-[[3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 280580-87-2 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-N4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 32 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:356161 HCAPLUS

DOCUMENT NUMBER: 133:4676

TITLE: Preparation of (piperazinylpropoxy)phenylureas as antihyperlipemics, antiarteriosclerotics, anticholesteremic agents, and neutral fat-reducing agents

INVENTOR(S): Inoue, Shinya; Usui, Yoshihiro; Seki, Masaki; Suzuki, Kazuo; Sugimoto, Kanami

PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000143629	A2	20000526	JP 1998-312003	19981102
			JP 1998-312003	19981102

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 133:4676


AB Title compds. I [R1 = Ph, pyridyl, pyrimidinyl; R2 = (un)substituted pyridyl, pyrimidinyl, triazinyl, pyridinonyl, pyrazolyl; X = single bond, O, S] are prepared 2-[3-[4-(2-Pyridyl)-1-piperazyl]propoxy]-6-methylaniline (1.0 g) was reacted with 0.5 g 3-(2-pyrimidyloxy)aniline in CH₂Cl₂ in the presence of (Cl₃CO)₂CO, Et₃N, and 1,4-diazabicyclo[2.2.2]octane under reflux for 15 h to give 1.3 g N-[3-(2-pyrimidyloxy)phenyl]-N'-[2-[3-[4-(2-pyridyl)-1-piperazinyl]propoxy]-6-methylphenyl]urea showing high activity against ACAT.

IT 269078-34-4P 269078-61-7P 269078-62-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (piperazinylpropoxy)phenylureas as antihyperlipemics, antiarteriosclerotics, anticholesteremic agents, and neutral fat-reducing agents)


RN 269078-34-4 HCAPLUS

CN Urea, N-[2-methyl-6-[3-[4-(2-pyridinyl)-1-piperazinyl]propoxy]phenyl]-N'-[3-(2-pyrimidinylloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 269078-61-7 HCAPLUS

CN Urea, N-[2-methyl-6-[3-(4-phenyl-1-piperazinyl)propoxy]phenyl]-N'-[3-(2-pyrimidinylloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 269078-62-8 HCAPLUS

CN Urea, N-[2-methyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]phenyl]-N'-[3-(2-pyrimidinyl)oxy]phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 33 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:227617 HCAPLUS

DOCUMENT NUMBER: 132:264953

TITLE: Substituted polycyclic aryl and heteroaryl
tertiary-heteroalkylamines useful for inhibiting
cholesteryl ester transfer protein activityINVENTOR(S): Sikorski, James A.; Durley, Richard C.; Mischke,
Deborah A.; Reinhard, Emily J.; Fobian, Yvette M.;
Tollefson, Michael B.; Wang, Lijuan; Grapperhaus,
Margaret L.; Hickory, Brian S.; Massa, Mark A.;
Norton, Monica B.; Vernier, William F.; Parnas, Barry
L.; Promo, Michele A.; Hamme, Ashton T.; Spangler,
Dale P.; Rueppel, Melvin L.

PATENT ASSIGNEE(S): Monsanto Company, USA

SOURCE: PCT Int. Appl., 440 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2000018721	A1	20000406	WO 1999-US22119	19990923
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345118	AA	20000406	CA 1999-2345118	19990923
AU 9960594	A1	20000417	AU 1999-60594	19990923
EP 1115693	A1	20010718	EP 1999-969710	19990923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525348	T2	20020813	JP 2000-572183	19990923
US 2003083331	A1	20030501	US 2002-154861	20020523
US 6696435	B2	20040224		
US 2003109528	A1	20030612	US 2002-155002	20020523
US 6699898	B2	20040302		
US 2003114454	A1	20030619	US 2002-155311	20020523
US 6710089	B2	20040323		
PRIORITY APPLN. INFO.:			US 1998-101663P	P 19980925
			US 1999-405524	B3 19990923
			WO 1999-US22119	W 19990923
			US 2001-991085	A1 20011114
			US 2001-991208	A1 20011114
			US 2001-991116	A1 20011115

OTHER SOURCE(S): MARPAT 132:264953


AB The title compds. (I) [wherein R1 = haloalkyl, haloalkenyl, haloalkoxyalkyl, or haloalkenyloxyalkyl; R2 = H, OH, (alkyl)amino, dialkylamino, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, (cyclo)alkoxy, (cyclo)alkenyloxy, or (hetero)aryl, alkylsulfinyl, arylsulfonyl, carboxy, carboxamido, phosphono, etc.; R3, R14, and R15 = independently H, OH, halo, CN, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, or (hetero)aryl, aryloxy, (alkyl)amino, dialkylamino, (hetero)arylthio, acylamido, alkylsulfinyl, arylsulfonyl, carboxy, phosphono, etc.; or R2 and R3 taken together may form a 3- to 8-membered cycloalkyl, a 5- to 8-membered cycloalkenyl, or a 4- to 8-membered heterocyclyl ring; R4-R13 = independently (un)substituted aryloxy, alkyl(oxy), acyl(oxy), carboxamido, (cyclo)alkylsulfinyl, aralkylsulfonyl, amino, phosphono, etc.; R16 = H, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, or (hetero)aryl, acyl, (hetero)aroyle, trialkylsilyl, or a spacer; D1, D2, D3, D4, J1, J2, J3, J4, K1, and K2 = independently C, N, O, S, or a covalent bond; X = H, F, O, S, S(O), NH, N(OH), N(alkyl), or N(alkoxy); Y and Z = independently single bond or (un)substituted (hetero)alkylene; n = 0-5] where prepared for the treatment of atherosclerosis and other coronary artery diseases. I are useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I). Examples include over 700 syntheses and data from two bioassays on CETP activity. For instance, reaction of 3-bromoaniline with 3-(1,1,2,2-tetrafluoroethoxy)benzaldehyde in the presence of NaB(OAc)3H and AcOH formed the secondary amine (96%). Addition of 1,1,1-trifluoro-2,3-epoxypropane in CH2Cl2 and YB(OTf)3 gave the alc. (99%), which was silylated with tert-butyldimethylsilyl trifluoromethanesulfonate (58%). Heating a solution of the tertiary amine with 4-chloro-3-ethylphenol, Cs2CO3, copper triflate benzene complex, and 1-naphthoic acid in 2:1 toluene:dimethylacetamide for 96 h gave II (23%). The latter inhibited CETP activity with IC50 values of 0.034 μ M and 0.88 μ M, resp., in the reconstituted buffer and human plasma assays.

IT 263346-45-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines as cholesteryl ester transfer protein inhibitors for the treatment of atherosclerosis and other coronary artery disease)

RN 263346-45-8 HCAPLUS

CN 2-Propanol, 1,1,1-trifluoro-3-[(3-phenoxyphenyl)[[3-(2-pyrimidinyl)oxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 34 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:161263 HCAPLUS

DOCUMENT NUMBER: 132:194385

TITLE: Preparation of bis(arylamino)pyrimidine derivatives as anticancer agents

INVENTOR(S): Breault, Gloria Anne; Pease, Janet Elizabeth

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012485	A1	20000309	WO 1999-GB2790	19990824
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954382	A1	20000321	AU 1999-54382	19990824
EP 1107957	A1	20010620	EP 1999-940401	19990824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523497	T2	20020730	JP 2000-567515	19990824
PRIORITY APPLN. INFO.:			GB 1998-18989	A 19980829

GB 1998-28433
WO 1999-GB2790A 19981224
W 19990824

OTHER SOURCE(S): MARPAT 132:194385


AB The title compds. (I) [wherein R1 = H or (un)substituted alkyl, alkenyl or alkynyl; Q1 and Q2 = independently (un)substituted Ph, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, and one or both of Q1 and Q2 is substituted with -X(CH₂)_nCHY(CH₂)_mZ; X = CH₂, O, S, or NH; Y = H or as defined for Z; Z = OH, SH, NH₂, alkoxy, alkylthio, (cyclo)alkylamino, or dialkylamino; n = 1-3; m = 1-3] were prepared as cyclin dependent kinase (CDK) and focal adhesion kinase (FAK) inhibitors. Examples include over 100 syntheses, descriptions of a number of biol. assays with some data, and 7 pharmaceutical formulations. For instance, 2-chloro-4-(2-bromo-4-methylanilino)pyrimidine (preparation given) was coupled with 4-[3-(N,N-dimethylamino)-2-hydroxypropoxy]aniline (preparation given) in BuOH to give II. The latter inhibited CDK4 with IC₅₀ = 0.6 μM and FAK with IC₅₀ = 3.3 μM. Typical IC₅₀ values for compds. of the invention when tested in the Sulforhodamine B (SRB) cell growth inhibition assay were in the range of 1 mM to 1 nM. I and their pharmaceutically-acceptable salts and in-vivo-hydrolyzable esters are useful as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents.

IT 260045-24-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of bis(arylamino)pyrimidine derivs. as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents)

RN 260045-24-7 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-(2-fluoro-5-methylphenyl)-N2-[3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 35 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:758643 HCAPLUS

DOCUMENT NUMBER: 130:73892

TITLE: Pyridoneazo compound and thermal-transfer printing material using it

INVENTOR(S): Mizukami, Junji; Ozawa, Tetsuo

PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

JP 10310583 A2 19981124 JP 1997-119521 19970509
 PRIORITY APPLN. INFO.: JP 1997-119521 19970509
 OTHER SOURCE(S): MARPAT 130:73892


AB The title compound has the general formula I [A = (substituted) aromatic ring; B = single bond or divalent linking group; X = N or CY1; Y1-4 = H, halo, straight-chain or branched alkyl which may be substituted, aryl, heteroaryl, alkoxy, cycloalkyl, alkenyl, allyl, aralkyl, dialkylamino, alkylamino, the plural groups of Y1-4 may be condensed to form a 5- to 7-membered ring; R1 = straight-chain or branched alkyl which may be substituted; R2 = straight-chain or branched alkyl which may be substituted, cycloalkyl, alkenyl, aryl, aralkyl, allyl]. The dye comprising the compound and the dye-donating material possessing a dye layer containing the dye on a support are also claimed. A thermal-transfer printing material comprises the dye-donating material and a dye image-receiving material possessing a image-receiving layer containing a dye-fixing material. The thermal-transfer material provides high quality images with high sharpness and storage stability and no transfer of the dye image to other is observed

IT 217963-38-7P 217963-39-8P 217963-40-1P
 217963-41-2P

RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (thermal-transfer printing material containing pyridoneazo dye)


RN 217963-38-7 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[[3-[(4-chloro-2-pyrimidinyl)oxy]phenyl]azo]-1,2-(2-ethyl-1-hexenyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 217963-39-8 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[[3-[(4-chloro-2-pyrimidinyl)oxy]phenyl]azo]-1,2-dihydro-6-hydroxy-4-methyl-1-octyl-2-oxo- (9CI) (CA INDEX NAME)




RN 217963-40-1 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[[3-[(4-chloro-2-pyrimidinyl)oxy]phenyl]azo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 217963-41-2 HCAPLUS
 CN 3-Pyridinecarbonitrile, 1-butyl-5-[[3-[(4-chloro-2-pyrimidinyl)oxyl]phenyl]azo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo- (9CI)
 (CA INDEX NAME)



L18 ANSWER 36 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:745030 HCAPLUS
 DOCUMENT NUMBER: 130:13915
 TITLE: Indole derivatives having combined 5HT1A, 5HT1B, and 5HT1D receptor antagonist activity
 INVENTOR(S): Gaster, Laramie Mary; Rami, Harshad Kantilal; Wyman, Paul Adrian
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
 SOURCE: PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850358	A1	19981112	WO 1998-EP2262	19980414
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874310	A1	19981127	AU 1998-74310	19980414
AU 732863	B2	20010503		
EP 975593	A1	20000202	EP 1998-921462	19980414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI			
TR 9902590	T2	20000621	TR 1999-9902590	19980414

JP 2001524116	T2	20011127	JP 1998-547660	19980414
BR 9809092	A	20020122	BR 1998-9092	19980414
ZA 9803242	A	19991018	ZA 1998-3242	19980417
TW 509687	B	20021111	TW 1998-87105843	19980417
NO 9905065	A	19991015	NO 1999-5065	19991015
MX 9909583	A	20000331	MX 1999-9583	19991018
PRIORITY APPLN. INFO.:			GB 1997-7829	A 19970418
			GB 1998-1882	A 19980129
			WO 1998-EP2262	W 19980414

OTHER SOURCE(S): MARPAT 130:13915


AB The title compds. I [Ra is a group of formula Q, in which P1 is Ph, bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; R1 = H, halo, C1-6alkyl, C3-6cycloalkyl, COC1-6alkyl, C1-6alkoxy, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, nitro, trifluoromethyl, cyano, SR9, SOR9, SO2R9, SO2NR10R11, CO2R10, CONR10R11, CO2NR10R11, CONR10(CH2)cCO2R11, (CH2)cNR10R11, (CH2)cCONR10R11, (CH2)cNR10COR11, (CH2)cCO2C1-6alkyl, CO2(CH2)cOR10, NR10R11, NR10CO2R11, NR10CONR10R11, CR10:NOR11, NR10COOR11, CNR10:NOR11, where R10 and R11 are independently hydrogen or C1-6alkyl and c is 1 to 4; R2 = H, halo, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkenyl, C1-6alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R10, CONR10R11, NR10R11 where R10 and R11 are as defined for R1; a is 1, 2 or 3; or Ra is a group containing bridged rings; Y = NH, alkylamino, CH2, O; V = O, S; D = N, C, CH; W = (CR16R17)t where t = 2-4 and R16 and R17 = H, alkyl, etc.; Rb = H, halo, OH, etc.; Rc = H, alkyl] were prepared and their 5HT1A,, 5HT1B, and 5HT1D receptor binding determined E.g., 5-methoxy-6-(4-methylpiperazin-1-yl)indole was treated with KOCMe3, then with 4-bromo-3-methylphenyl isocyanate to give 1-[(4-bromo-3-methylphenyl)aminocarbonyl]-5-methoxy-6-(4-methylpiperazin-1-yl)indole.

IT 216058-75-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. having combined 5HT1A, 5HT1B, and 5HT1D receptor antagonist activity)

RN 216058-75-2 HCAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-(2-pyrimidinyl)oxy]phenyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 37 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:788246 HCAPLUS

DOCUMENT NUMBER: 128:111860

TITLE: Herbicidal selectivity of post-emergence

N-acyl-N-phenyl-3,4,5,6-tetrahydrophthalamic acid derivatives in soybean


AUTHOR(S): Suzuki, Kiyoshi; Kume, Takashi; Takematsu, Tetsuo
 CORPORATE SOURCE: Plant Sci. Res. Inst., Tochigi, 329-11, Japan
 SOURCE: Zasso Kenkyu (1997), 42(3), 214-220
 CODEN: ZASKAN; ISSN: 0372-798X

PUBLISHER: Nippon Zasso Gakkai
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese

AB New n-acyl-N-phenyltetrahydrophthalamic acid derivs. have been found to show a high level of post-emergence herbicidal activity toward weeds, without injuring soybean. 1. Post-emergence herbicidal activity toward Abutilon theophrasti Medic. In an attempt to optimize the herbicidal activity of this series of compds., substitution at the 5 position of the aniline moiety (R1) was found to be the major determinant for enhancing the herbicidal activity while avoiding injury to soybean (cv. Hokai), and the methoxycarbonylmethylthio group appeared to be most effective. Alkyl esters mainly showed a higher activity than other aliphatic esters. Highest herbicidal activity was obtained with an Et moiety at the R2 position. Among the compds. tested, 4 new derivs. were selected for their strong herbicidal activity and superior selectivity. 2. Post-emergence herbicidal activity toward several upland weeds. Herbicidal activity of these compds. with high performance was investigated for other important weeds in upland fields. As a result, it was shown that Me N-propionyl-N-(4-chloro-2-fluoro-5-methoxycarbonylmethylthiophenyl)-3,4,5,6-tetrahydrophthalate (CUH-38) displayed the strongest activity among the compds. tested.

IT 152306-35-9
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study);
 USES (Uses)
 (herbicidal activity of N-acyl-N-phenyl-3,4,5,6-tetrahydrophthalamic acid derivs. in soybean)

RN 152306-35-9 HCAPLUS
 CN 1-Cyclohexene-1-carboxylic acid, 2-[[acetyl[4-chloro-2-fluoro-5-(2-pyrimidinylthio)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 38 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:788245 HCAPLUS
 DOCUMENT NUMBER: 128:111859
 TITLE: Herbicidal selectivity of N-acyl-N-phenyl-3,4,5,6-tetrahydrophthalamic acid derivatives under paddy conditions

AUTHOR(S): Suzuki, Kiyoshi; Kume, Takashi; Takematsu, Tetsuo
 CORPORATE SOURCE: Plant Sci. Res. Inst., Tochigi, 329-11, Japan
 SOURCE: Zasso Kenkyu (1997), 42(3), 206-213

CODEN: ZASKAN; ISSN: 0372-798X
 PUBLISHER: Nippon Zasso Gakkai
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese

AB Novel N-acyl-N-phenyltetrahydrophthalamic acid derivs. were synthesized and their herbicidal activity and selectivity were evaluated by a pot test in a greenhouse. In the structure of n-acyl-N-phenyl-3,4,5,6-tetrahydrophthalamic acid derivs., a 3-butyn-2-yloxy group at the 5 position of the aniline moiety (R1) was found to be the major determinant for herbicidal activity toward *Echinochloa oryzicola* Vasing. and selectivity between rice and *Echinochloa oryzicola*. Introduction of a 3-fluorobenzoyl group (R2) on the amide nitrogen atom significantly decreased the rice phytotoxicity without a concomitant loss of herbicidal activity. In addition, 2-methoxyethyl esters (R3) showed an equal to or higher activity than the corresponding Me esters. Among the compds. tested, 5 novel N-acyl-N-phenyltetrahydrophthalamic acid derivs. were selected for their strong herbicidal activity and high selectivity. Post-emergence herbicidal activity toward *Echinochloa oryzicola*, *Rotala indica* Koehne., *Cyperus difformis* L., *Scripus juncooides* Roxb., *Monochoria vaginalis* Presl. in water application was evaluated for the selected compds. Among them, 2-methoxyethyl N-(3-fluorobenzoyl)-N-[4-chloro-2-fluoro-5-(3-butyn-2-yloxy) phenyl]-3,4,5,6-tetrahydrophthalamate (CUH-35) showed the highest activity and effectively controlled these paddy weeds at a dose of 30 g a.i./ha except for *Scripus juncooides*, without adverse effect on transplanted rice.


IT 152306-35-9

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)

(herbicidal selectivity of N-acyl-N-phenyl-3,4,5,6-tetrahydrophthalamic acid derivs. under paddy conditions)

RN 152306-35-9 HCAPLUS

CN 1-Cyclohexene-1-carboxylic acid, 2-[[acetyl[4-chloro-2-fluoro-5-(2-pyrimidinylloxy)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 39 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1997:457074 HCAPLUS
 DOCUMENT NUMBER: 127:81461
 TITLE: Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors
 INVENTOR(S): Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719065	A1	19970529	WO 1996-GB2854	19961120
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5958935	A	19990928	US 1996-753041	19961119
AU 9676314	A1	19970611	AU 1996-76314	19961120
EP 862560	A1	19980909	EP 1996-939171	19961120
EP 862560	B1	20030402		
R: CH, DE, ES, FR, GB, IT, LI				
ES 2195020	T3	20031201	ES 1996-939171	19961120
US 6235746	B1	20010522	US 1999-249760	19990216
PRIORITY APPLN. INFO.:			GB 1995-23675	A 19951120
			US 1996-753041	A3 19961119
			WO 1996-GB2854	W 19961120

OTHER SOURCE(S): MARPAT 127:81461

AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom.


group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared. Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191728-57-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors)

RN 191728-57-1 HCAPLUS


CN 2,4-Pyrimidinediamine, N2-[3,4-dimethoxy-5-(phenylmethoxy)phenyl]-N4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




L18 ANSWER 40 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1997:123312 HCAPLUS
 DOCUMENT NUMBER: 126:220297
 TITLE: Potent and selective inhibitors of the ABL-kinase:
 phenylaminopyrimidine (PAP) derivatives
 AUTHOR(S): Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut;
 Meyer, Thomas; Lydon, Nicholas B.
 CORPORATE SOURCE: Ciba Pharmaceuticals Division, Oncology Research
 Department, Ciba-Geigy Limited, Basel, CH-4002, Switz.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(2),
 187-192
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Due to its relatively clear etiol., chronic myelogenous leukemia (CML)
 represents an ideal disease target for a therapy using a selective
 inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization
 of the class of phenylamino-pyrimidines yielded highly potent and
 selective Bcr-Abl kinase inhibitors.
 IT 150784-70-6P 152459-77-3P 152459-78-4P
 152459-79-5P 152459-80-8P 152459-82-0P
 152459-86-4P 152459-87-5P 152459-88-6P
 152459-89-7P 152459-90-0P 152459-91-1P
 152459-93-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylaminopyrimidine derivs. as inhibitors of ABL-kinase)
 RN 150784-70-6 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(3-pyridinyl)-
 (9CI) (CA INDEX NAME)




RN 152459-77-3 HCAPLUS
 CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA
 INDEX NAME)




RN 152459-78-4 HCAPLUS
CN 2-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-79-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-80-8 HCAPLUS
CN 4-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-82-0 HCAPLUS
CN Benzoic acid, 2-[[[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-
(9CI) (CA INDEX NAME)




RN 152459-86-4 HCAPLUS
CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-87-5 HCAPLUS
 CN Benzamide, 4-fluoro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-88-6 HCAPLUS
 CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-89-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-90-0 HCAPLUS
 CN Cyclohexanecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 152459-91-1 HCAPLUS
 CN Benzamide, 4-methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)



RN 152459-93-3 HCAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 41 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1996:574516 HCAPLUS
 DOCUMENT NUMBER: 125:221860
 TITLE: Preparation of 2-(pyrimidyloxy)benzoates as herbicides
 INVENTOR(S): Vogelbacher, Uwe Josef; Rheinheimer, Joachim; Baumann, Ernst; Walter, Helmut; Westphalen, Karl-Otto; Mislitz, Ulf
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 40 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19505182	A1	19960822	DE 1995-19505182	19950216
			DE 1995-19505182	19950216

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 125:221860

AB Title compds. [I; R = Z1Z2R5; R1,R2 = halo, (halo)alkyl, (halo)alkoxy, etc.; R3 = H, heteroaryl, OH, NH2, etc.; R4 = H, halo, alkyl; R5 = (un)substituted Ph, heteroaryl; Z = N or (alkyl)methine; Z1 = alkylene; Z2 = O or S] were prepared Thus, cyclohexanone oxime was treated with NaOMe in PhMe and the product condensed with 5-[2-(4-chlorophenyl)propoxy]-2,2-dimethylbenzo[1,3]dioxin-4-one after which 4,6-dimethoxy-2-methylsulfonylpyrimidine was added and the whole heated 1h at 100° to give, after saponification, title compound II which gave 95% control of

Broin
 inermis and Galium aparine at 0.5kg/ha postemergent.


IT 120259-38-3P 181263-26-3P 181263-27-4P

181263-28-5P 181263-29-6P 181263-30-9P
181263-31-0P 181263-32-1P 181263-33-2P
181263-35-4P 181263-36-5P 181263-37-6P
181263-38-7P 181263-39-8P 181263-40-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(pyrimidyloxy)benzoates as herbicides)


RN 120259-38-3 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-phenoxyethoxy)-
(9CI) (CA INDEX NAME)




RN 181263-26-3 HCAPLUS

CN Benzoic acid, 2-[2-(4-chlorophenoxy)propoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 181263-27-4 HCAPLUS

CN Benzoic acid, 2-[2-(4-acetylphenoxy)ethoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 181263-28-5 HCAPLUS


CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[2-(4-fluorophenoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 181263-29-6 HCAPLUS
 CN Benzoic acid, 2-[2-(2-(2-chlorophenoxy)ethoxy)ethoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 181263-30-9 HCAPLUS
 CN Benzoic acid, 2-[2-(2-(3-chlorophenoxy)ethoxy)ethoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 181263-31-0 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[2-(2-ethoxyphenoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 181263-32-1 HCAPLUS
 CN Benzoic acid, 2-[2-(2-(3,5-dimethoxyphenoxy)ethoxy)ethoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 181263-33-2 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(3-phenoxypropoxy)-
(9CI) (CA INDEX NAME)




RN 181263-35-4 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[3-(4-fluorophenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 181263-36-5 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[3-[4-(1,1-dimethylethyl)phenoxy]propoxy]- (9CI) (CA INDEX NAME)




RN 181263-37-6 HCAPLUS


CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[3-(2,4,6-trimethylphenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 181263-38-7 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(4-phenoxybutoxy)-
 (9CI) (CA INDEX NAME)



RN 181263-39-8 HCAPLUS
 CN Benzoic acid, 2-[4-(4-chlorophenoxy)butoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 181263-40-1 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[4-(2,4,6-trimethylphenoxy)butoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 42 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:495435 HCAPLUS
DOCUMENT NUMBER: 125:184908
TITLE: Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)
AUTHOR(S): Zimmermann, Juerg; Caravatti, Giorgio; Mett, Helmut; Meyer, Thomas; Mueller, Marcel; Lydon, Nicholas B.; Fabbro, Dorian
CORPORATE SOURCE: CIBA Pharmaceuticals Div., Oncology Virology Res. Dep., Ciba-Geigy Limited, Basel, CH-4002, Switz.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(7), 371-376
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Phenylamino-pyrimidines represent a novel class of inhibitors of protein kinase C with a high degree of selectivity vs. other serine/threonine and tyrosine kinases. Steady state kinetic anal. of N-(3-[1-imidazolyl]-phenyl)-4-(3-pyridyl)-2-pyrimidinamine, which showed potent inhibitory activity, revealed competitive kinetics relative to ATP. The adjacent H-bond acceptor of the pyrimidine moiety next to an H-bond donor of the phenylamine was found to be crucial for inhibitory activity. N-(3-Nitro-phenyl)-4-(3-pyridyl)-2-pyrimidinamine preferentially inhibited PKC- α (IC₅₀ = 0.79 μ M) and not the other subtypes tested. The inhibition consts. of PKC- α and the antiproliferative effect on T24 human bladder carcinoma cells showed a qual. correlation, although with some exceptions.


IT 152459-76-2P 152459-86-4P 152459-88-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylamino-pyrimidine derivs. as a new class of potent and selective inhibitors of protein kinase C)


RN 152459-76-2 HCAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-86-4 HCAPLUS

CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 152459-88-6 HCAPLUS
CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



L18 ANSWER 43 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:380210 HCAPLUS
DOCUMENT NUMBER: 125:114681
TITLE: Pyrimidine derivatives and processes for the
preparation thereof
INVENTOR(S): Zimmermann, Juerg
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, USA
SOURCE: U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5521184	A	19960528	US 1994-234889	19940428
CA 2148477	AA	19950413	CA 1994-2148477	19940921
PRIORITY APPLN. INFO.:			CH 1992-1083	A 19920403
			US 1993-42322	B2 19930402
			CH 1993-2966	A 19931001

OTHER SOURCE(S): MARPAT 125:114681


AB There are described N-phenyl-2-pyrimidine-amine derivs. (I) wherein R1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted Ph wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen; R2 and R3 are hydrogen or lower alkyl; one or two of R4, R5, R6, R7 are each nitro, fluoro-substituted lower alkoxy or -N(R9)C(:X)(Y)NR10. These compds. can be used, for example, in the therapy of tumoral diseases. Three example formulations are given.

IT 152459-76-2P 152459-77-3P 152459-78-4P
152459-79-5P 152459-80-8P 152459-81-9P
152459-82-0P 152459-86-4P 152459-87-5P
152459-88-6P 152459-89-7P 152459-90-0P
152459-91-1P 152459-92-2P 152459-93-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopyrimidine derivs. as antitumor agents)


RN 152459-76-2 HCAPLUS
CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-

(9CI) (CA INDEX NAME)




RN 152459-77-3 HCAPLUS

CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-78-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-79-5 HCAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-80-8 HCAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-81-9 HCAPLUS
 CN Benzamide, 2,3,4,5,6-pentafluoro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-82-0 HCAPLUS
 CN Benzoic acid, 2-[[[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-(9CI) (CA INDEX NAME)




RN 152459-86-4 HCAPLUS
 CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 152459-87-5 HCAPLUS
 CN Benzamide, 4-fluoro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-88-6 HCAPLUS
 CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-89-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-90-0 HCAPLUS

CN Cyclohexanecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-91-1 HCAPLUS

CN Benzamide, 4-methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)




RN 152459-92-2 HCAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 152459-93-3 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 44 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:368753 HCAPLUS

DOCUMENT NUMBER: 125:167896

TITLE: (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

AUTHOR(S): Zimmermann, Juerg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.; Traxler, Peter

CORPORATE SOURCE: Oncol. Res. Dep., Ciba Pharm. Div., Basel, CH-4002, Switz.

SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(11), 1221-1226

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB (Phenylamino)pyrimidines represent a novel class of inhibitors of the PDGF-receptor autophosphorylation with a high degree of selectivity vs. other tyrosine and serine/threonine kinases. Optimum activity of ca 10 nM (IC50) was observed when the phenylamino-group which is attached to the pyrimidine carries a benzamide-moiety with a lipophilic substituent in 4-position. The target compds. were derivs. of 4-methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine I (R2 = H, Me; R3 = H, benzoyl, Me, etc.; R4 = H, benzoyl, etc.). A 2-thienyl analog of I was also prepared and tested.


IT 152459-77-3P 180258-58-6P 180258-59-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of [(pyridinyl)pyrimidinyl]benzenediamines as tyrosine kinase or serine/threonine kinase inhibitors)


RN 152459-77-3 HCAPLUS

CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 180258-58-6 HCAPLUS

CN Benzamide, N-[4-chloro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 180258-59-7 HCAPLUS
 CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)



L18 ANSWER 45 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1995:990661 HCAPLUS
 DOCUMENT NUMBER: 124:29782
 TITLE: Preparation of pyrimidinyloxyphenyl ketones as herbicides
 INVENTOR(S): Yasuhara, Satoshi; Niitsuma, Shiro; Nakamura, Toshiki; Kusunoki, Masayuki; Ishikawa, Hiromichi; Yoshizawa, Hirokazu; Yamamura, Hiroshi
 PATENT ASSIGNEE(S): Hokko Chem Ind Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07215948	A2	19950815	JP 1994-25889	19940131
PRIORITY APPLN. INFO.:			JP 1994-25889	19940131
OTHER SOURCE(S): MARPAT 124:29782				

AB The title compds. I [R1 = R3CO, etc.; R3 = alkyl; R2 = alkyl, cycloalkyl] are prepared I [R1 = Q1; R2 = tert-butyl] (preparation given) (at 0.32 g/are) gave complete control of Echinochloa oryzicola and did not cause damage to paddy rice.


IT **171609-20-4P 171609-21-5P**
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidinyloxyphenyl ketones as herbicides)

RN 171609-20-4 HCAPLUS
CN 1-Propanone, 1-[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[1-[(phenylmethoxy)imino]ethyl]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 171609-21-5 HCAPLUS
CN 1-Heptanone, 1-[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[1-[(phenylmethoxy)imino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 46 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:610660 HCAPLUS
DOCUMENT NUMBER: 123:3387
TITLE: Preparation of pyrimidine derivatives as herbicides composition
INVENTOR(S): Sato, Masahiro; Kaku, Koichiro; Tachikawa, Shigehiko
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.
SOURCE: U.S., 18 pp. Cont.-in-part of U.S. Ser. No. 949,890, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5401711	A	19950328	US 1993-11908	19930201
JP 05032638	A2	19930209	JP 1991-213085	19910731
PRIORITY APPLN. INFO.:			JP 1991-213085	19910731
			US 1992-949890	19921125

OTHER SOURCE(S): CASREACT 123:3387; MARPAT 123:3387

AB The pyrimidine derivs. I [R1=trifluoromethanesulfonyloxy, (un)substituted ethenyl; R2=H, alky, 2-trimethylsilylethyl; R3,R4 =methoxy, halo; X = O,S; Z= methine] or I salts, are prepared as herbicides. 2-[(4,6-Dimethoxypyrimidin-2-yl)oxy]-6-(1-propenyl)benzoic acid (preparation given) totally controlled, at 100 g/10 are, barnyard grass, Monochoria and bulrush, in paddy soil, in a pot experiment


IT 150399-50-1P 150629-73-5P 150629-75-7P

150629-79-1P 163804-94-2P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as herbicide)

RN 150399-50-1 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-phenylethenyl)-
(9CI) (CA INDEX NAME)




RN 150629-73-5 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(phenylethynyl)-, compd. with N-ethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150629-72-4


CMF C21 H16 N2 O5



CM 2

CRN 109-89-7

CMF C4 H11 N




RN 150629-75-7 HCAPLUS

CN Benzoic acid, 2-(cyclohexylethynyl)-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150629-74-6
CMF C21 H22 N2 O5



CM 2


CRN 108-18-9
CMF C6 H15 N

i-Pr--NH--Pr-i

RN 150629-79-1 HCAPLUS
CN Benzoic acid, 2-(cyclopentylethynyl)-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-
, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150629-78-0
CMF C20 H20 N2 O5




CM 2

CRN 108-18-9
CMF C6 H15 N

i-Pr--NH--Pr-i

RN 163804-94-2 HCAPLUS
CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[2-(2-thienyl)ethenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 47 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1994:134516 HCAPLUS
 DOCUMENT NUMBER: 120:134516
 TITLE: Preparation of phenoxyazines as herbicides
 INVENTOR(S): Andree, Roland; Drewes, Mark Wilhelm; Santel, Hans
 Joachim; Luerksen, Klaus; Schmidt, Robert R.
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 564920	A1	19931013	EP 1993-104985	19930325
R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
DE 4211610	A1	19931014	DE 1992-4211610	19920407
US 5371062	A	19941206	US 1993-41650	19930401
CA 2093291	AA	19931008	CA 1993-2093291	19930402
JP 06049040	A2	19940222	JP 1993-101915	19930405
BR 9301464	A	19931013	BR 1993-1464	19930406
			DE 1992-4211610	19920407

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 120:134516

AB Title compds. [I; n = 0,1; Q1, Q3 = O, S, NH, alkylimino; Q2 = O, S, NR4, CR5R6; R1 = H, amino, OH, cyano, NO2, halo, (halo)alkyl, (halo)alkoxy, (halo)alkylthio, Ph, etc; R2 = H, OH, alkyl, (substituted) alkoxy, alkylthio, alkylamino, aralkoxy, aralkylthio, aryloxy, arylthio, arylamino, etc; R3 = substituted alkyl, (substituted) alkenyl; R4 = H, amino, (substituted) alkyl, alkenyl, alkynyl, aralkyl, aryl, alkoxycarbonyloxy, arylaminocarbonyloxy, carboxyalkoxy, alkoxycarbonylalkoxy, alkylamino, arylamino, alkylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, etc; R5 = H, halo, cyano, carboxy, alkoxycarbonyl, alkylcarbonylamino, dialkoxylphosphoryl; R6 = formyl, cyano, carboxy, hydroxymethyl, carbamoyl, (substituted) alkoxycarbonyl, cycloalkoxycarbonyl, aralkoxycarbonyl, arylaminocarbonyl, piperazinocarbonyl, etc; X, Y = H, halo, (halo)alkyl, alkoxy, alkylthio, alkylamino, etc; Z = N, CH, C-halo], were prepared as herbicides (no data). Thus, Me 2-hydroxy-6-styrylbenzoate and 4,6-dimethoxy-2-methylsulfonylpyrimidine were refluxed with K2CO3 in MeCN to give 54% title compound II. II was said to show strong pre- and postemergent activity against weeds.

IT 152383-63-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)

RN 152383-63-6 HCAPLUS
 CN Benzoic acid, 2-[2-(4-chlorophenyl)ethenyl]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 48 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1994:107056 HCAPLUS
 DOCUMENT NUMBER: 120:107056
 TITLE: Preparation of 2-anilinopyrimidines as antiatherosclerotics and neoplasm inhibitors
 INVENTOR(S): Zimmermann, Juerg
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 564409	A1	19931006	EP 1993-810219	19930325
EP 564409	B1	20000119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 188964	E	20000215	AT 1993-810219	19930325
ES 2142857	T3	20000501	ES 1993-810219	19930325
PT 564409	T	20000630	PT 1993-810219	19930325
CA 2093203	AA	19931004	CA 1993-2093203	19930401
CA 2093203	C	20021126		
CZ 283944	B6	19980715	CZ 1993-560	19930401
RU 2125992	C1	19990210	RU 1993-5357	19930401
IL 105264	A1	19990411	IL 1993-105264	19930401
SK 280620	B6	20000516	SK 1993-280	19930401
NO 9301283	A	19931004	NO 1993-1283	19930402
ZA 9302397	A	19931004	ZA 1993-2397	19930402
AU 9335694	A1	19931007	AU 1993-35694	19930402
AU 666709	B2	19960222		
CN 1077713	A	19931027	CN 1993-103566	19930402
CN 1043531	B	19990602		
HU 64050	A2	19931129	HU 1993-982	19930402
JP 06087834	A2	19940329	JP 1993-78096	19930405
JP 2706682	B2	19980128		
GR 3032927	T3	20000731	GR 2000-400623	20000310
			CH 1992-1083	A 19920403

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 120:107056

AB Title compds. [I; R1 = pyridyl, 4-pyrazinyl, (acyl)aminophenyl, etc.; R2, R3 = H, alkyl; 1 or 2 of R4-R8 = NO2, fluoroalkoxy, NR9C(:X)YnR10 and the others = H, alkyl, alkanoyl, CF3, etc.; R9 = H, alkyl; R10 = (cyclo)aliphatic


group, heterocyclyl, aryl, etc.; X = O, S, NH, etc.; Y = O or NH; n = 0 or 1] were prepared Thus, 3-(O₂N)C₆H₄NHC(:NH)NH₂ [preparation from 3-(O₂N)C₆H₄NH₂ given] was cyclocondensed with R₁COCH:CHNMe₂ (R₁ = 3-pyridyl) (preparation from 3-acetylpyridine given) to give I (R₁ = 3-pyridyl, R₂ = R₃ = R₅-R₈ = H, R₄ = NO₂). I had IC₅₀ of .apprx.0.5 to 5 μM against protein kinase C in vitro.

IT 152459-76-2P 152459-77-3P 152459-78-4P
 152459-79-5P 152459-80-8P 152459-81-9P
 152459-82-0P 152459-86-4P 152459-87-5P
 152459-88-6P 152459-89-7P 152459-90-0P
 152459-91-1P 152459-92-2P 152459-93-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiatherosclerotic and neoplasm inhibitor)


RN 152459-76-2 HCAPLUS

CN Benzamide, 4-chloro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-77-3 HCAPLUS

CN Benzamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-78-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-79-5 HCAPLUS


CN 3-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)




RN 152459-80-8 HCAPLUS
CN 4-Pyridinecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]-
(9CI) (CA INDEX NAME)




RN 152459-81-9 HCAPLUS
CN Benzamide, 2,3,4,5,6-pentafluoro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 152459-82-0 HCAPLUS
CN Benzoic acid, 2-[[[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 152459-86-4 HCAPLUS
CN Benzamide, 2-methoxy-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]- (9CI) (CA INDEX NAME)




RN 152459-87-5 HCAPLUS
CN Benzamide, 4-fluoro-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-88-6 HCAPLUS
CN Benzamide, 4-cyano-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-89-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-90-0 HCAPLUS
CN Cyclohexanecarboxamide, N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 152459-91-1 HCAPLUS
CN Benzamide, 4-methyl-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 152459-92-2 HCAPLUS
 CN Benzamide, 4-chloro-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
 (9CI) (CA INDEX NAME)



RN 152459-93-3 HCAPLUS
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 49 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1994:99436 HCAPLUS
 DOCUMENT NUMBER: 120:99436
 TITLE: Preparation of pyrimidines and herbicides containing them
 INVENTOR(S): Takematsu, Tetsuo; Komata, Takeo; Kume, Koji; Suzuki, Kyoshi; Kawamura, Matsue; Shirakawa, Yumiko; Mori, Kaoru
 PATENT ASSIGNEE(S): Central Glass Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05230034	A2	19930907	JP 1992-39810	19920226
			JP 1992-39810	19920226

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 120:99436

AB Herbicides contain pyrimidines I [R1, R2 = H, halo, lower alkyl, lower alkoxy; R3 = lower (halo)alkyl; R4 = lower alkoxy, lower alkenyloxy, lower alkynyloxy, lower alkoxyalkoxy, (un)substituted benzyloxy, lower haloalkyloxy, lower alkoxyalkoxy; X, Y = H, halo] prepared by


dehydration and chlorination of anilides II (R1-R3, X, Y = same as above; R5 = NHCOR3), followed by treatment of the resulting imidochlorides II (R1-R3, X, Y = same as above; R5 = N:CR3Cl) with cyclohexenecarboxylic acids III (R4 = same as above) in the presence of bases. Refluxing II (R1 = R2 = H, R5 = NHCOCH2Cl, X = F, Y = Cl) with polymer-bound Ph3P in CCl4-1,2-dichloroethane mixture for 2 h gave quant. II (R1 = R2 = H, R5 = N:CClCH2Cl, X = F, Y = Cl), which (1.05 g) was treated with 0.58 g III (R4 = OMe) and Et3N in C6H6 at 60° for 1.5 h to afford 1.1 g I (R1 = R2 = H, R3 = CH2Cl, R4 = OMe, X = F, Y = Cl). The product at 6.25 g/(10 are) showed 100% inhibition against *Panicum crus-galli* and broad-leaf weeds with minor damage to rice.

IT 152306-32-6P 152306-34-8P 152306-35-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 152306-32-6 HCAPLUS

CN 1-Cyclohexene-1-carboxylic acid, 2-[[[(chloroacetyl)[4-chloro-2-fluoro-5-(2-pyrimidinyl)oxy]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152306-34-8 HCAPLUS


CN 1-Cyclohexene-1-carboxylic acid, 2-[[[(chloroacetyl)[4-chloro-5-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-2-fluorophenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152306-35-9 HCAPLUS

CN 1-Cyclohexene-1-carboxylic acid, 2-[[[acetyl[4-chloro-2-fluoro-5-(2-pyrimidinyl)oxy]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

NAME)



L18 ANSWER 50 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:625965 HCAPLUS

DOCUMENT NUMBER: 119:225965

TITLE: Preparation of pyrimidines or triazines as herbicides.

INVENTOR(S): Sato, Masahiro; Kaku, Koichiro; Tachikawa, Shigehiko

PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9303017	A1	19930218	WO 1992-JP965	19920730
W: US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
JP 05032638	A2	19930209	JP 1991-213085	19910731
EP 555488	A1	19930818	EP 1992-916529	19920730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
PRIORITY APPLN. INFO.:			JP 1991-213085	19910731
			WO 1992-JP965	19920730

OTHER SOURCE(S): MARPAT 119:225965


AB The title compds. [I; R1 = CF₃SO₃, (un)substituted vinyl, (un)substituted ethynyl, (un)substituted aminoalkyl; R2 = H, alkyl, alkenyl, alkynyl, benzyl, etc.; R3, R4 = halo, alkyl, alkoxy, CHF₂, CF₃, etc.; X = O, S; Z = N, CH] are prepared e.g. by reacting the benzoic acid derivs. (II) with the appropriate pyrimidine or triazine derivs. III [L = leaving group]. Only general procedures for synthesizing I are presented. About 56 I were prepared with data. I [R1 = CH:CH-Me, R2 = H, R3 = R4 = MeO, X = O, Z = CH] at 100 g/10 are had ≥90% kill of barnyard grass.

IT 150399-50-1P 150629-73-5P 150629-75-7P
150629-79-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)

RN 150399-50-1 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-phenylethenyl)-
(9CI) (CA INDEX NAME)




RN 150629-73-5 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(phenylethynyl)-, compd. with N-ethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150629-72-4


CMF C21 H16 N2 O5



CM 2

CRN 109-89-7

CMF C4 H11 N




RN 150629-75-7 HCAPLUS

CN Benzoic acid, 2-(cyclohexylethynyl)-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150629-74-6

CMF C21 H22 N2 O5



CM 2

CRN 108-18-9

CMF C6 H15 N

i-Pr-NH-Pr-i


RN 150629-79-1 HCAPLUS

CN Benzoic acid, 2-(cyclopentylethynyl)-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-
, compd. with N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150629-78-0

CMF C20 H20 N2 O5



CM 2

CRN 108-18-9

CMF C6 H15 N

i-Pr-NH-Pr-i

L18 ANSWER 51 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:625910 HCAPLUS

DOCUMENT NUMBER: 119:225910

TITLE: Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

AUTHOR(S): Paul, Rolf; Hallett, William A.; Hanifin, John W.; Reich, Marvin F.; Johnson, Bernard D.; Lenhard, Robert H.; Dusza, John P.; Kerwar, Suresh S.; Lin, Yang I.; et al.

CORPORATE SOURCE: Med. Res. Div., American Cyanamid Co., Pearl River, NY, 10965, USA

SOURCE: Journal of Medicinal Chemistry (1993), 36(19), 2716-25
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of 4-aryl-2-(phenylamino)pyrimidines I (R = Ph, substituted Ph, R1 = 2-, 3-, 4-pyridyl, 2-, 3-thienyl, 2-, 3-furyl) were prepared as mediator release inhibitors, useful in treatment of asthma and other allergic disorders, and screened using human basophil. I were prepared by condensing heterocycles with R1COMe DMF di-Me acetal to form enaminones which were then cyclized with aryl guanidines RNHC(NH2):NH. After examining a large number of analogs, [(imidazolyl)phenylamino](pyrimidinyl)pyrimidine


II was chosen for toxicol. evaluation.

IT 112696-99-8P 145963-51-5P 150784-70-6P
150784-86-4P 150785-00-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as agent for asthma treatment)


RN 112696-99-8 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 145963-51-5 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 150784-70-6 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(3-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 150784-86-4 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 150785-00-5 HCAPLUS

CN 2-Pyrimidinamine, 4-(2-furanyl)-N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-
(9CI) (CA INDEX NAME)



L18 ANSWER 52 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:124558 HCAPLUS

DOCUMENT NUMBER: 118:124558

TITLE: Preparation of pyrimidine and analogs containing 2-phenyl-3-methoxypropenoates as agrochemical fungicides

INVENTOR(S): De Fraine, Paul John; Clough, John Martin; Worthington, Paul Anthony; Pilkington, Brian Leslie; Matthews, Ian Richard

PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9218487	A1	19921029	WO 1992-GB681	19920414
W: AU, BB, BG, BR, CA, CS, FI, GB, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
CA 2107084	AA	19921016	CA 1992-2107084	19920414
AU 9215380	A1	19921117	AU 1992-15380	19920414
AU 656958	B2	19950223		
EP 586393	A1	19940316	EP 1992-907662	19920414
EP 586393	B1	19980617		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507394	T2	19940825	JP 1992-507730	19920414
JP 3112479	B2	20001127		
BR 9205902	A	19941108	BR 1992-5902	19920414
HU 67924	A2	19950323	HU 1993-2795	19920414
HU 213320	B	19970528		
AT 167476	E	19980715	AT 1992-907662	19920414
GB 2270075	A1	19940302	GB 1993-19695	19930923
GB 2270075	B2	19950104		
US 5439910	A	19950808	US 1993-133047	19931012
PRIORITY APPLN. INFO.:				
			GB 1991-8094	A 19910415
			GB 1991-20642	A 19910927
			GB 1992-2071	A 19920131
			WO 1992-GB681	A 19920414

OTHER SOURCE(S): CASREACT 118:124558; MARPAT 118:124558

AB Title compds. I [A = hydrogen, halogen, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy or cyano; one of R1 and R2 is Me, MeSO₂, etc., and the other is substituted pyridyl, substituted pyrimidinyl or other substituted heterocycles, are prepared Me 2-[2-[(2-pyridylmethyl)sulfonyl](oxyiminomethyl)phenyl]-3-methoxypropenoate (preparation given) in CH₂Cl₂ was oxidized to give I (A = H, R1 = 2-pyridyl, R2 = MeSO₂). Also prepare was the title I (A = H, R1 = 2-pyridyl, R2 = Me) which at 100 ppm sprayed onto the foliage and applied to roots of plants in the

soil, shows no disease.


IT 145945-81-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and foliar fungicidal activity of)

RN 145945-81-9 HCAPLUS

CN Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-[3-(2-pyrimidinyl)oxy]phenyl]ethylidene]amino]oxy]methyl]-, methyl ester, (E,E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L18 ANSWER 53 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:101985 HCAPLUS

DOCUMENT NUMBER: 118:101985

TITLE: Preparation of a 2-[(imidazolylethoxy)anilino]-4-thienylpyrimidine as an antiallergic and antiasthmatic with improved bioavailability

INVENTOR(S): Paul, Rolf; Kelly, Robert G.; Torley, Lawrence W.

PATENT ASSIGNEE(S): American Cyanamid Co., USA

SOURCE: U.S., 14 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5162328	A	19921110	US 1991-816335	19911231
EP 549880	A1	19930707	EP 1992-119890	19921123
EP 549880	B1	19980916		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 171178	E	19981015	AT 1992-119890	19921123
ES 2121809	T3	19981216	ES 1992-119890	19921123
NO 9204760	A	19930701	NO 1992-4760	19921209
JP 05271227	A2	19931019	JP 1992-357370	19921224
CA 2086357	AA	19930701	CA 1992-2086357	19921229
AU 9230462	A1	19930708	AU 1992-30462	19921230
AU 651539	B2	19940721		
ZA 9210120	A	19940412	ZA 1992-10120	19921230
HU 66943	A2	19950130	HU 1992-4172	19921230
			US 1991-816335	19911231

PRIORITY APPLN. INFO.:


AB [3-[2-(1H-Imidazol-1-yl)ethoxyphenyl]guanidine was cyclocondensed with

3-dimethylamino-1-(2-thienyl)-2-propen-1-one to give N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine which had elimination half life of 2.27 and 1.47 h on days 1 and 3 in dogs compared to 0.65 and 0.96 h, resp., for 2-methyl-N4-[4-(4-pyridinyl)-2-pyrimidinyl]-1,4-benzenediamine dihydrochloride.

IT 145963-51-5P 145963-52-6P 145963-53-7P
 145963-54-8P 145963-55-9P 145963-56-0P
 145963-57-1P 145963-58-2P 145963-59-3P
 145963-60-6P 145963-61-7P 145963-62-8P
 145963-63-9P 145963-64-0P 145963-65-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of, as antiallergic and antiasthmatic agent)
 RN 145963-51-5 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 145963-52-6 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145963-53-7 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 145963-54-8 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-,

sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5


CMF C19 H17 N5 O S



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 145963-55-9 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-, phosphate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5


CMF C19 H17 N5 O S



CM 2


CRN 7664-38-2

CMF H3 O4 P



RN 145963-56-0 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-,
monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 145963-57-1 HCAPLUS
CN Sulfamic acid, compd. with N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 145963-51-5
CMF C19 H17 N5 O S



CM 2


CRN 5329-14-6
CMF H3 N O3 S



RN 145963-58-2 HCAPLUS
CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5
CMF C19 H17 N5 O S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 145963-59-3 HCAPLUS

CN Propanoic acid, 2-hydroxy-, compd. with N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5


CMF C19 H17 N5 O S



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 145963-60-6 HCAPLUS

CN Butanedioic acid, hydroxy-, compd. with N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5


CMF C19 H17 N5 O S



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 145963-61-7 HCAPLUS

CN Butanedioic acid, compd. with N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5


CMF C19 H17 N5 O S



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 145963-62-8 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5

CMF C19 H17 N5 O S




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 145963-63-9 HCAPLUS

CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5


CMF C19 H17 N5 O S



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 145963-64-0 HCAPLUS

CN D-Gluconic acid, compd. with N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5

CMF C19 H17 N5 O S




CM 2

CRN 526-95-4

CMF C6 H12 O7

Absolute stereochemistry.




RN 145963-65-1 HCAPLUS

CN L-Ascorbic acid, compd. with N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 145963-51-5

CMF C19 H17 N5 O S




CM 2

CRN 50-81-7

CMF C6 H8 O6

Absolute stereochemistry.



L18 ANSWER 54 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:407950 HCAPLUS

DOCUMENT NUMBER: 117:7950

TITLE: Benzaldoxime ether derivatives

INVENTOR(S): Rheinheimer, Joachim; Eicken, Karl; Vogelbacher, Uwe
Josef; Westphalen, Karl Otto; Gerber, Matthias;
Walter, Helmut

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4030929	A1	19920402	DE 1990-4030929	19900929
EP 479055	A1	19920408	EP 1991-115908	19910919
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
CA 2051988	AA	19920330	CA 1991-2051988	19910920
JP 04273862	A2	19920930	JP 1991-248919	19910927
PRIORITY APPLN. INFO.:			DE 1990-4030929	19900929
OTHER SOURCE(S): MARPAT 117:7950				
AB Benzaldoximes I (X = O, S; X1 = N, CH; R, R1 = alkyl, haloalkyl, alkoxy, haloalkoxy, alkylamino, alkylthio; R2 = OH, esterified OH, amino; R3 = alkyl, alkenyl, haloalkenyl, CH2Ph, substituted CH2Ph) were prepared Thus, 2,6-AcO(BrCH2)C6H3CO2Et was oxidized to 2,6-AcO(HCO)C6H3CO2Et which was treated with EtONH2 to give 2,6-AcO(EtON:CH)C6H3CO2Et (II). Hydrolysis of II with 50% aqueous NaOH gave 2,6-EtON:CH(HO)C6H3CO2H which was treated with 4,6-dimethoxy-2-methanesulfonylpyrimidine to give the oxime III. III had very good herbicidal activity against broad-leaf weeds at 0.25 kg/ha post-emergence.				
IT 141916-30-5P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 141916-30-5 HCAPLUS				
CN Benzoic acid, 2-[[[(4-chlorophenyl)methoxy]imino]methyl]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)				



L18 ANSWER 55 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1991:449114 HCAPLUS

DOCUMENT NUMBER: 115:49114

TITLE: Preparation of N-substituted benzyloxyimine derivatives as agrochemical fungicides

INVENTOR(S): Tsubata, Kenji; Niino, Nobuyuki; Endo, Katsutoshi; Yamamoto, Yoshinobu; Kanno, Hideo

PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 110 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414153	A1	19910227	EP 1990-115822	19900817
EP 414153	B1	19940126		
R: CH, DE, FR, GB, IT, LI				

US 5104872	A	19920414	US 1990-567525	19900815
CA 2023515	AA	19910223	CA 1990-2023515	19900817
CA 2023515	C	19970211		
AU 9061127	A1	19910228	AU 1990-61127	19900820
AU 628625	B2	19920917		
CN 1049654	A	19910306	CN 1990-107137	19900822
CN 1024662	B	19940525		
JP 03169842	A2	19910723	JP 1990-220388	19900822
CN 1088384	A	19940629	CN 1993-119492	19931022
			JP 1989-215684	A 19890822

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 115:49114


AB The title compds. [I; R1, R2 = alkyl; R3, R4 = H, cyano, NO2, (halo)alkyl, cycloalkyl, (halo)alkoxy, (halo)alkylthio, (substituted) Ph, etc.; R3R4 = alkylene, alkenylene containing optional hetero atom] are prepared KOH was added to a solution of bromide II and PhCH:NOH in Me2SO with stirring at room temperature to give 31% I (R1 = R2 = Me, R3 = H, R4 = Ph), which showed 95-100% control of powdery mildew of barley, downy mildew of cucumber, and rice blast at 200 ppm. Also prepared and tested were 407 addnl. I.

IT 134726-30-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agrochem. fungicide)

RN 134726-30-0 HCAPLUS

CN Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-[3-(2-pyrimidinyl)oxy]phenyl]ethylidene]amino]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 56 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1990:231326 HCAPLUS

DOCUMENT NUMBER: 112:231326

TITLE: Insecticides

INVENTOR(S): Anthony, Vivienne Margaret; Clough, John Martin; Godfrey, Christopher Richard Ayles; De Fraine, Paul John; Tapolczay, David Jozsef

PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK

SOURCE: Eur. Pat. Appl., 25 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 335519	A1	19891004	EP 1989-302330	19890309
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

AU 8931625	A1	19891005	AU 1989-31625	19890322
AU 610363	B2	19910516		
JP 01308206	A2	19891212	JP 1989-78691	19890331
PRIORITY APPLN. INFO.:			GB 1988-7682	19880331
			GB 1988-28545	19881207

OTHER SOURCE(S): MARPAT 112:231326

AB Compds. of the general formula I (R1 = H or alkyl; R2 = H, halogen, alkyl, alkenyl, alkylamino, etc.; R3 = H, OH, halogen, alkylamino, etc.; A1 = O, SOn, alkylamino, etc.; n =1-2) are insecticides, miticides or nematocides. Thus, I (A1 = O, R1 = R2 = R3 = H; E isomer) (500 ppm) caused 80-100% mortality of Diabrotica balteata when used as a 0.1% solution in acetone containing the wetting agent Synperonic NX.

IT **117428-36-1**


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)

(insecticidal activity of, structure in relation to)

RN 117428-36-1 HCAPLUS

CN Benzeneacetic acid, α -(methoxymethylene)-2-[[3-(2-pyrimidinylloxy)phenoxy]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L18 ANSWER 57 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:192853 HCAPLUS

DOCUMENT NUMBER: 110:192853

TITLE: Preparation of 2-phenoxy pyrimidines as herbicides

INVENTOR(S): Wada, Nobuhide; Saito, Yoshihiro; Kusano, Shoji; Toyokawa, Yasubumi; Miyazawa, Takeshige; Takahashi, Satoshi

PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63258463	A2	19881025	JP 1987-91785	19870414
PRIORITY APPLN. INFO.:			JP 1987-91785	19870414

OTHER SOURCE(S): MARPAT 110:192853


AB Title compds. I [X = R2SO3, R3 (CH2)nO, PhCH2S; R1 = CHO, CO2H; R2 = alkyl, Ph; R3 = (substituted) Ph, PhS, PhO, thienyl, (alkyl- or alkoxy-substituted) pyrimidinyl, PhCH2O, CO2R4, cyano; n = 1, 2; when n = 1, the Ph for R3 must be substituted with CO2H or alkoxy-carbonyl; R4 = H, alkyl] are prepared. A mixture of 6-(2-thenyloxy)salicylaldehyde, 4,6-dimethoxy-2-methylsulfonylpyrimidine, and K2CO3 in DMF was heated at 50° to give I (R1 = CHO; X = 2-thenyloxy). I [R1 = CO2H; X = PhO(CH2)2O] (II) at 40 g/av postemergent showed ≥90% control of *Echinocola crus-gali* and *Digitaria adscendens*, vs. 0% and 0-30% for Et 3-(4-chloropyrimidin-2-yloxy)benzoate, resp. A wettable powder was formulated containing II 10 emulgen-810 0.5, demol-N 0.5, kunilite-201 20, and zeeklite-CA 69%.

IT 120259-37-2P 120259-38-3P 120259-39-4P
 120259-41-8P 120259-46-3P 120259-47-4P
 120259-48-5P 120259-49-6P 120259-52-1P
 120259-53-2P 120259-54-3P 120292-06-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 120259-37-2 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(phenylsulfonyl)oxy]-
 (9CI) (CA INDEX NAME)




RN 120259-38-3 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-phenoxyethoxy)-
 (9CI) (CA INDEX NAME)




RN 120259-39-4 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(phenylmethyl)thio]-
 (9CI) (CA INDEX NAME)




RN 120259-41-8 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[[2-(methoxycarbonyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 120259-46-3 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-thienylmethoxy)- (9CI) (CA INDEX NAME)




RN 120259-47-4 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(2-phenylethoxy)- (9CI) (CA INDEX NAME)




RN 120259-48-5 HCAPLUS


CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 120259-49-6 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[2-(phenylthio)ethoxy]- (9CI) (CA INDEX NAME)




RN 120259-52-1 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(4,6-dimethyl-2-pyrimidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 120259-53-2 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(6-methoxy-2-methyl-4-pyrimidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 120259-54-3 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[2-(phenylmethoxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 120292-06-0 HCAPLUS

CN Benzoic acid, 2-[(2-carboxyphenyl)methoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 58 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:95264 HCAPLUS

DOCUMENT NUMBER: 110:95264

TITLE: Preparation and testing of 2-phenoxy-4,6-dimethoxypyrimidines as herbicides

INVENTOR(S): Wada, Nobuhide; Saito, Yoshihiro; Kusano, Shoji; Toyokawa, Yasufumi; Miyazawa, Takeshige; Takahashi, Satoru

PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.

SOURCE: Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 287079	A2	19881019	EP 1988-105901	19880413
EP 287079	A3	19910410		
EP 287079	B1	19941012		
R: CH, DE, FR, GB, IT, LI				
JP 63258464	A2	19881025	JP 1987-91787	19870414
JP 2530155	B2	19960904		
JP 01093576	A2	19890412	JP 1987-91788	19870414
JP 2530156	B2	19960904		
US 4889552	A	19891226	US 1988-181366	19880413
PRIORITY APPLN. INFO.:			JP 1987-91787	19870414
			JP 1987-91788	19870414

OTHER SOURCE(S): CASREACT 110:95264; MARPAT 110:95264

AB The title compds. [I; R = CHO, CO2R1; R1 = H, alkyl, 2-


methylsulfonylethyl, diethoxypropyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxyalkyl, hydroxyalkyl, cycloalkyl, Ph, (substituted) PhCH₂; X = halo, alkynyloxy, alkenyloxy, alkylthio, alkoxyalkoxy, haloalkoxy, carbamoyl, acetyloxy, benzoyloxy, CHO, CF₃, CO₂H, alkoxy carbonyl, dialkylamino, dimethoxymethyl; XX = OCH₂O] useful as pre- and postemergent herbicides, were prepared 4,6-Dimethoxy-2-methylsulfonylpyrimidine was added to Me 6-(dimethoxy)methylsalicylate and KH in DMF and the mixture was stirred at 90-100° for 12 h to give Me 2-(dimethoxy)methyl-6-(4,6-dimethoxypyrimidin-2-yl)oxybenzoate. At 400 g/10 are preemergent, several I were completely effective against *Echinochloa crus-galli*, *Digitaria sanguinalis*, *Polygonum lapathifolium*, *Amaranthus viridis*, *Chenopodium album*, and *Cyperus iria*.

IT 119158-38-2P 119158-40-6P 119158-41-7P
119158-42-8P 119158-44-0P 119158-45-1P
119158-46-2P 119158-47-3P 119158-48-4P
119158-74-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 119158-38-2 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 119158-40-6 HCAPLUS

CN Benzoic acid, 2-[(2-chlorophenyl)methoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 119158-41-7 HCAPLUS

CN Benzoic acid, 2-[(3-chlorophenyl)methoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 119158-42-8 HCAPLUS

CN Benzoic acid, 2-[(4-chlorophenyl)methoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 119158-44-0 HCAPLUS

CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-(1-phenylethoxy)- (9CI) (CA INDEX NAME)




RN 119158-45-1 HCAPLUS

CN Benzoic acid, 2-[(2,6-dichlorophenyl)methoxy]-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 119158-46-2 HCAPLUS


CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(2,4-dimethylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 119158-47-3 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(3,5-dimethylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 119158-48-4 HCAPLUS
 CN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-6-[(4-ethylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 119158-74-6 HCAPLUS
 CN Benzoic acid, 2-(benzoyloxy)-6-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI)
 (CA INDEX NAME)



L18 ANSWER 59 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1988:610725 HCAPLUS
 DOCUMENT NUMBER: 109:210725

TITLE: Methyl 3-methoxy-2-phenylpropenoate derivatives useful as plant fungicides and plant growth regulators, their fungicidal compositions, and processes and intermediates for their preparation

INVENTOR(S): Clough, John Martin; Godfrey, Christopher Richard Ayles; De Fraine, Paul John; Hutchings, Michael Gordon; Anthony, Vivienne Margaret

PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK

SOURCE: Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 278595	A2	19880817	EP 1988-300280	19880114
EP 278595	A3	19890405		
EP 278595	B1	19921111		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
GB 2201152	A1	19880824	GB 1988-827	19880114
GB 2201152	B2	19910814		
EP 472224	A1	19920226	EP 1991-117381	19880114
EP 472224	B1	19940427		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 82268	E	19921115	AT 1988-300280	19880114
AT 104948	E	19940515	AT 1991-117381	19880114
ES 2052696	T3	19940716	ES 1988-300280	19880114
ES 2053258	T3	19940716	ES 1991-117381	19880114
ZA 8800338	A	19880928	ZA 1988-338	19880119
IL 98741	A1	19930315	IL 1988-98741	19880119
IL 85122	A1	19941229	IL 1988-85122	19880119
IL 98742	A1	19960618	IL 1988-98742	19880119
IL 98743	A1	19961016	IL 1988-98743	19880119
IL 107289	A1	19970610	IL 1988-107289	19880119
AU 8810660	A1	19880811	AU 1988-10660	19880121
AU 615890	B2	19911017		
US 5021581	A	19910604	US 1988-151522	19880202
BR 8800503	A	19880927	BR 1988-503	19880208
HU 46510	A2	19881128	HU 1988-555	19880208
HU 204166	B	19911230		
DK 8800668	A	19880810	DK 1988-668	19880209
DK 173360	B1	20000814		
JP 63216848	A2	19880909	JP 1988-26710	19880209
JP 2559130	B2	19961204		
CN 1030749	A	19890201	CN 1988-100636	19880209
CN 1020391	B	19930505		
GB 2235454	A1	19910306	GB 1990-21527	19901003
GB 2235454	B2	19910807		
GB 2235455	A1	19910306	GB 1990-21627	19901004
GB 2235455	B2	19910814		
GB 2235456	A1	19910306	GB 1990-21727	19901005
GB 2235456	B2	19910814		
US 5438059	A	19950801	US 1993-88098	19930706
JP 09002906	A2	19970107	JP 1995-56403	19950209
JP 2904476	B2	19990614		
US 6653258	B1	20031125	US 1995-410732	19950327
DK 9900354	A	19990312	DK 1999-354	19990312

GR 3033171 T3 20000831 GR 2000-400864 20000407
 PRIORITY APPLN. INFO.: GB 1987-2845 A 19870209
 GB 1987-10594 A 19870505
 EP 1988-300280 A 19880114
 EP 1991-117381 A 19880114
 GB 1988-827 A3 19880114
 IL 1988-85122 A3 19880119
 US 1988-151522 A1 19880202
 JP 1988-26710 A3 19880209
 US 1991-667805 B1 19910311
 US 1993-88098 A1 19930706

OTHER SOURCE(S): CASREACT 109:210725; MARPAT 109:210725

AB Title esters I [R1 = (un)substituted aryl or heteroaryl; Y = O, S, NR4; R2-R4 = H, C1-4 alkyl, C2-4 alkenyl; X = halo, C1-4 alkyl, C2-4 alkenyl, C1-4 alkoxy, NO2, cyano; n = 0-4; when Y = O, n = 0, and R1 = Ph, then R2 and/or R3 ≠ H or Me] are prepared as fungicides and plant growth regulators. Etherification of 3-ClC6H4OH with 2-(BrCH2)C6H4CN using NaH in DMF, followed by reduction of the resultant nitrile by Raney Ni in 75% HCO2H, gave 2-(3-chlorophenoxy)methylbenzaldehyde. Condensation of the latter with MeSCH2S(O)Me, followed by cleavage using HCl in MeOH, gave Me 2-(3-chlorophenoxy)methylphenylacetate. This underwent condensation with HCO2Me in DMF containing NaH, followed by treatment with Me2SO4 and K2CO3 in DMF, to give Me [(chlorophenoxy)methylphenyl]methoxypropenoate II. A seed dressing is prepared from II 50, mineral oil 2, and China clay 48%. As a 100-ppm spray and 40 ppm root drench, II completely protected 7/7 plant hosts from 7 standard pathogens.


IT 117428-36-1P 117428-37-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as fungicide)

RN 117428-36-1 HCAPLUS

CN Benzeneacetic acid, α-(methoxymethylene)-2-[[3-(2-pyrimidinyl)phenoxy]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 117428-37-2 HCAPLUS

CN Benzeneacetic acid, 2-[[3-[(5-chloro-2-pyrimidinyl)oxy]phenoxy]methyl]-α-(methoxymethylene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L18 ANSWER 60 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1988:131844 HCAPLUS
 DOCUMENT NUMBER: 108:131844
 TITLE: Preparation of N-benzoyl-N'-[(azinyloxy)phenyl]ureas
 as neoplasia inhibitors
 INVENTOR(S): Takahiro, Haga; Nobutoshi, Yamada; Hideo, Sugi; Toru,
 Koyanagi; Hiroshi, Okada
 PATENT ASSIGNEE(S): Ishihara Sangyo Kaisha, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 63 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 226104	A2	19870624	EP 1986-116595	19861128	
EP 226104	A3	19880907			
EP 226104	B1	19910206			
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
AU 8665581	A1	19870618	AU 1986-65581	19861120	
AU 594098	B2	19900301			
ZA 8608883	A	19870729	ZA 1986-8883	19861124	
IL 80776	A1	19910310	IL 1986-80776	19861126	
AT 60760	E	19910215	AT 1986-116595	19861128	
ES 2033675	T3	19930401	ES 1986-116595	19861128	
JP 63099056	A2	19880430	JP 1986-291921	19861208	
JP 07045473	B4	19950517			
US 4863924	A	19890905	US 1986-939025	19861208	
CN 86108213	A	19870701	CN 1986-108213	19861210	
CN 1023316	B	19931229			
DD 258806	A5	19880803	DD 1986-297389	19861210	
CA 1266474	A1	19900306	CA 1986-524940	19861210	
PL 151012	B1	19900731	PL 1986-262901	19861210	
SU 1665876	A3	19910723	SU 1986-4028625	19861210	
DK 8605965	A	19870612	DK 1986-5965	19861211	
DK 164054	B	19920504			
DK 164054	C	19920928			
DK 9101183	A	19910618	DK 1991-1183	19910618	
PRIORITY APPLN. INFO.:				JP 1985-278180	19851211
				JP 1985-279884	19851212

JP 1985-280694
EP 1986-11659519851213
19861128

OTHER SOURCE(S): CASREACT 108:131844


AB $XnC_6H_4-nCONHCONHR$ [I; R = (azinyloxy)phenyl Q, Q1; A, B = CH, N (Q) or 1 of A, B = CH, the other = N (Q1); X = H, halo, NO₂; Y1 = (un)substituted alkyl, alkoxy, alkoxycarbonyl; Y2 = H, halo, NO₂, Y1; Z = H, halo, CF₃, NO₂; n = 1-3] were prepared as antitumor agents. 2,4-Me(H₂N)C₆H₃OH (2.0 g) and 2.0 g 2,5-dichloropyrimidine were heated 2 h at 100° in Me₂SO containing K₂CO₃ to give 2.0 g 4-[(5-chloro-2-pyrimidinyl)oxy]-3-methylaniline which was treated with 2-O₂NC₆H₄CONCO in dioxane at room temperature to give 2.82 g benzoylurea II. Mice implanted with P-388 leukemia cells and receiving 12.5 mg II/kg orally, 1 and 4 days after inoculation, had 147% increase in life span. Many formulation examples for I are given.

IT 111986-23-3P 111986-27-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)


RN 111986-23-3 HCAPLUS

CN Benzamide, N-[[[4-fluoro-3-[(5-iodo-2-pyrimidinyl)oxy]phenyl]amino]carbonyl]-2-nitro- (9CI) (CA INDEX NAME)



RN 111986-27-7 HCAPLUS

CN Benzamide, N-[[[3-[(5-bromo-2-pyrimidinyl)oxy]phenyl]amino]carbonyl]-2-nitro- (9CI) (CA INDEX NAME)



L18 ANSWER 61 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1988:112478 HCAPLUS

DOCUMENT NUMBER: 108:112478

TITLE: Preparation of 4,5,6-substituted 2-pyrimidinamines as allergy inhibitors, antiasthmatics, and hypoglycemics

INVENTOR(S): Torley, Lawrence Wayne; Johnson, Bernard B.; Dusza, John Paul

PATENT ASSIGNEE(S): American Cyanamid Co., USA

SOURCE: Eur. Pat. Appl., 94 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 233461	A2	19870826	EP 1987-100277	19870112
EP 233461	A3	19880525		
EP 233461	B1	19960320		
EP 233461	B2	20020529		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
US 4788195	A	19881129	US 1986-927572	19861106
AT 135699	E	19960415	AT 1987-100277	19870112
ES 2087056	T3	19960716	ES 1987-100277	19870112
DK 8700151	A	19870714	DK 1987-151	19870113
DK 171251	B1	19960812		
FI 8700113	A	19870714	FI 1987-113	19870113
FI 91150	B	19940215		
FI 91150	C	19940525		
AU 8767518	A1	19870716	AU 1987-67518	19870113
AU 591223	B2	19891130		
ZA 8700219	A	19870826	ZA 1987-219	19870113
JP 62223177	A2	19871001	JP 1987-5867	19870113
JP 07080857	B4	19950830		
HU 43582	A2	19871130	HU 1987-100	19870113
HU 198708	B	19891128		
CA 1320201	A1	19930713	CA 1987-527173	19870113
US 4876252	A	19891024	US 1988-194751	19880517
AU 9050578	A1	19900726	AU 1990-50578	19900228
AU 621461	B2	19920312		

PRIORITY APPLN. INFO.:

US 1986-817951 A 19860113
 US 1986-927572 A3 19861106

OTHER SOURCE(S): CASREACT 108:112478


AB The title compds. [I; R1 = H, C1-3 alkyl, EtO2CCO, Et2NCH2CH2; R2 = substituted Ph; R3 = Me2NC6H4, AcNMeC6H4, (un)substituted furanyl, thienyl, N-containing heteroaryl; R4, R5 = H, C1-3 alkyl] and their pharmacol. acceptable salts were prepared for treating asthma and allergic diseases, inflammation, and diabetes mellitus. A mixture of 7.04 g 3-(dimethylamino)-1-(3-pyridinyl)-2-propen-1-one and 18.72 g 3-F3CC6H4NHC(:NH)NH2.H2CO3 was refluxed 16 h in ProH to give 5.55 g pyridinylpyrimidinamine II. II inhibited histamine release from immunol. stimulated human basophils with an IC50 of 0.7 µM. II also gave 58.1% inhibition of lipoxxygenase activity in guinea pig neutrophils at 10 µg/mL.

IT 112696-99-8P 112697-00-4P 112697-01-5P
 112697-02-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)

RN 112696-99-8 HCAPLUS


CN 2-Pyrimidinamine, N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-pyridinyl)-(9CI) (CA INDEX NAME)




RN 112697-00-4 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-(4-pyridinyl)-
 (9CI) (CA INDEX NAME)



RN 112697-01-5 HCAPLUS
 CN 2-Pyrimidinamine, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-(2-thienyl)-
 (9CI) (CA INDEX NAME)



RN 112697-02-6 HCAPLUS
 CN 2-Pyrimidinamine, 4-(2-furanyl)-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-
 (9CI) (CA INDEX NAME)



L18 ANSWER 62 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1985:57843 HCAPLUS
 DOCUMENT NUMBER: 102:57843
 TITLE: Phenylpropyl ethers as pesticides
 PATENT ASSIGNEE(S): Katsuda, Ayao, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59157004	A2	19840906	JP 1983-31311	19830226
JP 03068841	B4	19911030		

PRIORITY APPLN. INFO.:

AB 2-Phenylpropyl ethers are prepared as pesticides. Syntheses of the compds. are described. Thus, 1:1000 solution of 3'-(4-pyridyloxy)benzyl 2-methyl-2-(4-ethoxyphenyl)propyl ether [94338-20-2] at 100 L/are controlled mites and cockroaches.


IT **94338-28-0P 94338-35-9P 94338-44-0P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and pesticidal activity of)


RN 94338-28-0 HCAPLUS

CN Pyrimidine, 2-[3-[[2-[4-(difluoromethoxy)phenyl]-2-methylpropoxy]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 94338-35-9 HCAPLUS

CN Pyrimidine, 5-chloro-2-[[3-[1-[2-methyl-2-(2-nitro-4-phenoxyphenyl)propoxy]-2-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 94338-44-0 HCAPLUS

CN Pyrimidine, 2-[5-[1-[2-[4-(1,1-dimethylethyl)-2-fluorophenyl]-2-methylpropoxy]-2-butynyl]-2-fluorophenoxy]-5-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 63 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1984:467792 HCAPLUS

DOCUMENT NUMBER: 101:67792

TITLE: 2-Phenoxypyrimidines and their use as herbicides

INVENTOR(S): Serban, Alexander; Watson, Keith Geoffrey; Warner, Richard Burridge

PATENT ASSIGNEE(S): ICI Australia Ltd. , Australia

SOURCE: Pat. Specif. (Aust.), 81 pp.

CODEN: ALXXAP

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----	-----	-----	-----
AU 535637	B2	19840329	AU 1978-39166
AU 3916678	A1	19810108	
			19770913
			AU 1978-39166
			19770913

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 101:67792


AB 2-Phenoxypyrimidines I (A, B, D, R2, R3, R4, R5, and/or R6 = substituent such as H, CN, NO2, alkyl, sulfonyl, etc.) having a specific substitution pattern, i.e. these compds. in which the pyrimidyl ring is substituted in the 5-position and/or the Ph group is substituted in the 3- and/or 5-positions, have a high level of herbicidal activity. These compds. were prepared by condensation of the appropriate pyrimidine with the appropriate phenol in the presence of an alkaline material. Thus, 5-bromo-2-(4-methoxyphenoxy)pyrimidine [69033-87-0] was prepared by treating 3 g 5-bromo-2-chloropyrimidine [32779-36-5] in Me Et ketone with 2.5 g p-methoxyphenol [150-76-5] in presence of K2CO3. Different postemergence and preemergence formulations of I are described. For example, (I, A = D = R2 = R4 = R5 = R6 = H; B = Cl; R3 = OMe) [73226-21-8] at 2 kg/ha caused no damage to wheat and 100% kill of annual ryegrass (preemergence treatment). 2-Phenoxypyrimidines having the described substitution pattern had a higher herbicidal activity than substituted 4-phenoxypyrimidines.

IT 73221-82-6P 73221-97-3P 73221-98-4P
 73222-02-3P 73222-04-5P 73222-09-0P
 73222-14-7P 73222-28-3P 73222-35-2P
 73226-71-8P 73235-71-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and herbicidal activity of)


RN 73221-82-6 HCAPLUS

CN Pyrimidine, 5-chloro-2-[3-[(4-chlorophenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 73221-97-3 HCAPLUS

CN Pyrimidine, 5-chloro-2-[3-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 73221-98-4 HCAPLUS


CN Pyrimidine, 5-chloro-2-[3-[(2,4-dichlorophenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 73222-02-3 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(4-nitrophenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-04-5 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(4-fluorophenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-09-0 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(3-chlorophenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-14-7 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(4-methoxyphenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-28-3 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(3,4-dichlorophenyl)methoxy]phenoxy]- (9CI)
(CA INDEX NAME)




RN 73222-35-2 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-chloro-5-[(4-chlorophenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 73226-71-8 HCAPLUS
CN Phenol, 3-[(5-chloro-2-pyrimidinyl)oxy]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 73235-71-9 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(2-chlorophenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 64 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1982:510026 HCAPLUS
 DOCUMENT NUMBER: 97:110026
 TITLE: Pyrimidinyloxybenzyl esters
 PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57046968	A2	19820317	JP 1980-122668	19800904
PRIORITY APPLN. INFO.:			JP 1980-122668	19800904

OTHER SOURCE(S): CASREACT 97:110026

AB The title esters [I; R = 2,2-dimethyl-3-(2,2-dimethylvinyl)cyclopropyl, 2,2-dimethyl-3-(2,2-dihalovinyl)cyclopropyl, 2,2,3,3-tetramethylcyclopropyl, 1-(4-halophenyl)isobutyl; R1 = H, cyano, HC.tplbond.C, Me], effective insecticides at 0.83-1.90 µg/fly, were prepared. Thus, 0.01 mol acid chloride (II; R2 = Cl) was added to a solution of 0.01 mol alc. III and 1.6 g pyridine in C6H6 and the mixture kept overnight at room temperature to give II [R2 = 3-(2-pyrimidinyl)benzyloxy]. Similarly prepared were 9 addnl. I.


IT 82440-29-7P 82440-30-0P 82440-31-1P

82440-32-2P 82440-33-3P 82440-35-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 82440-29-7 HCAPLUS

CN Benzeneacetic acid, 4-chloro-α-(1-methylethyl)-,
 [3-(2-pyrimidinyloxy)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 82440-30-0 HCAPLUS

CN Cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-,
 [3-(2-pyrimidinyloxy)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 82440-31-1 HCAPLUS


CN Cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-,
 1-[3-(2-pyrimidinyloxy)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)




RN 82440-32-2 HCAPLUS
 CN Cyclopropanecarboxylic acid, 3-(2,2-dibromoethenyl)-2,2-dimethyl-,
 [3-(2-pyrimidinyloxy)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 82440-33-3 HCAPLUS
 CN Cyclopropanecarboxylic acid, 3-(2,2-dibromoethenyl)-2,2-dimethyl-,
 1-[3-(2-pyrimidinyloxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 82440-35-5 HCAPLUS
 CN Cyclopropanecarboxylic acid, 2,2,3,3-tetramethyl-, [3-(2-pyrimidinyloxy)phenyl]methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 65 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1980:175773 HCAPLUS
 DOCUMENT NUMBER: 92:175773
 TITLE: Certain pyrimidine derivatives for inhibiting the
 growth of plants
 INVENTOR(S): Serban, Alexander; Watson, Keith Geoffrey; Warner,
 Richard Burridge
 PATENT ASSIGNEE(S): ICI Australia Ltd., Australia
 SOURCE: Braz. Pedido PI, 147 pp.
 CODEN: BPXXDX

DOCUMENT TYPE: Patent
 LANGUAGE: Portuguese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BR 7805949	A	19790502	BR 1978-5949	19780912
ZA 7804899	A	19790926	ZA 1978-4899	19780828
IL 55459	A1	19840430	IL 1978-55459	19780829
US 4427437	A	19840124	US 1978-939914	19780905
EP 1187	A1	19790321	EP 1978-300378	19780912
EP 1187	B1	19831207		
R: BE, CH, DE, FR, GB, NL, SE				
JP 54055729	A2	19790504	JP 1978-111384	19780912
CA 1092119	A1	19801223	CA 1978-311110	19780912
HU 24770	O	19830428	HU 1978-II272	19780912
HU 182509	B	19840130		
JP 62270562	A2	19871124	JP 1987-74569	19870330
JP 05009432	B4	19930204		

PRIORITY APPLN. INFO.:

AU 1977-1626 19770913


AB The pyrimidine derivs. I (A, B, and D = H, OH, CN, SCN, halo, NO₂, alkyl, alkenyl, alkenyloxy, alkynyloxy, thioalkyl, NH₂, Ph, CO₂H, alkoxy carbonyl, etc.; R₂-R₆ = H, halo, NO₂, CN, NCS, CHO, YR₁, or CO₂R; X and Y = O or S; R and R₁ = H, alkyl, acyl, alkenyl, etc.) are herbicides. Thus, 5-bromo-2-(4-methoxyphenoxy)pyrimidine [73226-26-3] (1 kg/ha), applied pre-emergence, controlled *Amaranthus retroflexus*, *Chenopodium album*, *Senecio vulgaris*, and other weeds. The synthesis of I is given.

IT 73221-82-6P 73221-97-3P 73221-98-4P
 73222-02-3P 73222-04-5P 73222-09-0P
 73222-14-7P 73222-28-3P 73222-35-2P
 73226-71-8P 73235-71-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and herbicidal activity of)


RN 73221-82-6 HCAPLUS

CN Pyrimidine, 5-chloro-2-[3-[(4-chlorophenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 73221-97-3 HCAPLUS


CN Pyrimidine, 5-chloro-2-[3-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 73221-98-4 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(2,4-dichlorophenyl)methoxy]phenoxy] - (9CI)
(CA INDEX NAME)




RN 73222-02-3 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(4-nitrophenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-04-5 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(4-fluorophenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-09-0 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(3-chlorophenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-14-7 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(4-methoxyphenyl)methoxy]phenoxy] - (9CI) (CA
INDEX NAME)




RN 73222-28-3 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(3,4-dichlorophenyl)methoxy]phenoxy] - (9CI)
(CA INDEX NAME)




RN 73222-35-2 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-chloro-5-[(4-chlorophenyl)methoxy]phenoxy] - (9CI) (CA INDEX NAME)



RN 73226-71-8 HCAPLUS
CN Phenol, 3-[(5-chloro-2-pyrimidinyl)oxy]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 73235-71-9 HCAPLUS
CN Pyrimidine, 5-chloro-2-[3-[(2-chlorophenyl)methoxy]phenoxy] - (9CI) (CA INDEX NAME)



L18 ANSWER 66 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1966:404434 HCAPLUS
 DOCUMENT NUMBER: 65:4434
 ORIGINAL REFERENCE NO.: 65:840f-h
 TITLE: Pyrimidine dyes
 INVENTOR(S): Benz, Jakob; Ischer, Hans
 PATENT ASSIGNEE(S): Sandoz Ltd.
 SOURCE: 6 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3247194		19660419	US CH	19581106

PRIORITY APPLN. INFO.:

AB Compds. of the general formula CuPc(n-SO₃H)m (n-SO₂NHC₆H₄OQ-3)pR (I), where Pc is phthalocyanine, Q is dichloropyrimidinyl, n is 3 or 4, m is 1.5-3, p is 1-1.5, and R is SO₂NHC₂H₄OH or H, are H₂O-soluble, turquoise dyes for natural and synthetic fibers. Thus, 57.6 parts CuPc was stirred with 300 parts ClSO₃H at 140° for 1 h., the mixture cooled to 70-80°, 45 parts SOCl₂ slowly added, stirring continued at 75-80° for 2 h., the mass poured on ice, the precipitated CuPc(SO₂Cl)₄ filtered, and washed with weakly acid ice-H₂O. The residue was stirred into ice-H₂O 500, 3-H₂NC₆H₄OH 11 parts added, the mixture neutralized with dilute NaOH, 60 parts NaHCO₃ added, the mixture stirred at room temperature for 12

h., heated to 70°, after 5 h. NaOH added until solution was complete, the intermediate precipitated with HCl, filtered, and washed with dilute HCl.


The

residue was stirred into 800 parts H₂O, neutralized with aqueous NaOH, 18.5 parts 2,4,6-trichloropyrimidine (II) added at 85-90°, the solution stirred for 12 h. at 85-90°, keeping the pH at 6-7 with dilute NaOH, 18.5 parts II added, and the mixture stirred at 85-90° for 12 h. to give I (n = 3, m = 3, p = 1, R = H), which dyed viscose rayon turquoise. Similarly, other I were prepared (n, m, p, and R given): 3, 1.5, 1.5, SO₂NHC₂H₄OH; 4, 3, 1, H; 3, 2, 1, H; 3, 3, 1, H (Pc metal-free).

IT 15024-37-0, Copper, [trihydrogen 4'''-[m-[(4,6-dichloro-2-pyrimidinyl)oxy]phenyl]sulfamoyl]-4,4',4'''-phthalocyaninetrisulfonato(2-)]-pyrimidinyl)oxy]phenyl]sulfamoyl]-3,3',3'''-phthalocyaninetrisulfonato(2-)]-pyrimidinyl)oxy]phenyl]sulfamoyl]phthalocyaninedisulfonato(2-)]- (preparation of)

RN 15024-37-0 HCAPLUS
 CN Cuprate(3-), [23-[[[3-[(4,6-dichloro-2-pyrimidinyl)oxy]phenyl]amino]sulfonyl]-29H,31H-phthalocyanine-2,9,16-trisulfonato(5-)-N29,N30,N31,N32]-, trihydrogen, (SP-4-2)-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 3 H⁺


RN 15024-38-1 HCAPLUS
 CN Copper, [trihydrogen 3'''-[m-[4,6-dichloro-2-pyrimidinyl)oxy]phenyl]sulfamoyl]-3,3',3'''-phthalocyaninetrisulfonato(2-)]-(7Cl, 8Cl) (CA INDEX NAME)





● 3 H⁺

RN 30232-36-1 HCAPLUS
 CN Cuprate(2-), [C-[[[3-[(4,6-dichloro-2-pyrimidinyl)oxy]phenyl]amino]sulfonyl]-29H,31H-phthalocyanine-C,C-disulfonato(4-)-N29,N30,N31,N32]-, dihydrogen (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L18 ANSWER 67 OF 67 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1963:21088 HCAPLUS

DOCUMENT NUMBER: 58:21088

ORIGINAL REFERENCE NO.: 58:3527h,3528a-d

TITLE: Reactivity of dichloro- and trichloropyrimidyl dyes and hydrolyzability of the dyeings

AUTHOR(S): Thumm, O.; Benz, J.

CORPORATE SOURCE: Sandoz A.-G., Basel, Switz.

SOURCE: Angew. Chem. (1962), 74, 712-16

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The resistance of dyeings made with reactive di- and trichloropyrimidyl dyes towards alkaline and acidic hydrolysis as well as the rate of fixation of

the dyes on cotton were investigated. The dyes studied had the general structure I, where R is 2,4,5-trichloro-6-pyrimidyl (II) or 2,4-dichloro-6-pyrimidyl (III) and X is a NH, NMe, CH₂O, or O bridge. I were dyed by the thermofixation process on mercerized cotton. The dyed cotton was then agitated 4 hrs. at 95° in a bath containing soap and 2 g. Na₂CO₃/l. (pH about 10). The dye which bled from the cotton was then dyed from the acidified bath onto wool. The acidic hydrolysis of the dyeings on cotton was performed by agitating the material with wool 1.5 hrs. at 98° in a bath containing Na₂SO₄ and 0.08 weight % H₂SO₄ (pH about 2); the bled dye is transferred to the wool. Color reproductions of the original dyeings on cotton and of the dyeings on wool after alkaline and acidic hydrolysis are given for the following I with R = II (X given): NH (IV), O (V), CH₂O (VI), and for the following with R = III (X given): NH (VII), NMe (VIII), O (IX). IV is practically resistant to alkaline hydrolysis, V and VI are less stable, VII is also stable under the same conditions, VIII slightly less so, while IX is least stable. The acidic hydrolysis of the dyes IV to IX approximates the alkaline hydrolysis. The locations of the cleavage of the dye-cellulose system were determined by column chromatography of the hydrolyzates obtained under more drastic conditions. In the dyeings with IV, VII, and VIII, cleavage occurs predominantly between cellulose and the reactive component. V and IX are cleaved at the phenol-ether linkage, and VI at the cellulose-reactive component and ether links. The reactivity of the various I with cellulose is affected by the nature of X. V and VI react much faster than IV, while maximum fixation from an alkaline bath is reached for V after about 30 min.; it requires about 50 hrs. for IV. Similarly, IX is more reactive than VII. VII is less reactive than VIII. The reactivities of the dyes X where R = II, 2,5-dichloropyrimidyl, and III determined at 50° by the slop-padding procedure were 11.4, 2.16, and 0.109 + 10⁻³/min., resp.

IT 96058-34-3, 1,7-Naphthalenedisulfonic acid, 3-[[m-[(4,6-dichloro-2-pyrimidinyl)oxy]phenyl]azo]-4-hydroxy-
 (dyeing cotton with, and effect of acid hydrolysis on fastness)
 RN 96058-34-3 HCAPLUS
 CN 1,7-Naphthalenedisulfonic acid, 3-[[m-[(4,6-dichloro-2-pyrimidinyl)oxy]phenyl]azo]-4-hydroxy- (7CI) (CA INDEX NAME)

